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SUMMARY
The effect of putrefaction on drug and poison determinations is a well known 
problem stemming from the beginning of modem forensic toxicology more than 
150 years ago. The problem arises from two main sources, the occurrence of 
endogenously produced interfering substances and the potential destruction by the 
putrefactive processes of a drug or poison present in the tissue. Most of the data 
available was obtained using older methods for drug and poison determinations 
like colour tests or thin layer chromatography. Also, putrefaction was studied 
separately from the stability of drugs. Studies involved the accumulation of data 
on the occurrence of putrefactive products in different types of tissues at 5°C, 25°C 
or else they involved the study of the stability of drugs in putrefied tissues without 
regard to the concentration of the interfering substances in the specimens under 
investigation.
More modern studies on the effect of putrefaction on drug determination and 
stability have been conducted for a short time. Periods varied from a few days to a 
maximum of 90 days. Again, the measurement of the amounts of putrefactive 
products formed in the samples when they were analysed for drug stability was 
not done. None of the published work in this field studied the effect of 
putrefaction on drug determination and stability at the three different 
temperatures 5°C, 25°C, -20°C, where samples could be kept for a long time, ie 
refrigerated, room temperature or deep frozen. In this thesis, the effect of 
putrefaction on drug determination in whole blood spiked with the acidic drugs, 
phenobarbitone, phenytoin and carbamazepine and the non-acid drugs, 
temazepam, morphine and buprenorphine over a period of one year at three
-  2  -
different temperatures is studied. The occurrence of the four main interfering 
substances, indole, 2-phenethylamine, tyramine and tryptamine was investigated. 
The drug stability without putrefaction was also studied at identical storage 
conditions for identical periods for reference purposes.
The interference of the four putrefactive amines with drug extraction, separation 
and detection using HPLC with ultraviolet detection for phenobarbitone, 
phenytoin, carbamazepine, temazepam and was investigated.
The liquid-liquid extraction methods used for the determination of putrefactive 
amines, Indole, 2-phenethylamine, tyramine and tryptamine is known to be 
tedious and time-consuming. Methods based on solid phase extraction was 
developed to extract the four amines. The extraction methods showed a good 
reproducibility and high efficiency. A method was developed to separate these 
putrefactive amines by HPLC using a normal-phase column for non-acid 
interferences. A reversed phase system was required to achieve Indole separation 
and determination of acid interferences.
The formation of the four purefactive amines was monitored in blood samples 
spiked with drug and found to be reduced dramatically regardless of the storage 
temperature, when blood samples were stored in sealed vials.
At a toxic level of each drug under study a reasonable amount of the drug was 
found to be detectable after one year of storage regardless of the storage 
temperature or media. The decrease rate of each drug concentration with time at 
the three storage tempereatures (5, 25, -20°C) was established and the feasibility of 
using this rate to predict the concentration after storage was investigated using 
authentic post-mortem samples. The possible interference from the four
putrefactive amines with the analytical methods was investigated and showed a 
possible interference from Indole with amylobarbitone and carbamazepine 
determination by HPLC system.
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CHAPTER ONE 
PUTREFACTION
1.1 - INTRODUCTION
Putrefaction is the result of bacterial and enzyme activity. The process begins 
immediately after death in the cellular structure but visible evidence is delayed for 
several hours under normal conditions. It becomes apparent after 48 to 72 hours. 
It may be hastened or delayed by one or more factors, such as atmospheric 
temperature and humidity [1].
The initial spread of putrefaction is largely influenced by two factors:
(a) The cause of death.
Where a person dies from acute intestinal obstruction, there is usually a frank 
bacteraemia before death, so that organisms from the bowel have already spread 
through the body.
- 5 -
(b) Residual Body Temperature.
The period of time that the internal temperature of the body remains above 70°F is 
of paramount importance.
Both the cited factors would hasten the onset of putrefaction. The first sign of 
putrefaction in the cadaver is the appearance of greenish discolouration of the skin 
(lower right anterior abdominal wall), followed by the appearance of blue or 
purplish/red  lines over the trunk, the root of the neck and upper arms and thighs. 
These lines are due to the decomposition and haemolysis of blood in the veins. As 
putrefaction continues, gases of putrefaction are produced in the internal organs. 
The composition of the gases varies according to the post-mortem interval and 
environment of the body [2].
Bacteria produces a large variety of enzymes and these break down the various 
tissues of the body, different enzymes acting on carbohydrate, fats and protein.
1.2 -  P o s t - m o r t e m  c h e m i s t r y  o f  b l o o d
With the development of automation in the hospital laboratory, ease of 
performance and low cost make routine post-mortem examinations of blood fluids 
both practical and desirable. A sufficient body of published knowledge has now 
been accumulated to enable an investigator to interpret post-mortem values for a 
wide variety of substances [3].
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The glucose and total reducing substances in post-mortem blood samples collected 
from five sites showed no significant difference in the values between the 
specimens grouped according to the time interval between death and collection 
(12-48 hours). The values for blood from the liver were highest and those for the 
peripheral blood the lowest [41.
Post-mortem urea nitrogen from individuals who died suddenly were all within 
the normal range. The stability of urea nitrogen was demonstrated by a variation 
of less than 3 mg per 100 ml in over 90% of the cases [5].
A sharp post-mortem increase of the free amino acid concentration in the blood 
was caused by enzymatic breakdown of proteins [3]. Values of less than 14 mg per 
100 ml were usually found when less than 10 hours had elapsed. Post-mortem 
concentration continued to increase until enzyme exhaustion with values 
frequently over 30 mg per 100 ml by 48 hours after death [6]. Ammonia showed a 
sharp rise in concentration after eight hours.
Other organic compounds
Serum fatty acid, total lipoproteins, and beta lipoproteins were all markedly stable 
post-mortem, showing little reduction due to autolysis, 0.5% per hour [7,8].
In a study of 94 individuals with normal antemortem bilirubins, it was found that 
there was a small but definite increase in average bilirubin concentration with 
increasing post-mortem time (0.2 mg per 100 ml in 2 hours, 0.7 mg per 100 ml in 20
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hours). The post-mortem levels of both total protein and albumin closely 
approximated known antemortem values [5].
Enzymes
Acid phosphatase, alkaline phosphatase, glutamic oxalic transaminase and lactic 
dehydrogenase showed a marked post-mortem elevation (of up to 20 times in the 
case of acid phosphatase) by 48 hours after death [9]. The values of alkaline 
phosphatase was tripled in 20 hours post-mortem [5]. Amylase glutamic 
oxaloacetic transaminase and lactic dehydrogenase showed post-mortem increases 
in their concentration with time [9] while blood cholinesterase remained stable [1 Oj
H orm ones:
Cortisol
Finlayson showed that post-mortem concentrations were the same as those during 
life and remained stable for at least 18 hours after death [11].
17-hydroxycorticosteroids
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A study from 64 individuals on blood samples obtained between 5 to 20 minutes 
after death showed an elevated level of 17-hydroxycorticosteroids [12].
Epinephrine and norepinephrine
The post-mortem catecholamines in the blood of normal individuals was found to 
be in higher concentration than those in the blood of living patients with 
pheochromocytomas and as high as those in blood from cases of accidental fatal 
adrenalin poisoning [13].
Thyroxine and thyroid stim ulating hormone
The values of thyroxine tend to fall. In contrast, thyroid stimulating hormone 
(TSH) remained in the normal range for one to two days after death [6].
Insulin
- 9 -
It has been shown that post-mortem serum insulin values are higher than those of 
healthy individuals and that in the same body there can be great variation in 
concentration depending on the source of the serum [14].
Chorionic gonadotropin
In cases of choriocarcinomas or related tumours, the post-mortem level of the 
chorionic gonadotropin concentration corresponded well with antemortem values
[15].
Electrolytes
Chloride showed an average rate of fall (0.97 m eq/litre per hour) and the same 
time sodium declined immediately after death with average rate of 0.9 m eq/litre 
per hour. In both cases there was a great deal of individual variation [5]. Within 
an hour after death, a marked increase in potassium values was noted followed by 
further gradual increase in the levels due to release of potassium from the cells
[16].
Calcium Phosphate
-  1 0  -
Calcium remains constant in the early post-mortem period whereas the organic 
phosphates and inorganic phosphates show an increase in their concentrations
[17].
Sulphur Magnesium
A study of the post-mortem stability using serial sampling revealed that the 
inorganic sulphur in the serum remained unchanged for the first 24 hours, and 
then decreased by 20% in the next two days [18]. Plasma magnesium 
concentration values showed a mild increase, but when haemolysis occurred, the 
plasma magnesium increased rapidly [17].
Hydrogen ion concentration [pH]
The acidity of the blood shows an increased after death. pH values averaged 6.73 
for the first 12 hours post-mortem and 6.43 for the next 12 hour period [17,19].
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CHAPTER TWO 
LITERATURE REVIEW
2.1 PRODUCTION OF INTERFERING SUBSTANCES
2.1.1 - Introduction
As the autolysis of the human body progresses releasing different putrefactive 
products, the presence of these materials in post-mortem specimens to be analysed 
for the presence of drugs and poisons has been a challenge for the forensic 
toxicologist. Some of these substances were encountered in the spectrometric 
analysis of alkaloids in autopsy materials.[20, 21].
The main interfering substances have been listed by Kaempe. He described some 
important characteristics of these compounds like infrared and ultraviolet spectra
[20].
The interfering substances are classified by Williams as either acidic or non-acidic
[22]. Acidic interfering substances are those that extract or theoretically should 
extract from aqueous acid solution into organic solvents.
-  1 2  -
They are substances that are co-extractable with acidic drugs. Non-acidic 
interfering substances (non-acids) are those extracted from ammoniacal or alkaline 
solutions by organic solvents. Some substances like Indole are extractable at any 
pH and are included in both the acid data accumulation and the non-acid data 
accumulation.
The effective quantitative and qualitative analysis of a drug in biological material 
can be hindered by the occurrence of interfering substances. These interfering 
substances can be divided into three major groups:
1. Naturally occurring
These are present in the biological material as normal components. This category 
includes vitamins, hormones, products of diet and the end of products of various 
biochemical cycles.
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2. Products of putrefaction
Putrefaction implies an intensive rotting of tissue or blood. This decay may be 
connected with autolysis, bacterial growth, photochemical effects or fungal 
growth.
3. Artefacts
An artefact is anything made by human workmanship. This broad definition of an 
artefact can describe substances produced on extraction or substances originating 
from a sample container.
2.1.2 Acidic Interferences
Table 1 lists the main interfering acids compounds with their predominant source.
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TABLE 1.
List of acid interfering substances.
COM M ON NAME PREDOMINANT SOURCE
B u ty r ic  a c id s P rod u ct o f  p u tr e fa c tio n
C h o le s te r o l N a tu r a lly  o ccu rr in g
4 ,4 -D  ih y d r o x y  ch a lco n e N a tu r a lly  occu rr in g
p -H y d r o x y b e n z  a ld e h y d e A rtefact, P rod u ct o f  p u tre fa c tio n
p -H y d r o x y b e n z o ic  acid P rod u ct o f  p u tre fa c tio n
5 -H y  d ro x y m e th y lfu r f  ural A rtefact
p -H y d r o x y p h e n y la c e tic  acid P rod u ct o f  p u tr e fa c tio n
p -H y d r o x y p h e n y le th a n o l P ro d u ct o f  p u tre fa c tio n
p -H y d r o x y p h e n y lp r o p io n ic  acid P ro d u ct o f  p u tre fa c tio n
P h e n y la c e tic  acid P rod u ct o f  p u tre fa c tio n
S tearic  acid N a tu r a lly  o ccu rr in g
S u c c in ic  acid N a tu r a lly  occu rr in g
In d o le P rod u ct o f  p u tre fa c tio n
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Phenolic acid has been noted to interfere with the determination of barbiturates
[23]. Phenylacetic acid imparts a mousy odour to human urine if present. Butyric 
acid is found in blood when a bacterial production of alcohol has occurred [24].
Indole
Indole is the most commonly used name for the benzopyrrole in which the 
benzene ring is fused at the 2- and 3- positions of the pyrrole ring. The NH group 
of Indoles is relatively acid [25] and forms the anion in the presence of strong 
bases. The low melting point and moderate polarity of Indole afford good 
solubility in a wide range of solvents including petroleum ether, benzene 
chloroform and alcohol and hot water.
Indole itself has been obtained from many naturally occurring materials by 
methods which suggest that the Indole is in many cases the product of 
decomposition of its derivatives. Indole is found in human and animal faeces.
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Indole is a tertiary amine and is a putrefactive base produced by the decay of 
protein [26]. Putrefactive bases with tertiary amine structure are important 
interfering substances, since they may be related to a whole series of drugs such as 
ergotamine and ergometrine which are derivatives of Indole. Its formation in the 
putrefaction of proteins is presumed to be the result of the decomposition of 
Tryptophan by an enzyme called 'tryptophanase' which catalyzes the direct 
removal of the side chain to form Indole [27], Figure 1. The first work mentioned 
Indole and measured its concentration in putrefied post-mortem material 
published in 1977. The study also showed that Indole production can be retarded 
by refrigeration [28].
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decarboxylation & side chain removal
Indole
H
Figure 1. The decomposition of Tryptophan during the
Putrefactive process to produce Indole.
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Indole has been mentioned as one of the putrefactive amines and the possible 
interferences with basic drugs determination in blood and urine samples [29].
2.1.3 Non-Acid Interferences
These compounds are known to be present in human tissue as interfering 
substances from different origins such as putrefaction, artefacts, natural occurrence 
[20].
This investigation concentrates on the four main putrefactive bases 2- 
phenethylamine, tyramine, tryptamine and Indole. These compounds are products 
of the decomposition of phenylalanine tyrosine and tryptophan and are seen to be 
predominant among the list of interfering substances. The investigation of 
interfering substances by Kaempe and Oliver represents the most important 
contribution in this field [20, 30]. Table 2 lists the main interfering non-acids.
2-Phenethvlamine
l-amino-2-phenylethane is an endogenous amine related structurally and 
pharmacologically to amphetamine. Fulton lists sixteen bases that are formed from 
amino acids [31]. Phenethylamine was mentioned on the list as a product of 
phenylalanine decarboxylation (decomposition) Figure 2.
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TABLE 2.
List of non-acid interfering substances.
COMMON NAME PREDOMINANT SOURCE
A d e n in e N a tu ra lly  occu rring
A m in e s  (s im p le ) P rod u ct o f  p u tre fa c tio n
C a ffe in e N a tu ra lly  occu rrin g  (d ietary)
(+ )-l,4 -D ip h e n y lb u ta n e -2 ,3  d io l N a tu ra lly  occu rring  (d ietary)
H arm an A rtefact
H y d ro x y  harm  an A rtefact
N ic o tin a m in d e N a tu ra lly  occurring
N ic o tin e N a tu ra lly  occurring
N or  harm  an A rtefact
P er lo lin e N a tu ra lly  occurring
1 -P h en e th y la m in e P roduct o f  p u tre fa c tio n
2 -P h en e  th y la m in e P roduct o f  p u tre fa c tio n
P ip er id in e P roduct o f  p u tre fa c tio n
P ip er id o n e P roduct o f  p u tre fa c tio n
P y rid in e P roduct o f  p u tre fa c tio n
T h y m in e , U racil N a tu ra lly  occurring
Tryp fam in e P roduct o f  p u tre fa c tio n
T yram in e P roduct o f  p u tre fa c tio n
X an th in e , H y p o x a n th in e N a tu ra lly  occu rring
-  2 0  -
COOH
c h 2-c h -n h 2
Phenylalanine 
1 decarboxylation
c h 2-c h 2-n h 2
2-Phenethylamine
Figure 2. The decomposition of Phenylalanine during the
Putrefactive process to produce 2-Phenethylamine.
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2-phenethylamine can be regarded as the parent compound of a large group of 
drugs known as the sympathomimetic amines. The structure is modified by 
substitution of the aromatic ring, the alpha and beta-carbon atoms and the terminal 
amino group to yield compounds with a wide range of pharmacological activity 
[32]. 2-phenethylamine received a great deal of attention in recent years because of 
its possible involvement in the etiology of a number of psychiatric and 
neurological disorders [33]. It is present in low levels in tissues and body fluids of 
living mammals. Patients suffering from paranoid schizophrenia and depression 
excrete relatively large amounts of 2-phenethylamine in their urine [34, 35].
In forensic toxicology 2-phenethylamine has been encountered as a putrefactive 
product which interferes with drug determination [36]. Oliver found that 2- 
phenethylamine was the most frequently encountered putrefactive base and he 
found that it was impossible to determine the degree to which it occurs with time 
or predict any pattern of occurrence for the other compounds [37].
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Kaempe showed that 2-phenethylamine within the wavelength range of 200-350 
nm at both acid and alkaline pH displays ultraviolet absorption curves similar to 
those of amphetamine and dextropropoxyphene [20]. It can interfere with the 
separation and detection of amphetamine by gas chromatography [37],
Tyramine
Tyramine [2-p-hydroxyphenylethylamine] is an endogenous putrefactive amine 
formed by decarboxylation of the amino acid tyrosine, [20], Figure 3. Tyramine is 
sympathomimetic amine found in cheese, fermented food and red wine [38, 39]. 
Elevated plasma levels of tyramine have been reported in patients with hepatic 
encephalopathy and liver cirrhosis [40].
Tyramine was encountered as an endogenous basic compound which appeared at 
seven days in macerated human liver left in an open jar [41]. Also tyramine has 
been identified in a one month old blood sample [37]. A high concentration of up 
to 500ug of tyramine was found in 50g of putrefied liver tissue sample [42]. The 
concentration of tyramine was shown to be independent of the state of the tissue 
(whole or minced) and of the place where the organ was kept [in the cadaver or in 
a glass tube at 4-5°C. Its concentration was not significantly different in 
individuals dying during the warm season from those dying at other times. 
Kaempe also noticed that Tyramine occurred more frequently and in higher 
concentrations after fairly long storage of the specimen [43]. Tyramine 
concentrations ranging from 3 to 10 ug per lg  of liver have not been noticed 
until
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HO D
COOH
c h 2-c h -n h 2
Tyrosine
decarboxylation
H O  \ C /  c h 2 'CH2'N H 2
Tyramine
Figure 3. The decomposition of Tyrosine during the
Putrefactive process to produce Tyramine.
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after storage for 14 days at 4-5°C. Tyramine was found in 25% of the specimens, 
stored at -18°C for 18 months but at low concentrations of about 0.4 ug per gram of 
liver. Using polarographic methods for the determination of morphine in a 
putrefied specimen, the presence of tyramine in the sample at 10 ug /gm  gave a 
false positive morphine concentration of 1.7 ug/gm , [20].
Tryptamine
Tryptamine [3-(2-aminoethyl) indole] is a decarboxylation product of the amino 
acid tryptophan [31]. Its structural formula can be seen in Figure 4. Tryptamine 
metabolites in human 5-hydroxytryptamine (5-HT), 5-hydroxyindole acetic acid (5- 
HIAA) and indole acetic acid (IAA) are important in diagnosis of pathological 
phenomena such as depression, carcinoid syndrome and essential hypertension 
[44].
Kaempe noticed that tryptamine interfered with the spectrophotometric estimation 
of ordinarily occurring alkaloids [43]. In a later study he found that tryptamine 
extracted with non-acid drugs from a strong alkaline solution displayed the 
ultraviolet absorption characteristics typical of Indole in aqueous acidic extracts 
[20]. Others [45] found that tryptamine interfered with desipramine determination 
in blood using gas chromatography. Oliver detected the presence of low 
concentrations of tryptamine in human tissue after putrefaction for 12 days at 21°C 
[28]. Stevens found that tryptamine caused serious distortion of the ultraviolet 
spectra of some drugs and therefore tryptamine required to be separated from the 
drug [41].
Q
‘N ‘
H
COOH
c h 2-c h -n h 2
Tryptophan
decarboxylation
.0.
'N '
H
c h 2-c h 2-n h 2
Tryptamine
Figure 4. The decomposition of Tryptophan during the
putrefactive process to produce Tryptamine.
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2.2 PUTREFACTION EFFECT ON DRUGS
2.2.1 Introduction
The effect of various stages of putrefaction on drug concentrations in autopsy 
specimens is largely unknown. Attempts to study this problem date back to 1942. 
The early studies are to be considered unreliable because of the poor sensitivity of 
the methods used. Meaningful quantitative methods were not produced until the
mid 1950's.
In one study, liver from humans who had died from barbiturate poisoning was 
allowed to putrefy in air for three months. Another portion of liver was fixed in 
formalin embalming fluid. The barbiturates were analysed by ultraviolet and 
paper chromatography. Unchanged barbiturates were recoverable from the liver 
after three months of putrefaction and after five-and-a-half months from liver fixed 
in formalin [23].
In a report of a fatal intoxication with chlorpromazine, putrefaction was shown to 
influence the toxicological analysis. A non-refrigerated blood sample analysed 
after six months showed a negative result, while at the time of death it showed a 
fatal dose concentration [46]. In this work nothing was mentioned about the 
detection of putrefaction products. Post-mortem changes in drugs of abuse like 
methamphetamine and amphetamine have been investigated [47]. The study 
showed a marked increase of amphetamine concentration in the liver samples after 
one month. This remained high at the end of a two year interval where the 
samples were stored in a sealed container. Methylamphetamine concentration in 
the muscle after one month of storage increased by about 4.5 times. In skin the 
increase was about 2.5 times over the initial level. This rapid increase could be
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explained in terms of the weight decrease due to the loss of water in the samples 
when preserved in open air.
In a study on dogs' blood, the effect of temperature on putrefaction and subsequent 
barbiturate determination was investigated. A remarkable difference between 
specimens kept in the refrigerator at 4°C and those affected by the onset of 
putrefaction at room temperature was observed. Also, there was a remarkable 
difference between specimens preserved under the same ambient conditions but in 
different containers, [48, 49]. The influence of putrefaction changes on the 
determination of the herbicide paraquat, showed a decrease in paraquat recovered 
from the stomach with time after death [50].
The post-mortem stability of some benzodiazepines has been studied over 90 days 
in blood and tissues at two different temperatures, 4°C and 25°C [51]. It was 
found that diazepam, flurazepam and N-l-desalkylflurazepam were stable when 
stored in blood at room temperature, while chlordiazepoxide, norchlordiazepoxide 
and nordiazepam were found to be unstable under similar storage conditions for 
both blood and tissues. No reference was made to the presence of putrefactive 
products or their interferences with the benzodiazepine determinations.
The most recent study [52] was undertaken to examine the stability of some 
antiepileptic drugs, benzodiazepines, carbon monoxide and cyanide in formalin- 
fixed tissues and formalin-blood solutions at toxic concentrations of the drugs. The 
study showed that the drugs can be measured in the samples up to 30 days after 
this treatment. The analysis for cyanide and carboxyhaemoglobin was 
significantly impaired in the presence of formaldehyde.
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The behaviour of 56 drugs and drug-related compounds containing various 
molecular structures in putrefied human liver has been investigated [41]. The 
samples were placed in an open shed to permit the access of blow-flies. Drugs 
containing nitro groups, N-oxides and oximes were found to be liable to 
putrefactive decomposition within 3 to 14 days, while the stability of other drugs 
indicated that there was a general resistance of carbon-oxygen, carbon-nitrogen, 
nitrogen-hydrogen and sulphur-oxygen bonds to change. Putrefactive amines 
showed some interferences with the morphine determination. Tyramine and 2- 
phenethylamine were encountered as putrefactive amines in the later stages of 
putrefaction.
By the mid-60's early 70's there was a growing interest on studying the occurrence 
of putrefactive products in putrefied human tissues. Kaempe listed the main 
interfering substances with a description of some important characteristics such as 
infrared and ultraviolet spectra [20]. Oliver and Smith investigated the 
interference of sixteen putrefactive bases in the analysis of biological materials for 
drugs. They found that 2-phenethylamine was the most frequently encountered 
putrefactive base. They could not however, predict the degree to which it would 
occur with time or predict the occurrence of the other compounds. Analytical data 
for the identification of sixteen putrefactive bases was presented. This included 
gas chromatography retention times, thin layer chromatography Rf values and 
ultraviolet spectral data [37].
Williams studied the interfering substances that are extractable from aqueous 
biological fluids with organic solvents. In addition to the above he used the 
technique of infrared spectroscopy and mass spectrometry [22].
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Fulton discussed the formation and occurrence of putrefactive bases and pointed 
out that many were the products of the decarboxylation of amino acids [31]. Most 
of the decomposition products of amino acids are water soluble. The 
decomposition products of just three amino acids, tyrosine, phenylalanine and 
tryptophan seem to be predominant among the lists of interfering substances.
2.2.2 - Acidic Drugs
2.2.2.1 - Anticonvulsants
In the literature, there is little data regarding the influence of putrefaction on the 
determination of acidic drugs. Most of the information available is focused on 
barbiturates [23, 48, 53], and the findings are contradictory. Barbiturates were 
found to be stable in putrefied liver after 3 months of putrefaction [23]. Other 
studies concluded that putrefaction increases the concentration of barbiturates in 
blood, and liver when stored at room temperature due to protein-bound drugs 
being released [53,54].
Coutselinis and Kiaris found a fluctuation in the barbiturate concentration of the 
specimens kept in the refrigerator. They observed, however, a reduction in the 
concentration of barbiturates in putrefied blood specimens kept at room 
temperature for up to two months [48].
The above contradictory findings with barbiturates was from the use of ultraviolet 
spectrometry to measure the drugs in aqueous solution following extraction from
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putrefied blood or tissue into organic solvents. This technique is no longer in use 
in the modern forensic toxicology laboratory for either quantitative or qualitative 
analysis of barbiturates since it is not conclusive [53].
A gas chromatograph was used for qualitative and quantitative determination of 
barbiturates in putrefied blood and tissues [55] following a multistep extraction of 
barbiturates from decomposed tissue as a clean up procedure. Still, it was found 
that the resulting co-extraction of interfering products rendered the quantitation of 
these drugs by GC impossible. When a slightly more polar solvent was used for 
the initial extraction, the problem was alleviated. In blood and liver greater than 
75% of the drugs were detected at the end of the two-to-three month period when 
stored at 4°C and 25°C.
In clinical use phenytoin and carbamazepine, as anticonvulsant drugs, are as 
important as barbiturates. Phenytoin has been studied to determine its stability in 
stored serum controls and in samples shipped through the mail. It was observed 
that a 20% decrease in plasma phenytoin concentration occurred when stored at 
4°C for eight weeks [56]. Schafer reported no decrease in the concentration of 
phenytoin when stored in serum at 4°C for about 12 weeks [57]. Phenytoin and 
other antiepileptic drugs were found to be stable in plasma when stored at room 
temperature (without being exposed to light) for at least six months [58].
There is no data available regarding the effect of putrefaction products on the 
phenytoin determinations or its stability in post-mortem blood.
Carbamazepine has been mentioned in only one study by Stevens. He studied the 
stability of carbamazepine in putrefied human liver stored for just 13 days at 25°C. 
The study showed carbamazepine to be stable in aqueous control solutions and in
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the liver macerates after 13 days of storage at 25°C [41]. There is no record in the 
literature on the effect of putrefactive products on carbamazepine determination or 
on the stability of the drug for a longer period of time or on the effect of other 
storage conditions, 5°C - 20°C on its stability. The stability of the drug in post­
mortem blood has not been reported.
2.2.3 Non-acid drugs
2.2.3.1 Benzodiazepines
The stability of benzodiazepines in putrefied post-mortem specimens was studied 
in the 1970's [59]. The investigation of flurazepam, diazepam, desmethyl- 
diazepam and chlordiazepoxide stored at 4°C for up to 120 days found that all 
were relatively stable except for chlordiazepoxide. This drug was shown to 
decompose rapidly in whole blood. It was stable in serum or plasma.
A study on the stability of four benzodiazepines in putrefying human liver 
macerates left to putrefy in the open air for 14 days with a shedroof to afford some 
protection against the weather, showed that flurazepam, lorazepam and diazepam 
were found to be stable while chlordiazepoxide, chlorazepam, nitrazepam and 
demoxepam were liable to decomposition, [41].
Desoxychlordiazepoxide and desmethyldiazepam were found in liver homogenate 
spiked with chlordiazepoxide and stored at 4°C for up to 20 days [60]. A study on
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diazepam  stability showed the plasma diazepam to be stable when stored at -20°C 
and 5 C up to one year and eight months respectively [61]. In a study of the effect 
of putrefaction products on the stability of benzodiazepines in blood and tissues at 
two storage conditions 4°C and 25°C over several months it was claimed that 
diazepam, flurazepam and N-l-desalkylflurazepam were stable when stored in 
blood at room temperature, while chlorodiazepoxide, norchlordiazepoxide and 
nordiazepam  were found to be unstable under similar storage conditions in both 
tissue and blood, [51]. These studies were in agreement regarding the stability of 
benzodiazepines over the different storage conditions and the specimen types 
'blood and tissue'. Studies on the effect of putrefaction on temazepam and its 
determination have not been recorded. Temazepam is an im portant drug to study 
since injectable temazepam has become a street drug of choice, particularly in 
Scotland [62].
2.2.3.2 Opiates
Aspects of the medical use of the opiate drugs have followed a typical life-cycle. 
Each new drug is initially hailed as a potent non-addictive analgesic agent which 
can safely be made available to medical practices and may even be useful in the 
treatment of pre-existing opiate addiction. Such was the history of morphine and 
heroin.
The effect of putrefaction on the determination and stability of morphine has not 
been thoroughly investigated. Morphine may be converted to pseudomorphine in 
cadavers and be found as such on exhumation, [63]. Morphine was found to be
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stable in macerated human liver when stored in sealed containers for a short 
period of time at ambient temperatures, [41]. A false positive morphine in 
putrefied tissue due to the presence of putrefactive products has been reported 
[53], thin layer chromatography (TLC) was used to purify the extract. Morphine 
was detected in the putrefied liver by GC after this purification. Nothing was 
mentioned about the storage temperature and the time elapsed before the analysis 
of the liver specimens. No knowledge could be gained regarding the stability of 
morphine or qualitative and quantitative of interfering substances in the specimen.
Buprenorphine is often prescribed for the treatment of chronic post-operative pain 
and for terminal cancer patients, [64] and it has also been used for the treatment of 
heroin addicts, [65]. Buprenorphine is a recently marketed opiate. Most of the 
published work focuses on quantitative and qualitative analysis of buprenorphine 
by radioimmunoassay, [66, 67] or the study of its pharmacokinetics [68, 69]. No 
data is available regarding the effect of putrefaction on buprenorphine 
determination or its stability in putrefied post-mortem specimens. Therefore 
buprenorphine has been selected with the group of drugs chosen to be studied in 
this work.
2.3 DRUGS UNDER INVESTIGATION
2.3.1 - Anticonvulsant
Introduction
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Anticonvulsant drugs are used chiefly in the treatment of various types of 
epilepsy. Epilepsy has been described as a chronic condition characterised by 
more or less frequent recurrence of seizures, associated with loss of or disturbance 
of consciousness and usually with convulsive or other body movement and 
correlated with an abnormal electro-encephalogram [70].
Over the centuries, many substances and concoctions have been used for the 
control of epilepsy, but the best early hope was offered by the recognition of 
bromide's antiepileptic properties in the mid-1800's and by the synthesis and 
clinical application of phenobarbitone in the 1912. Both substances were generally 
considered valuable remedies, but were not ideal. The search for better 
antiepileptic drugs continued into late nineteenth and early twentieth centuries, 
leading to the discovery of phenytoin, carbamazepine and other drugs.
Phenobarbitone
Phenobarbitone is a 5,5 substituted barbituric acid, 5-ethyl-5-phenyl barbituric 
acid. The well known structural formula is shown in Figure 5. It was introduced 
into the treatment of epilepsy in 1912 and was the first effective organic 
antiepileptic agent. Most other antiepileptic drugs were later developed as 
structural variations of phenobarbitone.
Most barbiturates have anticonvulsant properties. However, the capacity of some 
of these agents such as phenobarbitone to exert maximal anticonvulsant action at
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Figure 5. Chemical Structure of Phenobarbitone.
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doses below those required for hypnosis, determines their clinical usefulness as 
antiepileptics.
Phenobarbitone is an effective agent for generalised tonic-clonic (grand mal) and 
cortical focal seizures. During chronic medication in adults, plasma concentrations 
of phenobarbitone average lOug/ml following a daily dose of 1 m g/kg. Plasma 
concentrations of 10 to 25 ug/m l are usually recommended for the control of 
epilepsy [71] while the lethal concentration in blood is 75 ug /m l [72]. 
Phenobarbitone elimination rates are very low compared to other antiepileptic 
drugs. The major metabolites are N-glucopyranosylphenobarbitone and 4- 
hydroxyphenobarbitone [73]. The elimination rate is influenced by urine flow and 
urinary pH.
Carbamazepine
Carbamazepine, 5H-dibenz(b,f)azepine-5-carboxamide, was developed in the 
laboratories of J.R. Geigy AG (Basel, Switzerland) in the late 1950's. The compound 
was introduced as an antiepileptic drug in Europe and Australia in the early 1960's 
[74], and its anticonvulsant properties were demonstrated in 1963 [75]. 
Carbamazepine behaves as a neutral lipophilic substance. Carbamazepine is 
related chemically to the tricyclic antidepressants such as imipramine and 
clomipramine. It is a derivative of iminostilbene with a carbamyl group at the 5 
position; this moiety is essential for potent antiepileptic activity. The structural 
formula of carbamazepine is shown in Figure 6. After oral administration of 600
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Figure 6. Chemical Structure of Carbamazepine.
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to 1,200 m g/day  the plasma concentration of carbamazepine and its active 
metabolite, carbamazepine 10,11, epoxide, may vary from 2 to 20 ug /m l without a 
clear relationship between the concentration of the parent compound and the 
metabolite [76]. Other metabolites like trans 10,11,dihydro-10,11-dihydroxy 
carbamazepine, and glucuronic acid conjugation also occur, [77].
Phenytoin
Phenytoin is a weak organic acid. Its generic name is 5,5 diphenylhydantoin. It 
has a chemical structure as shown in Figure 7. It is a primary drug for all types of 
epilepsy except absence seizures [71]. Phenytoin was first synthesized in 1908 by 
Biltz but its anticonvulsant activity was not discovered until 1938. Phenytoin was 
the product of a search among non sedative structural relatives of phenobarbitone 
for agent capable of suppressing electroshock convulsion in laboratory animals. It 
was first introduced for the treatment of epilepsy in 1938 [78]. Phenytoin is still 
one of the most widely used anticonvulsants, since it can produce effective 
anticonvulsant action without significant sedation [79]. Following oral doses of 
100 mg three times a day, maximum steady-state plasma concentrations of 3.4 to 
30.5 ug /m l (mean 11.8) were reported [80], while fatalities have been associated 
with blood concentrations greater than 70 ug/m l [81]. Phenytoin is partially 
metabolized and partially excreted unchanged in the urine. About 4% of the dose 
is excreted in the urine unchanged and the excretion of unchanged drug is 
increased when the urine is alkaline [82].
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Figure 7. Chemical Structure of Phenytoin.
2.3.2.- Benzodiazepines 
Introduction
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The term benzodiazepine refers to the position of the structure composed of a 
benzene ring (A) fused to a seven-membered diazepine ring (B). The structure of 
benzodiazepines are illustrated in Figure 8 with the structure of temazepam. 
Benzodiazepines have been widely used as tranquillisers, anti-anxietics, sleep 
inducers, antiepileptic and hypnotics since the early 1960's. It also can show 
amnesiac action. More than 300 benzodiazepines have been synthesized and 25 are 
in clinical use in various parts of the world [83]. Prescribing rates of 
benzodiazepines increased tenfold from the age of 20 to 70 years and were higher 
in women than in men, [84].
Temazepam
Temazepam is 7-chloro-l ,3-dihydro-3-hydroxy-l -methyl-5-phenyl-2H-l ,4-benzo- 
diazepin-2-one. The structural formula is shown in Figure 8.
Temazepam is used as a hypnotic in the short term management of insomnia in 
doses of 10 to 30 mg and in premedication before minor surgical or investigative
procedures [85].
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Figure 8. Chemical Structure of Temazepam(A and B represent
the core Benzodiazepine).
- 42 -
Therapeutic concentrations 0.22 to 0.75 ug/m l (mean 0.5) were attained in about 
two hours. After a single oral dose of 30 mg [86], about 97% of Temazepam binds 
to protein. About 80% of a dose is excreted as the glucuronic acid conjugate. 
Temazepam has become a street drug of choice [62].
2.3.3 Opiates and Opium 
Introduction
Opium, the dried, compressed resin from the seed case of the poppy Papaver 
somniferum (papaveraceae), has been recognised as a pain-killer for over 4,000 
years. The word opium itself derived from the Greek name of juice of the poppy. 
Opium contains more than 20 distinct alkaloids. In 1803, a German chemist W.W. 
Serturner isolated from opium, an alkaloid which he named morphine. The 
discovery of other alkaloids in opium quickly followed that of morphine; codeine 
by Robiquet in 1832, papaverine by Merck in 1848 [87]. By the middle of the 
nineteenth century the use of pure alkaloids began to spread throughout the 
medical world. The problem of addiction to opioids stimulated a search for potent 
analgesics that would be free of the potential to produce addiction. This led to the 
discovery of new drugs such as the relatively pure antagonist naloxone and 
compounds with mixed actions (butophanol and buprenorphine). Such drugs 
helped in understanding the action of the opioids through the discovery of opioid
receptors.
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Drug abuse as a significant social problem has only existed in Britain since the 
early 1960 s and drug use in Britain until then was exceptional only for its trivial 
extent [88].
M orphine
Morphine is the principle alkaloid of opium. Its structure shown in Figure 9. 
Morphine acts as an agonist with steriospecific and saturable binding sites in the 
brain and other tissues [87]. These sites are widely but unevenly distributed 
throughout the central nervous system. It is believed that morphine, its analogs 
and antagonists occupy the sites normally occupied by B-endorphine and the 
enkephalins. These are endogenous peptides which act as neurotransmitters or 
modulators of neurotransmission.
Morphine and related opioids produce their major effect on the CNS and the 
bowel. Morphine produces analgesia, drowsiness, changes in mood, respiratory 
depression, nausea, vomiting and alteration of the endocrine and autonomic 
nervous systems [87]. Other effects are dilatation of the pupils and dilation of the 
surface capillaries causing flushes. Toxic effects follow from therapeutic effects. 
An increase respiratory depression can lead to coma and so to death. An 
increase in smooth muscle relaxation can then lead to muscle spasm and 
convulsions.
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Figure 9. Chemical Structure of Morphine.
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Secondary effects from the drug include pneumonia through the anti-tussive effect 
of morphine coupled with dangers of inhalation of gastric contents. Morphine 
levels in the body fluids can be used to indicate whether the drug is present in 
therapeutic or harmful quantities. Peak levels of morphine of lu g /m l in plasma 
have been reported following bolus doses prior to surgery [89]. The therapeutic 
range has been reported as 0.04 to 0.5 ug/m l, [81], and as 0.01 to 0.07 ug/m l. [63]. 
This wide range (0.01 to 1 ug/m l overall) is due to the fact that the body can 
develop tolerance to morphine. Tolerance leads to decreased intensity of the 
pharmacological effects and shortened duration of action, therefore drug addicts 
require increased doses for the same effect. A habitual morphine user can take 20- 
30 times the therapeutic dose. This makes the interpretation of blood 
concentrations of morphine difficult. Morphine 3 and 6-glucuronides are the major 
metabolites and accounts for about 65 to 70% [63].
Buprenorphine
This is a semi-synthetic, highly lipophilic opioid derived from thebaine. Its 
structural formula is shown in Figure 10. It is 25 to 50 times more potent than 
morphine. Buprenorphine is a relatively new drug with mixed agonist and 
antagonist opiate action. After sublingual administration of 0.4 - 0.6 mg. 
buprenorphine concentration is in the range - 1 - 4 ng/m l after about two hours 
[90]. Little is known about the toxicity of buprenorphine in man. The median 
lethal single doses (LD 50's) for buprenorphine in mice were 24 - 29 m g/kg, 90 - 97 
m g /kg  and 260 - 261 m g/kg for intravenous, intraperitoneal and oral 
administration respectively [91]. Buprenorphine shows a much lower physical
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dependence liability than morphine [91]. However, buprenorphine does show 
withdrawal symptoms, albeit milder than those seen in other opiate withdrawal. 
Recently, buprenorphine was reported to be abused [92].
About 96% of buprenorphine circulating in blood at therapeutic levels is bound to 
plasma protein [93]. Detoxification of buprenorphine occurs by conversion to 
water soluble molecules through conjugation with glucuronic acid to 
buprenorphine 3-glucuronide and N-desalkylbuprenorphine [91].
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Figure 10. Chemical Structure of Buprenorphine.
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2.4 - CHROMATOGRAPHIC ANALYSTS
2.4.1. Introduction
The term chromatography has been adopted universally to cover the 'science of 
separation.' More accurately the term embraces techniques which enable samples 
of chemical mixtures to be separated by exploiting the difference in their physical 
or chemical properties. The separation of compounds is achieved as a result of a 
partition between two different phases, one mobile phase and the other stationary 
[94]. Each compound in the mixture partitions to a different degree between the 
two phases. The longer this process is allowed to continue, the greater the 
separation achieved until the components emerge from the bed one by one.
There are many forms of chromatography available. Two forms of 
chromatography will be discussed here; HPLC (high performance liquid 
chromatography), and GLC (gas liquid chromatography). The chromatogram 
obtained in both systems shown in Figure 11 contains analytical data for the 
components of a mixture. Qualitative information appears in the characteristic 
retention time of each compound.
Quantitative information is contained in the peak height or area. A chromatograph 
is also a valuable measure of the performance efficiency of the chromatographic 
system which produced it. The retention time, or retention volume in HPLC is a 
characteristic of a given sample/chromatographic system combination expressed
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Time
Figure 11. Schematic diagram of GC and HPLC chromatogram showing the 
measurable parameters.
Tq = elution time of the unretained solute
Ta and Tj, = retention time of peaks a and b,
Wa and = peak width at half height of peak a and b
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in absolute terms. When it is related to a non-retained sample, usually solvent, it is 
called the relative partition coefficient or capacity factor (K'):
_ (^ a )" (To) Equation 1
(To)
where U  and are as defined in Figure 11.
If the peaks are sufficiently symmetrical, and if their area ratio is greater than 0.5, 
then the resolution (R) is considered adequate if:
^  _ tms (b) - tms (a) >1 Equation 2
b 0.5(b) + b 0.5 (a)
tms: total retention time; residence time of sample substance in the mobile and the 
stationary phase.
The separation factor rab given by:
Kbrab = = a  Equation 3
Where K'a and K'b are the capacity factor for components a and b respectively and
a  is the selectivity factor.
The column efficiency is measured by (H), the 'height equivalent to a theoretical 
plate (HETP)
H = column length Equation 4
N
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Where N is the number of theoretical plates, which measure the column efficiency 
in producing narrow peaks as is given by:
2
N = 5.54 Equation 5
The linear velocity of the mobile phase (U) is given by:
U = column length Equation 6
These parameters can be calculated and used as a guide to the operation of the 
column and for determining the changes that can be made to achieve optimum 
performance for a given analysis. They are also dependent on the specific mobile 
phase and stationary phase used and the physical characteristic of the column. The 
column parameters are described in the Van Deemter equation
Where U is the flow rate of the mobile phase and A, B and C are constants which 
are related to the physical processes occurring within the column, a full discussion 
of the equation is given in the literature [95, 96].
H = A + B/U + CU Equation 7
2.4.2. - Gas Chrom atography
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Gas chromatography is analogous to other forms of chromatography. The 
separation is performed on a column containing the stationary phase, which is 
maintained at a defined temperature in an oven and has a constant flow of carrier 
gas. When a mixture of substances is injected at the inlet on to the start of the 
column, molecules with the greatest affinity for the stationary phase take more 
time to reach the detector. The detector produces a signal dependent on the mass 
of substance passing through it and this signal is processed and fed to a chart 
recorded or an integrator. Each substance passing through the column will have a 
characteristic retention time. In order to be able to communicate gas 
chromatographic retention data between laboratories independent of the 
instrument used, the concept of Retention Index (RI) has been introduced to GC 
analysis. The Retention Index is a measure of retention times in relation to 
standards that are analysed under the same conditions.
The first RI system developed and still widely used, is the Kovats Retention Index 
(RIj^). In this system, normal alkanes are assigned and RIj^ value of 100 x carbon 
number. For isothermal operation values are calculated according to the following 
expression:
log ti' - log t’n + 100 n Equation 8
lo8 t'n + 1 - lo8 1 n
Where W = corrected retention time of sample peak [h - tairh t'n = corrected 
retention time of normal alkane with carbon number N, which elutes before the 
sample peak, and t'n+ |  = corrected retention time of normal alkane with normal
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carbon number n + 1, which eluted after the sample peak. Full discussion and the 
graphical representation of Kovats Retention Index values is given in the literature 
[95, 96].
Gas chromatography may be divided into gas-solid chromatography (GSC) and 
gas liquid chromatography (GLC). Only the GLC will be discussed.
2.4.2.1 - Gas Liquid Chromatography
The stationary phase in GLC is liquid coated on a support material. The support 
material should have a very large surface area and uniform particle size, free from 
fines, and should be mechanically robust and chemically inert.
The most common support particles are formed from diatomites. The stationary 
phase is selected to suit the analysis required from non-polar, moderately polar 
and polar liquid phases such as SE-30, OV-17 and OV-225 respectively. Higher 
efficiency and lower column bleed is obtained with a low loading of the stationary 
phase (weight percent of the support material), in the range of 1 - 8%
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2.4.2.2 - GC Columns
Two main column types are in common use - packed and capillary columns. The 
packed columns have, in general, low efficiency and separating capabilities, but 
have a higher capacity for the sample material. Capillary columns are available in 
glass, stainless steel and fused silica. The first two are not frequently used now 
due to the fragility of the glass and the presence of active sites on the stainless steel. 
The coating of the stationary liquid phase inside the capillary column can be in 
three forms: wall coated open tubular (WCOT), support coated open tubular 
(SCOT) and porous-layer open tubular (PLOT).
Chemical bonding of the stationary phase to the column (chemically bonded 
columns) provides stability of the phase and the columns will retain their efficiency 
longer than non-bonded columns.
Fused silica columns are flexible, and with an external coating of polyimide 
polymer, are extremely rugged. Both polar and non-polar stationary phases with 
high efficiency are available. They have superior resolution which can separate 
complex mixtures with narrow peaks, considerably enhancing the detection limit. 
Derivatization of polar compounds and non-volatile compounds might be required 
to convert them to more volatile and easily chromatographed compounds. 
Alcohols and phenols are reacted to form more inert ester, ether or silyl 
derivatives.
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2.4.3 - Gas Chromatography-Mass spectrometry
2.4.3.1 - Introduction
The combination of the gas chromatography with mass spectrometry has resulted 
in an instrument of considerable importance in the field of organic chemistry, 
pharmacology, biochemistry, pollution studies and toxicology. It is now a well- 
established routinely-used technique. In this instrument, the gas chromatography 
provides the separation of compounds and introduces them to mass spectrometry 
through the interface. MS produce ions from a molecule, separates these ions as a 
function of their mass-to-charge (M/Z) ratios and records and displays the relative 
abundance of these ions. Figure 12 shows the basic component of a typical GC-MS 
system.
The relative GC-MS techniques applied during the research work will be discused 
in this thesis. More details of GC-MS are available in references [97,98, 99,100].
2.4.3.2 GC-MS Interface
The gas chromatography element leaving the column at atmospheric pressure 
while the MS ion source operates at 10'^ Torr. So for the direct connection of GC 
and MS the volume or pressure of the carrier gas must be reduced to avoid 
destroying the high vacuum condition. The ideal interface device would remove 
all the chromatographic mobile phase and transfer all the solute to the ion source
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without degrading chromatographic elution. The flow rate of a capillary column is 
in the range of 0.5 - 3 m l/m in. which can be accommodated by the vacuum system 
of the MS while still maintaining a suitable pressure in the ion source. So, it is 
possible to introduce the fused silica column directly into the ion source. All of the 
sample eluted from the GC enters the MS ion source.
2.4.3.3 - Ionization Systems
Mass spectrometry requires that molecules for analysis have first to be ionised. 
The ion source system, Figure 13 incorporates ion lens plates to focus the ion beam 
as well as extracting and accelerating the ions into the analyser. Two types of 
ionization systems are available, namely Electron Impact (El) and Chemical 
Ionization (Cl). Only one type will be discussed (El).
I - Electron Impact
Electron Impact is the most widely used method of ionization. The vaporized 
sample molecules are bombarded with a stream of electrons which will ionize and 
fragment the molecules. The majority of El work has been done at 70 eV, where 
the fragmentation pattern at this relatively high electron energy does not vary 
so much. The excess energy absorbed causes fragmentation of sample
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Figure 13.
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molecules to produce both positive and negative ions which can be represented by 
the following equation:
Positive Ions
Equations 1 0 - 1 3  represent fragmentation of the molecular ions where ABCDt 
represents a radical ion.
A. etc. represents a free radical.
AB+ etc. represents an even-electron ion.
Equation 9 represents the formation of the molecular ion.
Parent molecule ABCD +e~—►ABCDt + 2"e Equation 9 
Equation 10 
Equation 11 
Equation 12 
Equation 13
ABCD+— ► A+ + BCD. or A. +BCD+
— ►AB+ CD. or AB. +CD+ 
— ►ABC* +D. or ABC. + D+ 
AB+ — ►A+ +B or A + B+
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Negative Ions
AB + e"—►A+ + B~ + e“ Equation 14
AB + e-—►A + B' Equation 15
AB + e:—►AB" Equation 16
Equations 14, 15 and 16 represent production of an ion pair, capture of an electron
with dissociation and capture of an electron respectively.
Ions with a life time more than 10“^  sec will be detected intact. Those with very 
short life times, less than 10"^ sec will decompose in the source of the mass 
spectrometer and will not be detected. The ions of intermediate life time 
(10'^-10'6 sec) are accelerated from the source of the mass spectrometry with mass 
(M |) but decompose to a smaller ion of mass (M2 ) before reaching the detector.
2.4.3.4 Ion Separation
After leaving the ion chamber in the source, the ions are accelerated with an 
acceleration potential (V) of about 8Kv into the mass analyser where they are 
separated according to their m /z  ratios by employing a magnetic sector or 
quadrupole filter. The ions follow a path of radius. Ions of different m /z  may be 
brought to focus at the detector by variation of the magnetic field. Further 
discussion of the theory of ion separation is given in references 101, 102.
- 61 -
2.4.3.5 - Ion Detection and Amplification
The vast majority of mass spectrometers use electron multipliers for ion detection 
(EM) which have a fast response and high sensitivity. The other mean of detection 
is a conversion dynode and photomultiplier. The current generated is amplified 
typically by a factor of 10^ the output being recorded by a data handling system.
2.4.3.6 Data analysis
Modern GC-MS systems acquire data by continuous repetitive scanning of the GC 
column eluate. The rate of scanning usually have values in the range of 0.1 -1.5 sec 
per scan. The data system of GC-MS unit is capable of displaying the stored data 
in a number of ways:
I -Reconstructed gas chromatograph
A chromatogram can be reconstructed as components elute from the column by a 
plot of the total ion current stored and summed by the computer for each spectral 
scan. This record is similar to the chromatogram of the GC effluent produced by a 
flame ionization detector (FID).
II - Mass Chromatogram
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When the proper ions are chosen, the use of MC can be very effective for 
identification when obtaining a peak at the correct mass and retention time for a 
specific compound is strong evidence for the presence of that compound in the 
sample. MC is especially useful for rapid surveys of complex GC-MS data.
Ill - Selected Ion Recording
Selected ion recording [SIR] is used for the detection of very low ion abundance. In 
this technique the mass spectrometer is only tuned to a few pre-selected ions.
In SIR practice, a few ions are sequentially monitored. Increased sensitivities of 50 
- 500 for specific compounds are obtained. Amounts lower than lp g  can be 
detected on SIR.
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2.4.4 - High Performance Liquid Chromatography
2.4.4.1 - Reversed-phase chromatography (RP)
RP Chromatography is so named because it behaves in the opposite way to 
Normal Phase Chromatography. The stationary phase is silica chemically bonded 
with organosilanes to give non-polar, hydrophobic surfaces. Solute retention is 
mainly due to hydrophobic interaction between solutes and the 
hydrocarbonaceous stationary surface. Polar mobile phases, usually water with 
miscible organic solvents, are used for elution. Solutes in reversed phase 
chromatography are eluted in order of decreasing polarity (increasing 
hydrophobicity).
The most popular RP packing is C18 octadecylsilane (ODS). The retention of 
solutes usually increases proportionately with the carbon chain length of the 
bonded group under identical HPLC conditions.
Reversed-phase chromatography is the most versatile and most widely used HPLC 
mode. Some additives can be used with the mobile phase to give special 
selectivities to produce a new RP concept like ion pair [IP], ion suppression [IS], 
etc.
RP columns are stable in the pH range [2 - 7] and at elevated temperatures. The 
classification of RP chromatography is discussed in references [103,104].
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2.4.4.2 - Normal-phase (NP) chromatography
Adsorption chromatography is also referred to as normal-phase (NP). NP 
chromatography involves interaction between adsorbent, usually silica, and the 
solute and solvent molecules in solution. The process considered as competition 
between the solute and solvent molecules for adsorption sites on the solid surface. 
The interaction of solute and solvent molecules to the surface of the column 
packing may be considered as a dynamic equilibrium. The mechanism of 
adsorption chromatography and the dynamic equilibrium between mobile phase 
and the adsorptive surface are shown in Figures 14,15.
The solutes are eluted from normal-phase columns in order of increasing polarity 
and retention decreases with increasing solvent polarity. NP chromatography is 
best for the separation of compounds having high solubility in organic solvent, or 
have low stability or aggregation problems in aqueous mobile phases, (lipid) to 
separate isomers and to separate compounds are difficult to retain on reversed 
phase columns. A full discussion of normal phase chromatography theory and its 
application in forensic science is discussed in reference [105].
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2.5 EXTRACTION METHODS
2.5.1. - Solid Phase Extraction
2.5.1.1 - Introduction
Over the past decade, sorbent extraction has emerged as a powerful tool for 
chemical isolation and purification in a broad range of applications: 
pharmaceutical, fine chemical, biomedical, food analysis, organic synthesis, 
environmental and many others [106].
Sorbent extraction is a physical extraction process that involves a liquid and a solid 
phase. In sorbent extraction the solid phase has a greater attraction for the isolate 
than the solvent in which the isolate is dissolved. As the sample solution passes 
through the sorbent bed, the isolate concentrates on this surface, while the other 
sample components pass through the bed. Very selective extractions resulting in 
highly purified and concentrated isolates can be achieved by choosing sorbents 
with an attraction for the isolate but not for the other sample components.
Sorbents are formed by reaction of organosilanes with activated silica. The 
product is a sorbent with the functional group of the organosilane attached to the 
silica substrate through a silyl ether linkage. The product is stable within a pH 
range of approximately 2 to 7.5. Above pH = 7.5 the silica substrate is susceptible 
to dissolution in aqueous solutions. Below pH 2.0 the silyl ether linkage is labile 
and the functional groups on the surface will begin to cleave. In practice bonded 
silicas may be used for sorbent extractions in pH range 1 to 14 since degradation of 
the sorbent is a finite process and sorbents are typically exposed to solvents for 
only short periods of time. Bonded silica sorbents are rigid materials that do not 
shrink or swell in different solvents, unlike many polystyrene-based resins. For
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this reason, bonded silicas equilibrate rapidly to new solvent conditions. This 
allows complex extraction procedures involving many different solvent changes to 
be performed rapidly. The bonded silica sorbents have a particle size distribution 
of 15 - 100 microns. The nominal porosity of most of the sorbents is 60 angstroms, 
adequate for compounds with molecular weights up to approximately 15000 to 
pass through the sorbent.
At the microscopic level, a silica sorbent resembles a forest of functional groups 
anchored through a root system of siloxane bridges. These bonds and the silicas 
beneath them are responsible for two important properties of silica sorbents: the 
need for solvation of the materials and the potential for secondary interactions 
with isolate molecules. Therefore solvation of a sorbent is necessary before the 
sorbent will interact reproducibly with the isolate. Solvation is a wetting of the 
sorbent creating an environment suitable to the isolate. Retention is accomplished 
by passing several bed volumes of a suitable solvent. The adsorptive properties of 
bonded silica are due principally to the functional groups bonded to the silica 
substrate. Any unbonded silanols remaining on the surface are also a contributory 
factor.
Interaction between the substrate and isolate molecules is called secondary 
interaction. It may be the predominant active property of a sorbent. As a 
particular sample is passed through a sorbent bed, compounds present in the 
sample will either pass through the sorbent or be retained on the sorbent due to an 
attraction which exists between the sorbent and the isolate molecules, causing the 
isolate to be immobilized; this phenomenon is called "retention" while the process 
by which an isolate is removed from a sorbent bed in which it has been retained is 
called "elution."
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The capacity of a given sorbent is defined as the total mass of a strongly retained 
isolate that can be retained by a given mass of the sorbent under optimum 
conditions. Capacity values range from less than 1% to 5% of sorbent mass that is, 
100 mg of sorbent might retain as much as 5 mg of a strongly retained isolate.
The selectivity of the sorbent is the ability of the sorbent to discriminate between 
the isolate and all other matrix components. It is a function of three parameters: 
the chemical structure of the isolate, the properties of the sorbent and the 
composition of the sample matrix. Maximum selectivity is achieved when a 
sorbent is chosen that interacts through isolate functional groups that are not 
common to other matrix components.
2.5.1.2 -Non-Polar Interactions
Non-polar interactions occur between the carbon-hydrogen bonds of the sorbent 
functional groups and the carbon-hydrogen bonds of the isolate. Most of the 
organic compounds containing alkyl, aromatic alicyclic or other functional groups 
with significant hydrogen structure will exhibit non-polar interaction.
Non-polar interaction is useful when isolates vary widely in chemical structure. In 
general, non-polar sorbent are not very selective since most matrix components 
tend to have some degree of non-polar character. Non-polar interaction can be 
very strong with non-polar isolates of high molecular weight. In which case, 
isolates are often difficult to remove.
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Buffer or aqueous matrices of high ionic strength may promote isolate elution by 
reducing the sorbent functional groups interaction with the isolate. The effect of 
this can be reduced by lowering the ionic strength of the sample through dilution 
and equilibrating the sorbent with organic buffers only. The non-polar interactions 
between the isolate and the sorbent are best disrupted by solvents having some 
degree of non-polar character.
Octadecyl silane 'CIS*
Octadecyl silane in the most retentive of all sorbents for isolates being retained by 
non-polar mechanism. It is the most widely used sorbent for non-polar 
interactions. It is very effective for isolating groups of compounds that are 
dissimilar in structure, therefore C18 is regarded as the least selective sorbent. 
Since it retains almost everything from aqueous matrices, very non-polar 
compounds are difficult to remove from this sorbent, conversely C18 does not 
retain certain very polar molecules such as carbohydrates.
2.5.1.3 Polar-interactions
Polar interactions are exhibited by many different sorbents and functional groups 
on isolates. The most characteristic molecules isolated by this type of sorbent are 
those containing dipoles. This includes most groups containing hetero-atoms as
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well as functional groups with resonance properties, for example, aromatic rings. 
Polar interactions are very flexible because so many functional groups exhibit polar 
interactions (dipole/dipole, induced dipole/dipole, pi-bonding and a variety of 
other interactions) in which the distribution of electrons between individual atoms 
in the functional groups is unequal, causing positive and negative polarisations. 
Retention of isolates by polar interactions is facilitated by non-polar solvents while 
elution of isolates from polar sorbents is facilitated by polar solvents and high ionic 
strength.
Polar interactions are very useful for highly selective separation of molecules 
having similar structures.
Activated Silica (SI)
Unbonded activated silica is fairly acidic and is generally regarded as the most 
polar sorbent available. SI sorbent in known to have a strong tendency to adsorb 
water and other polar solvents such as methanol. SI is one of the best sorbent for 
selectively separating isolates of very similar structure.
Aminopropyl (NFU)
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NH 2  is a very polar sorbent with a capability of exhibiting all possible interactions. 
NH 2  is a strong hydrogen bonder that also can function as an anion exchanger. 
Since the PKa of the NH 2  sorbent is 9.8 at any pH below 9.8 NH 2  is positively 
charged. Although NH 2  has been used for non-polar isolations from polar 
solvents, its extreme polarity makes its non-polar character less significant than its 
other properties. NH 2  is excellent for the separation of structural isomers.
2.5.1.4 - Ion-Exchange Interactions
This interaction occurs between an isolate molecule carrying a charge (either 
positive or negative) and a sorbent carrying a charge opposite to that of the isolate. 
Groups of isolates and sorbents that can exhibit ionic properties divide into two 
classes: cationic (positively charged) include primary, secondary, tertiary amines, 
etc. Anionic (negatively charged) include carboxylic, sulfonic, etc.
The ionic strength of solvent/matrix and the PKa of isolate and sorbent play an 
important role in retention and elution of isolates by ion-exchange interactions.
Carboxymethyl (CBA)
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One of the most useful characteristics of CBA is its weak cation exchange 
properties. The most commonly encountered cations in organic isolates are 
amines. The pka value of CBA is 4.8 at pH above 4.8. CBA carries a negative 
charge that can be used for retaining cationic isolates, dropping the pH below 4.8 
neutralize the CBA permitting the retained isolates to elute from the sorbent. For 
this reason CBA is often the best choice for cation exchange, especially when 
dealing with very strong cationic i.e. high pka cations.
Propvlbcnzenesulfonyl (SCX)
SCX is a strong cation-exchanger with very low pka due to the presence of the 
benzene ring on its surface. SCX sorbent show a potential for non-polar 
interactions. This dual nature is useful with isolates that exhibit both cationic and 
non-polar character. After retention of the isolate on the column, the sorbent can 
be washed with non-polar solvents and with high ionic strength solvents without 
displacing the isolate from the sorbent. Tire isolate can then be eluted from the 
sorbent with a solvent that disrupts both ionic and non-polar interactions 
simultaneously such as methanolic hydrochloric acid.
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2.5.2.5 - Bond Elute Certify
This is a new bonded silica solid phase extraction (SPE) column to extract acidic 
neutral and basic drugs from urine and with special sample preparation in case of 
blood. The manufacturer of this sorbent did not reveal the chemical structure of 
this column. Bond elute certify is conditioned with phosphate buffer pH 5.0 for the 
extraction of basic drugs like amphetamine, while for opiate extraction, the column 
is conditioned with acetate buffer at pH 4.0.
2.6 ANALYSIS OF INTERFERING SUBSTANCES
2.6.1 Acid Interference
In general these compounds can be extracted from aqueous acid solution or 
usually co-extracted with acidic drugs such as barbiturates in putrefied tissues or 
blood. Kaempe published work in which interfering compound were positively 
identified [43, 20].
An atlas of properties of acidic interference compounds was produced by Williams 
which included the ultraviolet, infra-red, colour reagent, thin layer 
chromatography, mass spectra and gas chromatography [22]. Others produced 
HPLC retention times using two types of mobile phase, one for carboxylic acids 
and the other for indoles and neutral interfering substances [107].
Indole
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The first published work recognizing Indole as an interfering substance with drug 
determinations, and the quantitative analysis of the compound in putrefied blood 
and tissue using gas liquid chromatography was described by Oliver [28]. 
Thelmar and Stevens published data regarding Indole derivatives such as Indole-3- 
acetic acid (IAA) and Indole-3-aldehyde in putrefied human liver using thin layer 
chromatography and colour tests [107]. All the clinical works relating to Indole is 
focussed on neurochemically important Indoles like Indole-3-acetic acid (IAA), and 
5-hydroxyindole acetic (5-HIAA) [108, 109]. Different analytical techniques were 
used to analyse trace amounts of Indole derivatives, e.g. GC-MS [110]. A reversed- 
phase high performance liquid chromatography using ODS columns with 
electrochemical [109, 111, 112] and fluorometric detection have been described 
[113, 114, 108]. Most of the recent work on Indole derivative analysis has been 
focussed on HPLC systems. The availability of highly efficient HPLC allows the 
ready analysis of thermally labile, high molecular weight, hydrophilic and 
hydrophobic compounds. Another advantage of HPLC is the selectivity of 
retention times which gives a good marker for identification.
A literature search revealed nothing on the analysis of Indole by HPLC. Most of 
the published work is on Indole derivatives, both qualitative and quantitative, is as 
discussed earlier. Therefore, a method for Indole analysis using high performance 
liquid chromatography has been developed using ultraviolet detection for 
qualitative and quantitative analysis of the substance in putrefied post-mortem 
blood.
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2.6.2 Non-acid Interferences
Non-acid Interferences is a group of compounds which extract from basic aqueous 
solution into organic solvents. Kaempe and others published data according to the 
incidence of non-acid interfering substances in liver and visceral material [43, 28]. 
Their data was obtained using thin layer chromatography, ultra-violet 
spectrometry and gas chromatography. The gas chromatography column used 
silicone gum rubber (SE30) as liquid phase for separation and flame ionisation for 
detection. The retention indices of 296 compounds has been produced on gas- 
chromatography with SE30 and OV-1 columns which are usually used in 
toxicological analysis has revealed the presence of 2-phenethylamine, tyramine and 
tryptamine as interfering substances [115].
The relative retention times of some endogenous putrefactive amines on OV-17 
have been measured and shown to be a source of interfering peaks in the gas 
chromatographic screening of direct chloroform extracts of blood for drugs [45]. 
There has been an increase in the number of publications on the analysis of trace 
amines [116,117, 118]. This has been stimulated in particular by the recognition of 
the role of 2-phenethylamine, tyramine and tryptamine in neural transmission, 
particularly where impaired metabolism of these amines is implicated in certain 
pathological conditions such as migraine, Parkinson's disease, schizophrenia, 
phenylketonuria and depressive illness [40].
The most specific methods for trace amines analysis include radioenzymatic assay 
[119], and gas chromatographic-mass spectrometry (GC-MS) [120, 121]. The 
techniques require expensive instruments, purified enzymes or radioactive 
compounds. Most of them are not suitable for the simultaneous determination of 
all trace amines. The most recent analytical method for trace amine analysis is
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reversed-phase high performance liquid chromatography with electrochemical 
detection [122, 123, 124, 125, 126]. Others used fluorometric detection, [127, 128]. 
These provide good separation and sensitivity with relatively inexpensive 
equipment. Reversed-phase chromatography has been used to separate the so- 
called trace amines which include the three putrefactive amines under 
investigation - 2-phenethylamine, tyramine, tryptamine. It is known that these 
amines "basic compounds" with nitrogen atoms can show tailing peaks in reversed 
phase high-performance liquid chromatography when using bonded 
hydrocarbonaceous packing material. These problems are believed to arise from 
interaction between the compounds and the adsorption sites on the silica matrix of 
the packing material, [129, 130, 131, 132, 133, 134]. Most HPLC methods with the 
ODS-columns use ion-pairing to overcome the tailing and improve the efficiency, 
[123, 125]. Gradient elution [118], or amine modifiers have been used to reduce 
peak tailing of 2-phenethylamine drugs in reversed-phase high performance liquid 
chromatography, [135]. They found large improvements in peak shape by the 
addition of some amines. Detection was achieved electrochemically or 
fluorimetrically this latter requiring post-column derivatization. Another 
limitation of most of the applications in trace amine analysis is that the techniques 
have been developed for special types of samples like serum, cerebrospinal fluid 
and urine. As an alternative approach to the separation of the trace amines has 
been achieved on silica "normal phase" columns.
The use of non-aqueous ionic elements has many advantages in the analysis of 
basic compounds by HPLC-using silica columns. Greater flexibilities are offered by 
the ability to control retention and selectivity by the adjustment of pH, ionic 
strength and the composition of the organic components [136]. Another advantage 
of silica over ODS columns for basic compound analysis is a sharp peak with a fast 
elution time without using an ion-pair reagent which requires a few hours to
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equilibrate with the ODS-column before the analysis can be started. The use of 
silica HPLC columns has been widespread in forensic laboratories for the screening 
and quantitative analysis of basic drugs, [137,138,139]. These were introduced for 
the separation of a wide range of drugs and drugs of abuse. An HPLC system was 
developed for the analysis of the antiarrhythmic drug, amiodarone based on a 
silica column [140]. A silica column was used for lysergic acid diethylamide (LSD) 
separation [141], and an HPLC system with silica has also been used for the 
separation and quantitative determination of morphine [142] and tricyclic 
antidepressants, [143].
A comprehensive evaluation of biogenic amine analysis in biological system is 
given in the literature [144]. The literature search revealed no data regarding the 
analysis of the three putrefactive amines simultaneously from post-mortem blood. 
A method has been developed for their analysis using normal phase HPLC-system 
with ultra-violet detection. The reports include the development of appropriate 
mobile phases for fast analysis.
2-Phenethvlamine
2-Phenethylamine (PEA) can be viewed as the parent compound of a large group 
of drugs known as sympathomimetic amines [145]. Relatively large amounts of 
PEA is excreted from the urine of patients suffering from paranoid schizophrenia, 
[34]. Because of its clinical and pharmacological importance PEA received a great 
deal of attention in recent years in relation to the development of methods to 
analyse the normally low levels in tissue and body fluids.
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A gas chromatographic procedure for the analysis of 2-phenethylamine in 
tissues and body fluids has been described involving the use of pentafluoro- 
benzenesulphonyl chloride for extraction and derivatization of 2-phenethylamine 
[146].
2-phenethylamine with other sympathomimetic drugs was analysed on reversed- 
phase high performance liquid chromatography with pre-column derivatization 
and electrochemical detection [147].
Tyramine (TYR)
Tyramine is an indirectly acting sympathomimetic amine found in cheese, 
fermented foods and red wine, [38, 39]. The involvement of Tyramine in a number 
of neurological disorders has been postulated. A fluorometric method used for 
quantitative analysis of Tyramine is based on the reaction of para substituted 
phenols with l-nitroso-2-naphthol and NaN02, [43].
Oliver and Smith successfully analysed Tyramine by gas liquid chromatography 
using a flame ionisation detector [37]. Data is available in the literature regarding 
its analysis for clinical purposes in plasma and cerebrospinal fluids. Reversed- 
phase HPLC with fluorescence detection has been used for Tyramine and other 
biogenic amines, [127].
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A method for plasma Tyramine analysis using reversed-phase ion pair HPLC with 
electrochemical detection has been described [125] while one other, [118] used 
derivatization reagent with ultraviolet and fluorescence detection.
Tryptamine (TRY)
Oliver and others analysed Tryptamine by gas liquid chromatography and 
provided mass and ultraviolet absorption spectra [28]. Marsen and Joseph 
investigated the analysis of biogenic amines including Tryptamine by reversed- 
phase ion pair high performance liquid chromatography with electrochemical 
detection [148]. A gas chromatograph-mass spectrometer equipped with negative 
ion chemical ionization was developed for the Tryptamine analysis [149], A 
simultaneous determination of Tryptamine and its metabolites in mouse brain by 
high performance liquid chromatography with fluorometric detection has been 
described [125].
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2.7 - DRUGS ANALYSIS
2.7.1 - Acidic Drugs
2.7.1.1 Anticonvulsant (ACD)
The literature survey shows numerous publications concerning analytical methods 
for anticonvulsant drugs in biological specimens. The methods are designed for 
the analysis of two or more of the anticonvulsant drugs [150,151,152].
Most of the methods are developed towards clinical applications in drug 
monitoring, either therapeutic or overdose. The samples used are serum or 
plasma.
Gas chromatography was used for determining phenytoin, phenobarbitone and 
other anticonvulsants in plasma [153, 151]. Enzyme immunoassay [ElA] has been 
developed for routine therapeutic monitoring of anticonvulsant drugs [154].
High performance liquid chromatography is an accurate and precise technique for 
the analysis of drugs. A number of liquid chromatographic methods has been 
reported in the literature for the determination of anticonvulsant drugs in 
physiological fluids. Most of the methods used reversed-phase HPLC. Williams 
and Viola [155] compared the results of reversed-phase HPLC analysis of 
anticonvulsant drugs with gas chromatography and immunoassay technique. The 
agreement was excellent with a correlation coefficient of 0.95. A very fast HPLC 
analysis was achieved with a C8-column (100 mm x 4.6 mm, 3 um particle size). A 
reversed-phase HPLC method is described [156] for the analysis of eight common
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anticonvulsant drugs and metabolites in serum. High performance liquid 
chromatography has the advantage that the analysis of anticonvulsant drugs 
requires no derivatization.
HPLC has another advantage. It is a useful method to separate the parent drug 
from its metabolites [157]. The method used in this work for anticonvulsant drugs 
is specially developed for post-mortem blood using reversed-phase high 
performance liquid chromatography [158]. The effect of interfering substances 
present in putrefied post-mortem specimens on anticonvulsant drugs analysed by 
this method has never been previously investigated.
2.7.2 - Non-Acidic Drugs
2.7.2.1 Benzodiazepines
Numerous methods are currently available for the analysis of the benzodiazepine 
drugs in biological samples. Immunochemical techniques generally employed as a 
screening test are able to identify the presence of benzodiazepines at nanogram 
levels but they do not discriminate within the group. Moreover, quantitative 
analysis is difficult because of the responses of the different benzodiazepines and 
their metabolites towards the antigen-antibody reaction is not the same. Most of 
the techniques used for benzodiazepine analysis are focused on high performance 
liquid chromatography and gas chromatography.
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Methods for toxicological analysis of the common benzodiazepines in biological 
fluids and tissues either using gas chromatography with nitrogen-phosphorus or 
electron capture detection to measure benzodiazepines and metabolites have been 
described [159, 160]. Underivatized benzodiazepines were successfully separated 
using gas chromatography by Ferguson and Curi [161]. Some benzodiazepines 
such as chlorodiazepoxide are thermolabile and therefore cannot be subjected to 
the high temperatures needed for GC.
High performance liquid chromatography (HPLC) has been used to analyse a 
single benzodiazepine [162], or a wide group of benzodiazepines and their 
metabolites, [163, 164]. Reversed-phase HPLC with a photodiode array 
spectrophotometric detector has been described [165] which makes the HPLC 
detection more reliable, informative and non-destructive.
2.7.2.2 Opiates
Analyses of opiates by chromatographic techniques are the methods of choice. 
High performance liquid chromatography with ultra-violet detection has been 
described [166, 167], but showed a lack of sensitivity due to the low extinction 
coefficient of morphine. It utilizes the ability of the phenol moiety of morphine 
and structurally-related drugs to absorb UV light.
Analysis by HPLC with electrochemical detection has been described for morphine 
and buprenorphine in urine and blood [168, 169]. They achieved a sensitivity of 
0.5 - lOng/ml. The major problem with electrochemical detection is with the
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contamination of the electrode surface during operation. HPLC with 
chemiluminescence (CL) detection has been used for opiate analysis, [170]. In this 
technique morphine is oxidized to pseudomorphine by potassium permanganate 
solution.
The use of the native fluorescence of morphine and its metabolites by using 
fluorescence detection following HPLC separation has been described [171, 172]. 
The tedious optimization of the operating conditions for fluorometric 
derivatization and detection, the frequent contamination of the electrodes in 
electrochemical detector, the interferences from matrix and the huge influence of 
the mobile phase composition have decreased the extensive application in routine 
analysis of these techniques. Gas chromatography is employed as a screening 
procedure for morphine and other narcotics as well as confirming the positive 
results of the preliminary screening methods [TLC, UV, RIA]. Both packed and 
capillary columns have been used. The capillary column provides better resolution 
and sensitivity. Since morphine is a polar drug the extracts for morphine analysis 
have to be derivatized before application to the GC column.
^ N i  electron-capture gas chromatography with pentafluoropropionic acid 
anhydride [PUPA] as derivatization reagent has been used to analyse morphine, 
[173], buprenorphine and its metabolites in urine and blood with sensitivity down 
to 1 ng/m l. [174]
Other derivatization reagents have been used such as acetic anhydride [175] and 
Trimethylsilylimidazole, [176]. Any of the above derivatization procedures are 
suitable for detection of morphine to low nanogram levels.
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Analysis of opiates by mass spectrometry coupled to gas chromatography [GC-MS] 
provides sufficient sensitivity and offers the best available technique for the 
unequivocal identification of opiates in biological material. Mass spectrometry in 
the SIR mode has been applied to the detection of opiate drugs in both electron 
impact, [177, 178] and chemical ionization [179, 180]. Selective ion recording (SIR) 
enhances the sensitivity of detection by a factor of 50-500 or more when 
monitoring the effluent of a GC column [181].
From the literature review above, it can be seen that the analysis for morphine and 
buprenorphine with the different techniques are mostly dealing with each drug 
separately. A method has been developed by Battah to analyse both morphine 
and buprenorphine from post-mortem blood with gas chromatography-mass 
spectrometry [182] using the same extraction procedure and derivatization reagent 
has been adopted in this work for analysis of morphine and buprenorphine.
2.8 EXTRACTION OF INTERFERING SUBSTANCES
2.8.1 Acid Interferences
Indole
The NH group of Indole is relatively acidic [25]. Indole has been shown by 
Williams to be extractable from both acidic and basic solutions [22]. Therefore 
Indole could interfere with both acid and basic drug determinations. Oliver 
demonstrated the extraction of Indole from putrefied biological materials with 
about a 1007o efficiency using diethylether from the alkalinized sample [28]. Indole 
derivatives Indole-3-acetic acid (IAA) 5-hydroxyIndole acetic acid (5-HIAA) have
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been shown to have considerable clinical and biochemical importance [108]. Indole 
derivatives have been analysed following extraction from biological fluids using 
organic solvent [112]. The use of solid-phase sorbent, C18-column, to extract 
Indoles from serum [111] and Amberlite ion-exchange column to extract Indoles 
derivatives from urine have been described [183]. The derivatives have been 
analysed directly by injection of the supernatant after protein precipitation of 
biological materials with mainly 0.1M perchloric acid or trichloroacetic acid [113, 
114, 184]. A literature review provides no reports on the extraction of Indole from 
post-mortem blood employing solid phase sorbent systems. A method has been 
developed to extract Indole from putrefied post-mortem blood using a solid phase 
sorbent described in this thesis, 3.6.1.
2.8.2 - Non Acid Interferences
Of the group of compounds known as biogenic amines, 2-phenethylamine, 
Tyramine and Tryptamine are the most frequent non acid interference substances 
encountered. The three biogenic amines are primary amines and can be extracted 
from biological material at pH 8-10 with high efficiency using chloroform as 
extracting solvent. Tyramine extracted with the solvent mixture 
chloroform/Isopropanol (4:1 v /v) at pH = 9.5 and 2-phenethylamine extracted at 
pH above 12 with chloroform, gave high extraction efficiencies 95-100% [43]. 2- 
phenethylamine was extracted from aqueous solution using ethyl acetate at a pH 
range of 4-9, [126] reflecting the high lipophilicity of 2-phenethylamine. 
Tryptamine was found to be extracted well from strongly basic aqueous 
homogenates in high yield, using polar solvents such as butanol and methylene
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chloride. A further extraction and purification step were needed since a large 
amount of lipids were co-extracted with Tryptamine. Most of the extraction 
methods focus on extracting one biogenic amine [185, 125,128, 186, 146]. There is 
less published work describing the extraction of two or more of the three biogenic 
amines from biological material [4, 118]. All the procedures available in the 
literature are based on solvent extraction which require long analysis times, large 
volumes of solvent and centrifugation steps, the latter to overcome emulsion 
formation. Amberlite was used to extract 2-phenethylamine and tyramine from 
biological material with an efficiency of 63% and 83% for 2-phenethylamine and 
tyramine respectively. This method was used as a cleaning step before further 
extraction, [4]. The extraction of 2-phenethylamine, Tyramine and Tryptamine 
from post-mortem blood using bonded phase has not yet been reported. Post­
mortem blood requires special treatment prior to application to solid-phase 
sorbent. A method has been developed to extract the three putrefactive amines 
using Extrelut^ and solid phase sorbent.
2.9 DRUGS EXTRACTION
2.9.1 Acidic Drugs
2.9.1.1 Anticonvulsant Drugs [ACD]
Of the various sample preparation methods, liquid-liquid extraction with non­
polar, water-insoluble organic solvents has been most widely used. A single 
organic solvent for extraction was used by Scheal et al [187], Thomas et al [188] and 
Kabra et al [189] while others used a mixture of different solvents [190]. The 
methods can extract drugs present in low concentrations.
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Extraction of biological materials with organic solvents is a common means of 
obtaining solutions suitable for instrumental analysis. Therefore a clean-up 
procedure of extracts is needed to minimise the interfering substance. Barbiturates 
from blood analysed by GC needed three extraction-purification steps, to produce 
a 1000-fold reduction of the interfering lipid level [191]. This makes liquid-liquid 
extraction a long and tedious method compared with solid-liquid (solid phase) 
extraction.
The solid phase extraction has advantages which include the simultaneous 
extraction of a number of samples, the prevention of emulsion formation, the short 
sample preparation time, the removal of evaporation steps and the potential for 
automation.
Solid material such as activated charcoal has been used for anticonvulsant drug 
extraction, [192] where drugs are first adsorbed onto charcoal and eluted from it 
with organic solvent. The extract is clean, but the procedure is time-consuming and 
gives extraction efficiencies ranging from only 41 - 73%. Extrelut^, "Diatomaceous 
earth," has been described for extracting AD from blood [193,194, 195]. The use of 
bonded silica to extract ACD from serum has been described [196]. Post-mortem 
blood is not directly applicable to bonded silica, therefore, a protein precipitation 
step is needed before applying the sample onto the bonded silica column. The use 
of diatomaceous earth for extraction is more versatile since post-mortem blood can 
be applied directly to sorbent. A method for extraction of acidic drugs and 
anticonvulsants has been described [158] which demonstrate a detection limit of 
0.25 ug /m l for each drug. This method has been adopted in this work to extract 
and analyse the drugs under investigation.
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2.9.2 Non-Acidic Drugs Extraction
2.9.2.1 Benzodiazepines Extraction
Until recently the majority of methods used for extracting benzodiazepines from 
biological fluids have been based on liquid-liquid extraction [197, 198, 199]. 
Recoveries of drugs with liquid-liquid extraction are dependent on the number of 
extractions and back extractions performed. A high recovery >90%, of some 
benzodiazepine from plasma with liquid-liquid extraction has been obtained [200]. 
Enzymic digestion can be used to release the benzodiazepines and their 
metabolites from human tissues to yield higher recoveries [201]. Eppel described a 
method for some benzodiazepine analysis including the one under investigation 
"Temazepam" [202]
In forensic science work, as elsewhere, the application of solid-phase extraction has 
been promoted by the commercial availability of prepacked columns and 
cartridges. An extraction procedure for one of a group of benzodiazepines and 
metabolites using bonded-phase extraction columns from serum with a recovery of 
>80% has been reported by Good and Andrews [203] and Carlucci [204]. The 
limitation of this procedure is that it is not applicable to post-mortem blood or 
tissue. Moore and Oliver developed a rapid solid-phase extraction procedure for 
benzodiazepines from greyhound urine following enzyme hydrolysis [205]. A 
method for the extraction procedure for most encountered benzodiazepines in 
forensic and clinical toxicology has been described [206]. It is claimed by Suzuki et 
al that an excellent recovery for all benzodiazepines in urine has been achieved.
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The recovery of medazepam in plasma was, however, only 10 to 20%. Improved 
recoveries were achieved by deproteinization of the plasma samples.
The post-mortem blood routinely encountered in forensic toxicology casework is 
varying and usually extensive haemolysis and is often putrified. Large amounts of 
solidified and coagulated material may be present and therefore may cause serious 
contamination if applied directly to the solid-sorbent. It is possible, therefore, that 
protein precipitation followed by filtration of the extract would be necessary prior 
to pH adjustment before extracting the sample through the solid-phase sorbent. In 
general the recoveries by SPE of benzodiazepines after protein precipitation have 
been shown to be low [206]. However, others [198] obtained a recovery >75% from 
a small sample volume of 200 ul of blood for sixteen benzodiazepines. A method 
for benzodiazepines extraction from post-mortem blood based on liquid-liquid 
extraction has been adopted in this work [202]. The presence of interfering 
substances in benzodiazepine analysis by this method have been investigated.
2.9.2.2 - Opiate Extraction
Morphine and related drugs need a rigourous extraction procedure to isolate them 
from biological media with sufficient purity and efficiency. Opiate-type drugs are 
polar and hydrophilic. At physiological pH, morphine and buprenorphine 
molecules have a low lipophilicity due to protonation of the amine group. 
Therefore their extraction efficiency at the physiological pi 1, is poor. The pKa 
values of morphine are 8.0 for the amine group and 9.9 for the phenol group (log P 
(octanol/pH  7.4) - 0.1) [63]. For buprenorphine the pKa values are 8.24 and 10.0 for
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the amine and phenol groups respectively [207]. To increase the solubility of the 
opiates in organic solvent, the lipophilicity of morphine and buprenorphine should 
be increased. This can be achieved by adjusting the pH of the specimens to the 
range of 8.5 -10. This pH range gives the optimum extractability, [182]. Extraction 
of morphine and related compounds with one solvent [177, 208] or solvent 
mixtures [180, 175, 209] have been described. Butanol or isopropanol are usually 
used in solvent mixtures to increase the polarity of the extracting solvent. In liquid 
extraction, the solvent used is usually three to four times the volume of the 
aqueous layer. After centrifuging, the extracting solvent is usually back extracted 
into 0.1M hydrochloric acid or 0.05M sulphuric acid to purify the extract from co­
extracted endogenous material co-extracted from the biological sample. The acid 
aqueous portion is then made alkaline to pH 8-10 and extracted again twice with 
organic solvent which is separated and evaporated to dryness. The extract is then 
reconstituted with an appropriate solvent for chromatographic analysis (TLC, GC, 
HPLC). Acid hydrolysis with hydrochloric acid or enzymatic hydrolysis 
(glucuronidase) is usually used for estimating the total morphine in biological 
specimens. In general liquid extraction procedures of opiates require long analysis 
times, large volumes of solvent and are complicated by potential emulsion 
formation and the need for several centrifugation steps. Adoption of solid-phase 
extraction for opiate analysis is known to be efficient, require short analysis times 
and minimal solvent consumption. Various materials have been used in SPE for 
the analysis of opiates such as XAD-2, a neutral styrene-divinylbenzene which has 
the capacity to adsorb drugs (organic material) from aqueous solution [210].
Diatomaceous earth (Extrelut^) adsorbs the sample when applied to prepacked 
columns The aqueous material adsorbs into the Extrelut^ leaving the drug 
available for elution with organic solvent. High recoveries (98%) are achieved 
even when the eluate from the Extrelut^ column is back extracted into acid and re­
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extracted using Extrelut^ for further purification [211]. The types of chemically 
bonded silica and their selective properties for extraction procedure has been 
described earlier (2.5).
Silica bonded to octadecyl (18-carbon straight-chain hydrocarbon) is the most 
commonly used reversed-phase packing material to extract morphine or its 
metabolites [212, 167, 170] A range of solid-phase extraction columns have been 
used, including C2, C8, C l8 and phenyl to extract morphine and its metabolites, 
the morphine 3 and 6 glucoronides [172].
Until recently, no method has been described for the extraction and analysis of 
morphine and buprenorphine together. Battah developed an extraction procedure 
for morphine and buprenorphine in post-mortem fluids using a combination of 
Extrelut and the ion exchange column (SCX). This was followed by derivatization 
of morphine and buprenorphine with diethyl tetramethyldisilazane (DETMDS) 
prior to analysis [182]. The method showed an extraction efficiency 95 ± 4% at a 
concentration of 560 ng/m l blood, for morphine and 87 + 5% at 8 ng/m l blood for 
buprenorphine.
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CHAPTER 3
EXPERIMENTS
3.1 D r u g  S p ik in g
Blank blood supplied from the Scottish Blood Transfusion Service was tested for 
the presence of all of the drugs under investigation and found to be negative. A 
portion was transferred into clean vials and sealed, designated as blank blood and 
was stored with spiked samples under the same conditions. Other portions were 
used for the preparation of drug solutions in blood. They, and aqueous solutions 
of the drugs under investigation were prepared and stored for the same period of 
time and at the same temperature. This enabled a comparison to be made between 
the amount of chemical decomposition and of putrefactive degradation for each 
drug. The concentration of drug in blood and the aqueous solution was the same 
and was equivalent to the toxic level of each of the drugs under investigation. At 
the day of spiking a sample of spiked blood and of aqueous solution was analysed 
to measure the concentration of the drug on that day. This was designated as day 
zero concentration.
s
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3.1.1 - Acid Drugs "Blood and Water Spiking" 
3.1.1.1. Anti-Convulsants
Phenobarbitone;
20 ml of 100 ug/m l of phenobarbitone in methanol were added into a clean conical 
flask. The methanol was evaporated to dryness under a steam of nitrogen on hot 
plate at 60°C. The phenobarbitone was reconstituted with 200 ml of the blank 
blood and then mixed for two hours using a magnetic stirrer to ensure both the 
solubility and the proper distribution of the drug in the blood. The same 
procedure and quantity of drug was used to produce an aqueous solution of the 
drug. The resulting concentration of phenobarbitone in blood and control water 
was 10 ug/m l. The water used was double deionized water. The pH of the water 
was adjusted to physiological pH 7.4 by adding dilute sodium hydroxide. 5 ml of 
each (blood/aqueous solution) was individually transferred into clean 6 ml 
capacity hypo-vials which were then sealed with butyl rubber septa. The vial was 
stored at different selected temperatures and times.
Carbamazepine
20 ml of stock standard solution of 30 ug/m l carbamazepine in methanol was 
evaporated to dryness. The residue was reconstituted with 200 ml of blank blood 
added as above to produce a spiked blood of 3 ug carbamazepine per ml. The
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procedure was repeated with water to produce an aqueous solution with 
concentration of 3 ug carbamazepine per ml. Aliquots were transferred into hypo- 
vials and sealed for further investigation as above.
Phenytoin
20 ml of stock standard solution of 100 u g /m l of phenytoin in methanol was 
processed as above to produce a concentration of 10 ug phenytoin per ml of blood. 
The procedure was repeated to prepare the aqueous solution. Aliquots were 
transferred into hypo-vials and sealed for further investigation as above.
3.1.2 - Non-acidic drugs
3.1.2.1 - Benzodiazepine 
Temazepam
A stock standard solution of Temazepam was made up in methanol (10 ug/m l). 60 
ml of the above stock was transferred into a clean conical flask and evaporated to 
dryness under nitrogen steam on a hot block 60°C. The Temazepam was 
redissolved in 600 ml of the blood as above to produce a concentration of 1 ug 
drug per ml of blood. 15 ml aliquots were transferred into clean hypo-vials of 25 
ml capacity and then sealed with butyl rubber septa. The procedure was repeated 
with water to produce an aqueous solution of Temazepam.
3.1.2.2 Opiates
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A standard solution of morphine (0.5 ug/m l) and buprenorphine (0.25 ug/m l) in 
blood and aqueous solution were prepared as above. Five ml aliquots were 
transferred to pre-silanised hypo-vials as above. All the glass vials were silanised 
with dimethylchlorosilane [HfCHg^Si Cl] and then washed with methanol to react 
with the excess DMCS and left to dry before use.
3.2 DRUGS STORAGE
Two vials for each measurement of spiked blood, aqueous solution and blank 
blood for each drug were stored at different temperatures and periods of time 
before re-analysis to measure the effect of temperature and time interval on the 
drug concentration. The interval of times between each analysis was designated as 
two, four, six, eight weeks and three, six, nine and twelve months. The drugs were 
stored at 5°C, 25°C and -20°C. Two samples each of spiked blood, blank blood 
and aqueous solution of each drug were removed from storage, opened and 
analysed at each designated period of time.
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3.3 - TEMPERATURE MONITORING OF SPIKED SAMPLES
The spiked blood and aqueous solution with drugs under study was monitored 
from the day of spiking until the end of the experiment at the three storage 
temperatures (5, 25, -20°C).
3.4 - ANALYSIS OF INTERFERING SUBSTANCES
3.4.1 - Acid Interferences MIndole"
Equipm ent
The method used for Indole analysis was high performance liquid chromatography 
based on a Pye Unicam PU 4015 pum p (Philips) with dual piston heads. The 
detector used was a variable wavelength ultra-violet detector (Pye Unicam PU 
4025) with an 8 ul flowcell with a path length 10 mm. The column was 25cm x 4.6 
mm I.D. (internal diameter) cartridge pre-packed with Hypersil 5 um ODS C18 
(Capital HPLC Specialists) fitted with 5 cm 4.6 mm I.D. ODS C18. guard column. 
The injector port was a Rheodyne 7125 with 20 and 100 ul loop. Indole was 
detected at 210 or 273 nm. The chromatograms were recorded on a BBC Goerz 
M etrawalt SE120 recorder, operated at 1 cm /m in and at lOmV full-scale deflection.
Mobile Phase
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The mobile phase used to separate Indole consists of 0.02M sodium 
acetate/acetonitrile/methanol (400:180:180 v /v /v ). The pH of the mixture was 
adjusted to 5.5 using glacial acetic acid. Sodium acetate buffer of 0.02M was 
prepared by dissolving 2.72g of sodium acetate (M.wt.136) in deionised water and 
made up to 1 litre.
Choice of Internal Standard
Indolin has the same Indole structure with only one difference, there is no double 
bond on position (2-3). A standard solution of Indolin was prepared in methanol 
to give a concentration of 1 ug/m l.
Indomethacin is an analgesic and one of the Indole derivatives. A standard 
solution of Indomethacin was prepared by dissolving 2 mg in 100 ml methanol to 
produce a concentration of 2 0  ug/m l.
Fenoprofen Standard solution of Fenoprofen was prepared by dissolving 10 mg in 
1 0 0  ml methanol to produce a standard concentration of 1 0 0  ug/m l.
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Butalbital is used as an internal standard for acidic drugs determination. 
Standard solution of butalbital prepared in methanol with a concentration of 10 
ug/m l. by dissolving 1  mg of butalbital in 1 0 0  ml methanol.
Butobarbitone
A standard butobarbitone solution with a concentration of 16 ug /m l was prepared 
by dissolving 1 . 6  mg in 1 0 0  ml methanol.
5-ChloroIndole
5-ChloroIndole is also one of the Indole derivatives, a stock standard solution of 5- 
Chlorolndole was prepared by dissolving 5 mg of 5-ChloroIndole in 100 ml 
methanol to produce a stock standard solution of 50 ug/m l. This solution was 
diluted with methanol or deionized water to obtain standard solution of 5 ug/m l.
The Maximum Absorptivity of Indole:
The UV spectrum of Indole and the chosen internal standard in the above mobile 
phase was obtained using a diode array spectrophotometer (Hewlett Packard 
8751 A), the cell volume was 3 ml with a 10 mm path length.
-  1 0 0  -
Linearity and Minimum Detectability of the HPLC System
A series of Indole standards was made up in the mobile phase. The concentration 
range was 0.5, 1.0, 2.0, 3.0, 4.0 and 5 ug/m l. Six analyses at each concentration 
were carried out at 0.02 and 0.08 AUFS. The average peak heights were used to 
construct the calibration curve for the Indole analysis.
A serial dilution of the Indole standard of 500 ng/m l in mobile phase was used to 
determine the minimum detectability.
Reproducibility of the HPLC System
A standard solution of Indole at a concentration of 1 ug/m l was prepared in the 
mobile phase. The reproducibility of the HPLC was determined by injecting the 
standard Indole (1 ug/m l) twenty times each day over three successive days under 
the same conditions. Flow Rate = 2  m l/m in. : Range (AUFS) = 0.02 : Chart Speed = 
1 cm /min. using the described HPLC [3.4.1].
3.4.2 Non Acid Interferences
-  1 0 1  -
The three putrefactive amines, 2-phenethylamine, tyramine and tryptamine were 
analysed with the developed high performance liquid chromatograph system 
described below.
Equipment
The chromatographic system was based on a Pye Unicam PU 4015 pump 
incorporating a two piston head. The eluent was monitored at 210 nm using a Pye 
Unicam PU 4025 variable wavelength ultra-violet detector incorporating an 
analytical flow cell assembly of volume 8  ul and path length 1 0  mm. Spectra were 
recorded on a BBC Georz Metrawatt SE 120 recorder operated at 1 cm /m in and 
lOmV full-scale deflection. The column used for separation of the three 
putrefactive amines was 5 cm x 4.6 mm internal diameter pre-packed with silica 
and fitted with guard column 1 cm. x 4.6 ID supplied from Jones Chromatography 
fitted with a 20,100, 500 ul loop in Rheodyne 7125 injection valve.
-  1 0 2  -
Preparation of Standard Solutions
A stock standard solution of the three putrefactive amines was made up in 100 ml 
methanol to produce the following concentration 15 ug /m l Tryptamine 
hydrochloride, 5.4 ug /m l 2-phenethylamine hydrochloride and 52 ug /m l 
Tyramine hydrochloride. These solutions were diluted with the mobile phase to 
obtain the desired concentrations.
M obile Phase Development
It is known that the separation of basic compounds can be achieved by normal 
phase chromatograph (silica column) with a non-aqueous mobile phase, [136, 137]. 
A mobile phase has been developed for fast and better separation of the three 
putrefactive amines by using different ratios of acetonitrile/m ethanol/am m onia.
Choice of Internal Standard
The internal standard should not be expected to be found in putrefied blood, 
therefore different chemicals and drugs have been tested for their suitability to 
working as internal standard in the analysis of the three putrefactive amines. 5- 
chlorolndole, amitriptyline, phenylethylacetylurea, Flupenthixol, nalorphine,
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morphine and dihydrocodeine, have been tested. A standard solution of each drug 
was prepared in mobile phase. 20 ul was injected in the normal phase HPLC 
system to investigate their separation by HPLC.
Linearity of the HPLC-svstem
Standard solutions of 0.5, 4, 8 , 16 ug /m l of 2-phenethylamine hydrochloride and 
0.5, 2, 4, 6 , 8 , 10 ug /m l both tyramine and tryptamine hydrochlorides were 
individually prepared in methanol. Five analyses were performed at each 
concentration within the same day.
Minimum Detectability and Maximum Absorptivity
Standard solutions of 0.4 ug /m l 2-phenethylamine 0.2 ug /m l Tryptamine and 0.2 
ug /m l tyramine was made up in mobile phase. A serial dilution of the three 
putrefactive amines standard solutions in mobile phase was used to determine the 
minimum detectability of the three amines on the HPLC system described in 3.4.2. 
The wavelength of maximum absorption of the three putrefactive amines was 
determined by scanning a standard solution of 2 0  ug /m l of each in the mobile 
phase. A Hewlett Packard 8451 A diode array spectrophotometer was used to scan 
the solutions over the spectrum range 200-350 nm.
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Reproducibility of the HPLC-svstem
Standard solutions of 2 ug/m l of 2-phenethylamine, Tyramine, Tryptamine 
hydrochloride were prepared in methanol. Five injections of each amine were 
performed to determine the day variation and day-to-day variation.
3.5 DRUGS ANALYSIS
3.5.1 Acid Drugs 
3.5.I.I. - Anticonvulsants 
Preparation of Standard Solutions
Stock standard solutions of 100 ug/m l phenobarbitone, 30 ug /m l carbamazepine, 
1 0 0  ug /m l phenytoin and 1 0 0  ug /m l butalbital (internal standard) were made up 
in methanol.
Mobile Phase Equipment and Column
The equipment and column used to analyse acid drugs is as described in 3.4.1.
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The mobile phase used for separation of acid drugs consists of 0.02M sodium 
acetate/m ethanol/acetonitrile (400:180:180 v /v /v )  Battah [158]. The pH of the 
mobile phase was adjusted to 5.5 using glacial acetic acid and was degassed for 10 
minutes before use.
3.5.2 Non-acid Drugs
3.5.2.1 Benzodiazepine - HPLC System
M obile Phase
The separation of Temazepam and the internal standard prazepam was achieved 
by preparing a mobile phase of 0.01M ^^H P O ^/m ethano l (25:75 v /v ) as 
described by Eppel [202]. The pH of the mixture was 8 .8 .
Equipm ent and Column
The pum ping system, the detector and the column is used as described in 3.4.1. 
The eluent of the column was monitored at 230 nm. and a flow rate of 1.5 m l/m in. 
20 ul of Temazepam was injected into the HPLC system.
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Preparation of Standard Solutions
A stock standard solution of Temazepam 10 u g /m l and Prazepam (internal 
standard) 30 u g /m l were made up in methanol and used to prepare a working 
standard temazepam of 1 ug /m l and 3 u g /m l for prazepam (I.S) in blood and 
aqueous solution.
3.5.2.2 Opiates 
Equipm ent
The separation of derivatized morphine, buprenorphine and their internal 
standard D3 -morphine and D2 "buprenorphine were achieved using Hewlett 
Packard model HP5980 gas chromatograph fitted with a capillary column 
(Chrompack CP-Sil 5, 25m-x-0.32mm internal diameter with 0.4 um film thickness). 
The injector temperature was 300°C. The initial oven temperature was 180°C. 
This was maintained for one minute and then increased at 10°C/m in to 300°C. 
This final temperature was maintained for ten minutes. The capillary interface to 
the mass spectrometer was kept at 250°C. The mass spectrometer used was a VC 
model 70-250 S operated at 8 kv. High resolution selective ion recording was used 
to reduce interference in the analysis. The SIR channels were calibrated and tuned 
using perfluorokerosene (PEK) reference mass at m /z  454 at a resolution of 1000.
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Then the peak height was reduced to 10% by the exit slit. The peak was reduced 
by a further 50% by closing the collector slit to give a resolution of 10,000. The 
collector was then opened slightly to obtain a flat peak top. Electron Impact (El) 
was used as ionization method.
Gas Flow Rate on the GC-MS
Helium was used as a carrier gas. The linear velocity was approximately 60 
cm /sec through the column achieved by maintaining a column head pressure of 5 
psi.
Preparation of Standard Solutions
A stock standard solution of morphine hydrochloride and buprenorphine 
hydrochloride were made up in methanol at a concentration of 5 ug /m l and 2.5 
ug/m l respectively. The internal standards were also made up in methanol at 
concentrations of 5 ug/m l for D3 -morphine hydrochloride and 2.5 ug /m l D 2 - 
buprenorphine hydrochloride.
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Synthesis of the derivatization Reagent (DETMDS)
A 250ml three neck round bottom flask was used for the reaction. The middle neck 
was connected to a venting tube containing calcium oxide granules. A 
thermometer was fitted through the second neck to monitor the reaction 
temperature and a gas leak was fitted to the third neck permitting small bubbles of 
ammonia to pass through the reaction mixture. The flask was placed in a liquid 
paraffin bath on a stirrer hot plate. Stirring of the mixture was accomplished with 
magnetic stirrer bars in both flask and the paraffin bath. Liquid was placed in a 
500 ml round bottom flask which was cooled in a bath of acetone and dry ice. 
Ammonia gas effluent was passed through two Drischel baths, the first containing 
a layer of liquid paraffin to monitor the flow rate and the other (empty) bottle was 
to prevent the solvent from the reaction mixture sucking back. 150 ml of dry 
redistilled benzene was added to the reaction flask and the flask was purged with 
ammonia gas for a few minutes at 50-60°C before the addition of 30 grams of 
dimethylethylchlorosilane with continuous stirring for 45 min. The reaction was 
stopped by disconnecting the ammonia supply. The following procedures were 
conducted to isolate the product diethyltetramethyldisilazane (DETMDS). The 
bulk of the solvent containing the product was filtered through a filter paper 
placed on a Buchner funnel. Vacuum was generated by a water pump, so this step 
was conducted very quickly to minimise exposing the product to hydrolysis. The 
collected clear solvent was placed in a distillation apparatus and the bulk of 
benzene was removed by distillation. The remaining fluid (25 ml) was transferred 
to a smaller distillation apparatus where the benzene residue was removed by 
distillation at 78°C. The product was recovered at 172°C and stored at 4°C.
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Derivatization with DETMDS
The derivatization reagent was prepared from 40% of DETMDS in solvent 
composed of acetonitrile and toluene (7:3 v /v ) stored at 4°C in a screw capped 
readi-vial. This mixture was used for the derivatization of morphine and 
buprenorphine in extracts reviously evaporated to dryness, then heating the 
samples at 60°C for 15 minutes with 100 ul of the derivatization reagent in a screw 
capped readi-vial.
3.6 EXTRACTION OF INTERFERING SUBSTANCES
3.6.1 - Acid Interferences
The following experiments were conducted to select a quick and efficient protein 
precipitation reagent for the Indole extraction procedure to provide an extract 
suitable for application to solid-phase extraction.
Protein Precipitation M ethods
Removal of protein by precipitation is an effective method of sample preparation. 
The advantages of this technique are the speed at which the sample can be 
prepared and its simplicity. The ratios of protein precipitation reagent to whole 
blood to give precipitation >95% protein has been discussed in the literature [213].
-  1 1 0  -
a) Methanol
0.1 ml of blood spiked with Indole at a concentration of 50 ug /m l (blood) was 
added 0.3 ml methanol. The mixture was vortexed for one minute and then 
centrifuged for five minutes. Aliquots of the supernatant was injected onto the 
HPLC system.
b) Isopropanol
0.3 ml Isopropanol was added to 0.1 ml blood and the sample processed as above.
c) Zinc Sulphate/Methanol
This protein precipitation reagent was prepared by dissolving 5gm of ZnS04 in 100 
ml distilled water. 70 ml of this solution was mixed with 30 ml Methanol and 
stored in a sealed reagent bottle. 0.2 ml of the ZnS04/M ethanol reagent was 
mixed with 0 . 1  ml blood and processed as above.
d) Perchloric Acid
- I l l  -
Stock solution (3.0M) of perchloric acid was diluted with water to prepare an 0.4M 
solution. 0 . 2  ml of the reagent was added to 0 . 1  ml blood and processed as above.
e) Sulphosalicvlic Acid
To produce a 10% w /v  of sulphosalicylic acid reagent, lOg of sulphosalicylic acid 
was dissolved in 1 0 0  ml of water. 0 . 2  ml of the reagent was mixed with 0 . 1  ml 
blood and processed as above.
f) Protein Precipitation with Methanol/Isopropanol
0.1 ml each of stock Indole standards and internal standard 5-ChloroIndole in 
concentrations of 2.5, 10 and 50 ug/m l were added to 0.8 ml of blank blood to 
produce spiked blood Indole and 5-ChloroIndole at concentrations of 0.25,1 and 5 
ug/m l. To each of five 1 ml samples of spiked blood in a screw-capped vial 2 ml 
M ethanol/Isopropanol (5:1 v /v) was added. The vial was sealed, vortexed for one 
minute and then centrifuged at 5000 rpm on an angle head centrifuge for three 
minutes. The supernatant was transferred to a clear vial for analysis by HPLC.
-  1 1 2  -
Recovery of Indole with Methanol/Isopropanol
Five samples of spiked blood Indole and 5-chloroIndole (I.S) at three different 
concentrations (0.25,1, 5 ug/m l) were treated as in 'f  above. The supernatant was 
analysed to estimate the Indole and 5-chloroIndole recoveries over the above 
concentration range. A set of Indole standards and 5-chloroIndole standards were 
prepared in Methanol/Isopropanol (5:1 v /v) at the above concentrations to 
estimate Indole and 5-chloroIndole recoveries.
Solid Phase Extraction of Indole 
Standard Solution Preparation
A stock standard Indole solution was prepared by dissolving 5 mg of Indole in 100 
ml deionized water to produce a stock solution of 50 ug/m l. Further dilutions 
were made up in methanol to produce working standard solution of 0.5 and 5 
ug/m l. The same procedure was repeated to produce standard solutions of 5- 
Chlorolndole (internal standard).
Bond Elut Certify
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This type of sorbent was recently introduced by Analytichem in columns with 5 ml 
capacity. The column was conditioned with 2 x 2 ml of methanol followed by 2 x 2 
ml of 0.1 M phosphate buffer pH 6.0. One ml of Indole standard stock solution 5 
ug /m l was prepared in deionized water and mixed with 5 ml phosphate buffer in 
a screw-capped vial. The specimen was added to the column. The specimen was 
drawn slowly through the column. The effluent of the column was collected and 
analysed for the presence of Indole (un-retained Indole). The column was rinsed 
with 1 ml 0.1 M phosphate buffer pH 6 /Methanol (80:20 v /v ) and then washed with 
1 ml 1.0M acetic acid followed by 1 ml hexane. The effluent of the column from 
the three washing steps were collected and analysed for the presence of Indole to 
measure the losses during the washing steps. Indole was eluted with 2 x 1 ml 
dichloromethane. The 0.1M phosphate buffer was prepared by dissolving 13.61g 
of KH2P04 (M.wt.136.09) in deionized water and made up to 1 litre. The pH was 
adjusted to 6  with 1.0M potassium hydroxide. The 1.0M acetic acid was prepared 
by pipetting 5 . 7 5  ml glacial acetic acid into a 1 0 0  ml volumetric flask half filled 
with deionised water. This was mixed and brought to volume with deionised 
water.
Non-Polar Sorbent C18
Bond Elut C l8  columns of 3, 6  ml capacity were pre-conditioned with two bed 
volumes of methanol followed by two bed volumes of deionised water.
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Buffers Preparation
Different buffers were tested for their suitability for conditioning and extraction of 
Indole by solid phase sorbent. 0.5M disodium hydrogen phosphate (M.wt. 141.96) 
was prepared by dissolving 70.98g in deionised water and made up to 1 litre. The 
resulting pH was 9.5. A low ionic strength of disodium hydrogen phosphate 0.05 
M was prepared by dissolving 7.1g of Na2HP04 deionised water and made up to 
in 1 litre. The third buffer was sodium acetate with 0.1M prepared by dissolving 
1.36g of sodium acetate (M.wt. 136) in deionised water and made up to 100 ml. 
The pH was adjusted to 12 by adding a few drops of 0.1M sodium hydroxide.
Extraction
The Indole standard was mixed with each buffering system individually. The 
mixture was slowly drawn through a pre-conditioned C18-column under vacuum 
and then washed with 2  x 1 ml of deionized water. Indole was eluted from the 
column with 2 x 0.5 ml methanol and analysed by HPLC.
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Recoveries of Indole on Bond Elut C18 with Sodium Acetate Buffering
Indole and 5-chloroIndole standards (20 samples) were extracted using 0 8 -  
columns. The recovery was calculated by comparing the peak height of extracted 
Indole with non-extracted Indole standards analysed at the same time by HPLC.
Day-to-day Recoveries of Indole on Bond Elut C18
A set of standard Indole samples were extracted with C18-columns on a weekly 
basis for three weeks. The Indole standard concentrations were 0.5 and 5 ug/m l.
Re-using Bond Elut C18-Columns
Ten samples of Indole standard was extracted through the same column. The 
eluent of the column was collected and analysed by HPLC. The experiment was 
conducted in duplicate and with different Bond Elut C18-lot numbers.
-  1 1 6  -
Indole Extraction Calibration Curve
A set of Indole standards were prepared from a stock solution of 50 ug /m l to 
produce different concentrations of Indole. The concentration of the internal 
standard 5-chloroIndole was 5 ug /m l while Indole concentrations in whole blood 
were 0.1, 0.25, 0.5, 2.5, 5 ug/m l. M ethanol/Isopropanol (5:1) was used to 
precipitate the protein as described earlier. The supernatant was mixed with 2 ml 
of 0.1M sodium acetate buffer and extracted through the C18 columns. Six samples 
were extracted on C l8  for each concentration and analysed by HPLC.
The Effect of Column Washing on Extract Cleanliness
The effect of washing C18-column with 12% M ethanol/water was investigated by 
applying a washing step before eluting the Indole from the column, and others left 
without washing. The eluent of both groups were analysed by HPLC.
Indole Losses With Storage
A standard Indole concentration of 0.6 ug /m l was prepared in deionised water. 
Aliquots of 1 ml were placed in a screw-capped vial and left at room temperature. 
The concentration of Indole was measured after five days. A fresh standard Indole 
was prepared to calculate the losses of Indole with storage.
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3.6.1.1 Acid Interferences in Blood Samples Spiked With D rugs
The whole blood samples spiked with anticonvulsants, benzodiazepine and 
opiates were stored at three difference storage conditions (5, 25, -20°C) for different 
time intervals were analysed for Indole concentration. The drugs concentrations 
are given in 3.1.
3.6.2 - Non-acid Interferences
Standard Putrefactive Amines Preparation
2-phenethylamine stock solution (lOmg/ml) was prepared by dissolving 1.047 ml 
of 2-phenethylamine (parity 99%, density 0.965) in deionozed water to a total
volume of 1 0 0  ml.
A standard solution of 2-phenethylamine (100 ug/m l) was prepared by adding 1 
ml of aqueous stock 2 -phenethylamine solution ( 1 0  m g/m l) into 1 0 0  ml volumetric 
flask. The volume was made up to 100 ml by adding deionized water. A standard 
solution mixture of 2 -phenethylamine, tyramine and tryptamine were made up by 
dissolving 1 mg of tyramine and tryptamine free base in 1 0 0  ml deionised water 
followed by adding 0 . 1  ml of stock 2 -phenethylamine free base solution ( 1 0  
m g/m l). The resulting concentration for the three putrefactive amines was 10 
ug/m l.
Protein Precipitation
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Whole blood cannot be extracted directly through solid phase sorbent therefore 
treating the whole blood with a protein precipitation reagent is necessary to obtain 
a supernatant which is easily applicable to the solid phase sorbent.
a. M ethanol
Spiked blood with 2-phenethylamine was prepared by adding 0.1 ml of a stock 
solution (100 ug/m l) of 2-phenethylamine free base in water to 0.9 ml blank blood, 
producing sample concentration of 10 ug/m l. Three mis of methanol was added to 
a screw-capped vial containing the spiked blood. The sample was then vortex- 
mixed for one minute, centrifuged for five minutes using an angle head centrifuge 
at 5000 rpm. The supernatant was transferred into a clean vial. 20 ul aliquots of 
the supernatant was injected onto the HPLC system in three successive injections.
b. Zinc Sulphate
Preparing zinc sulphate as a protein precipitation reagent was described in 3.6.1. 
Sheep serum was supplied by the Scottish Antibody Production (Lanarkshire, 
Scotland). The serum was spiked with 2-phenethylamine free base to produce a 
concentration of 1 0  ug/m l. 2  mis of zinc sulphate reagent were added to vials 
containing the serum spiked with 2-phenethylamine. The sample was vortex
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mixed for 30 seconds then left to stand for five minutes at room temperature before 
being centrifuged on an angle head centrifuge for five minutes. The supernatant 
extracted through C18-column as described below and analysed for 2 - 
phenethylamine by HPLC.
c. Acetonitrile/Isopropanol (5:1 v/v)
Five samples of sheep serum was spiked with the three putrefactive amines, 2- 
phenethylamine, tyramine and tryptamine, in concentrations of 10 ug/m l. The 
samples were processed as above and 2 0  ul of the supernatant was injected onto 
the HPLC system.
Diatomaceous Earths (Extrelut^)
Column Preparation
A Merck ExtrelutR was washed with dichloromethane before use and left to dry at 
room temperature. A plug of glass wool treated with dimethyldichlorosilane was 
introduced into a 10 ml plastic syringe. On the top of the glass wool plug the 
syringe was filled with 1.5 gm of Exrelut^.
-  1 2 0  -
Preparing of Standard Solution
A mixed standard solution containing 100, 100, 50 ug /m l of 2-phenethylamine, 
Tyramine and Tryptamine mixture in deionized water, (0.1 ml) was added to 0.9 
ml of blank blood to produce a working standard concentration of 10, 10, 5 u g /m l 
of 2-phenethylamine, Tyramine and Tryptamine respectively.
Sample Preparation
Two buffering systems were investigated for sample extraction from Extrelut. The 
two buffers were 0.5M N ^ H P C ^  and 57o w /v  sodium bicarbonate (NaHCC^). 1 
ml of spiked blood was mixed with 2  ml of buffer and added to the column and 
allowed to stand for 1 0  minutes prior to elution.
Elution
The three putrefactive amines were eluted from the diatomaceous earth column 
with about 12 ml of diethylether/isopropanol (7:3 v /v) to produce a total volume 
of 8  ml. 20 ul was injected into the HPLC system as described in 34.3.2. The 
effluent was monitored at 230 nm.
-  1 2 1  -
Solid Phase Extraction 
Non-Polar sorbent C18
A working standard of 2-phenethylamine free base (10 ug/m l) was prepared from 
a stock solution of 1 0  m g/m l in methanol by adding 0 . 1  ml of stock to 1 0 0  ml 
methanol, the same procedure repeated to prepared a standard 2 -phenethylamine 
solution of 1 0  ug /m l in deionized water.
Condition of the Column
Bond Elut C l 8  columns of 3 ml capacity were used. The columns were 
conditioned with two bed volumes of methanol followed by two bed volumes of 
water followed by 2 and 3 ml 0.1M sodium acetate buffer pH = 12.
A ddition of Sample and Elution
1 ml samples of the standard 2 -phenethylamine solution ( 1 0  ug/m l) were mixed 
with 2 ml 0.1M sodium acetate buffer pH = 12, then added to pre-conditioned 
columns and drawn through under vacuum. The columns were then washed with 
deionized water ( 2 x 0.5 ml). The elution of 2-phenethylamine was achieved
-  1 2 2  -
0.5 ml of elution mixture (82:25:0.3 v /v /v )  acetonitrile/methanol/ammonia or 2 x
0.5 ml methanol. The eluent was analysed by HPLC.
Bond Elut Certify Column
Bond Elut certify is a newly marketed solid phase sorbent from Analytichem 
International. They claim that the certify column is capable of extracting acidic, 
neutral and basic compounds from urine and with special sample preparations in 
the case of blood [214].
Bond Elut Certify Conditioning
The column was conditioned by passing 2 ml methanol followed by 2 ml 0.1M 
sodium acetate buffer, pH 6 .
Sample Preparation
Spiked sheep serum containing 2-phenethylamine, Tyramine and Tryptamine free 
base at a concentration of 1 0  ug /m l were prepared by adding 0 . 1  ml of each stock
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standard (100 ug/m l) solution of each drug to 0.7 ml sheep serum. 2 ml of zinc 
sulphate was used to precipitate the proteins [214]. The mixture was vortexed for 
30 seconds, let stand for five minutes at room temperature, vortexed again for 30 
seconds and centrifuged for 10 minutes at 3000 rpm. The supernatant was 
transferred to each column. The column was positioned in a 10 column capacity 
VaC Elut^ system. 2 ml 0.1M sodium acetate buffer, pH 6 , was added and allowed 
to stand for 10 seconds to allow mixing. The vacuum was applied and the sample 
was drawn slowly through the column. It took at least two minutes for the 
specimen to pass through the Bond Elut Certify column. The column was washed 
with 1 ml 1.0M acetic acid, dried under full vacuum for five minutes and then 
washed with 6  ml methanol. The column was dried under full vacuum for two 
minutes and the putrefactive amines eluted with 2  x 1 . 0  ml 
acetonitrile/m ethanol/am m onia (82:25:0.3 v /v /v ) .
Cationic Exchange Sorbent 
Conditioning of the SCX Column
The SCX column of 1 ml capacity were conditioned with 2 x 1 ml methanol 
followed by 2 x 1 ml diethylether/Isopropanol (7:3 v /v).
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Preparation of the Standard Solution
A standard solution mixture containing 1 , 1 , 0.5 ug /m l of 2-phenethylamine, 
Tyramine and Tryptamine respectively as their free bases were made up in diethyl 
ether/isopropanol (7:3 v/v).
Addition of the Sample
1 ml of the above standard putrefactive amine mixture was added to the SCX 
column drawn slowly through by controlling the vacuum. The effluent of the 
columns was collected and analysed for unretained putrefactive amines.
Elution
The putrefactive amines were eluted in turn with 2 x 0.5 ml of:
1) 15% ammonia in diethyl ether/Isopropanol (7:3 v/v).
2 ) 2 0 % ammonia in methanol.
3) Acid methanol (25 ul 10% H 2 SO4  in 5 ml methanol).
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Conditioning of CBA Column
The CBA columns of 1 ml capacity were conditioned with two column volumes of 
methanol followed by one column volume of water and two column volumes of 
diethylether/isopropanol (7:3 v/v).
Standard Putrefactive Amine Preparation
The three putrefactive amines were prepared in diethylether/isopropanol (7:3 v/v) 
at different concentrations of 1, 1, 0.5 ug /m l and 10, 10, 5 ug /m l for 2- 
phenethylamine, Tyramine and Tryptamine free base respectively.
Specimen Application
1 ml of the standard solution mixture was added to the pre-conditioned CBA- 
column via an adaptor. The specimen was drawn slowly through the column with 
vacuum pressure of 5 mm Hg.
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Elution of Putrefactive Amine
Acid methanol was prepared by adding 10 ul of 10% H 2 SO4  to 5 ml methanol. The 
molarity of acid in methanol was 3.6 x 10"^M. 2 x 0.5 ml of acid methanol was used 
for elution.
Re-Using CBA-Columns
1 ml capacity CBA-columns of different lot numbers were tested for their ability to 
be used several times. Six samples of the three putrefactive amines standard 
mixture at concentrations of 1 u g /m l 2-phenethylamine, Tyramine and Tryptamine 
as their free bases were prepared in diethylether/isopropanol (7:3 v/v). The CBA- 
columns were positioned in a 10 column capacity Vac Elut^ system. The pressure 
was adjusted to 5 mm Hg and then each column was conditioned with 2 x 1 ml 
methanol followed by 2 x 1 ml deionized water. One ml of the standard solution 
was applied to the columns and drawn through.
The adsorbed putrefactive amines were eluted from the column with 2 x 0.5 ml 
acid methanol. 100 ul of the effluent was analysed by HPLC. The same procedure 
was repeated six times using the different lot number CBA-columns.
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Anion Exchange Column
Amino propyl N H 2  column is a weak anion exchange sorbent. It has been used for 
the purification of C18-extracts of some steroids [215]. Amino propyl columns of 3 
ml capacity were conditioned with 2 x 3 ml methanol followed by 2 x 3 ml 
deionized water. The ability of the column to give a clean extract was tested by 
passing acidic methanol (3.6 x 10'^M H 2 SO4  containing the three putrefactive 
amines mixture in a concentration of 1, 1, 0.5 u g /m l for 2-phenetheylamine,
Tyramine and Tryptamine respectively. The effluent was collected and analysed
by HPLC. The un-extracted standard mixture was used to calculate the recoveries.
Recoveries from Combined Extrelut-CBA-NH2  Column
Extrelut is used as an alternative to the protein precipitation in sample preparation 
for solid phase extraction. The reproducibility of the combined Extrelut-CBA and 
N H 2  were investigated. A set of standard solutions of the three putrefactive 
amines mixture were prepared in blank blood to produce the following 
concentrations of putrefactive amines:
1. 0.1 u g /m l 2 -phenethylamine, Tyramine, Tryptamine
2. 1 ug /m l 2 -phenethylamine, Tyramine, Tryptamine
3. 5 u g /m l 2 -phenethylamine, Tyramine, Tryptamine
4. 10 u g /m l 2 -phenethylamine, Tyramine, Tryptamine
Six samples of each concentration set were extracted through Extrelut^ and eluted 
to produce a total volume of 8  ml diethylether/Isopropanol (7:3 v/v). The Extrelut 
eluent was passed through the pre-conditioned CBA-column. The three amines
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were eluted from the 1 ml capacity CBA-column with acidic methanol (2 x 0.5 ml) 
then the acidic methanol was passed through a pre-conditioned N H 2  column of 3  
ml capacity. The effluent of the N H 2  column was analysed by HPLC.
Calibration Curve
A set of the three putrefactive amines standards mixture were prepared in whole 
blood in concentrations of 0.1,1, 5,10 ug/m l. The samples were extracted through 
the combined Extrelut-CBA-NT^-Column. The internal standard concentration 
was 2 ug/ml. The peak height ratio in duplicate, against concentration were 
plotted to construct a calibration curve for each amine.
3 .6 .2.1 Non-Acid Interferences in Samples Spiked with Drugs
Samples of whole blood spiked with anticonvulsants, benzodiazepines and opiates 
which were stored at different temperatures and times as described earlier, were 
extracted by the appropriate methods described earlier to investigate the presence 
of the three putrefactive amines in blood stored in sealed vials over the different 
storage intervals and times.
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Standard and Internal Standard Solutions
A standard solution mixture of the putrefactive amines containing 20 u g /m l of 2- 
phenethylamine, tyramine, tryptamine respectively as their free base were 
prepared in deionized water. The internal standard (dihydrocodeine) stock 
solution was made up in deionized water at a concentration of 2 0  ug/m l.
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Preparation of the Samples for Extraction
In a 6  ml screw-capped vial containing 1 ml of whole blood sample (spiked, post­
mortem) was mixed with 2 ml 57o w /v  NaHC 0 3  and 0.1 ml of 20 ug /m l internal 
standard dihydrocodeine.
Standard and Blank Preparation
0 . 1  ml of the above standard solution ( 2 0  ug/m l) of the three putrefactive amines 
mixed with 0 . 9  ml deionized water in a 6  ml capacity screw-capped vials. 0 . 1  ml 
(I.S.) and 2 ml 5% w /v  NaHC 0 3  were added. The blank sample was prepared by 
adding 1 ml deionized water to a vial containing 2 ml of 5% w /vN aH C 0 3  and 0.1 
ml (I.S.). The total volume in all samples (blood, standard, blank), was 3.2 ml. The 
prepared samples were extracted using the procedure mentioned above.
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3.7 DRUGS EXTRACTION
3.7.1 - Acid Drugs 
3.7.1.1. Anticonvulsants 
Preparation of Extrelut— Column
150g of Extrelut^ was washed with 500 ml of dichloromethane, then the Extrelut 
was collected on filter paper and allowed to dry out completely at room 
temperature.
A plug of silanised glass wool was introduced into small Pasteur pipettes then 
filled with the washed Extrelut^ to 1 cm from the top (approximately 0.6g of 
Extrelut^).
Standard Preparation
A standard solution containing each of 100 ug /m l phenobarbitone and phenytoin 
and 30 ug /m l carbamazepine was made up in methanol. A solution of 100 ug /m l 
butalbital (internal standard) was made up in methanol.
Extraction Procedure 
Extraction Buffer Preparation
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70.98 grams of disodium hydrogen phosphate (Na2 HP0 4 ) were dissolved in 
deionized water and made up to 1 litre to produce a buffering solution of 0.5M 
Na2 HP0 4  with a pH of 9.0.
Specimen Preparation 
Standard
0.1 ml of the acid drug standard was added to 0.9 ml of blank blood or deionized 
water in a screw-capped vial and mixed well.
Sample - "Blood Spiked with Anticonvulsant Drugs"
In a glass screw-capped vial, 0.4 ml of sample or spiked standard was mixed with 
0 . 4  ml of extraction buffer and 0 . 1  ml of internal standard (butalbital 1 0 0  ug/ml), 
and allowed to stand for two minutes.
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Blank
0.4 ml of blank blood or deionized water was mixed with 0.4 ml of extraction 
buffer and 0 . 1  ml internal standard (butalbital 1 0 0  ug/m l) in a glass screw-capped 
vial and allowed to stand for two minutes.
Extraction Procedure Using Extrelut— Column
0.65 ml of the prepared specimen "standard, sample, blank" was applied to the 
Extrelut column and allowed to absorb for 10 minutes. It was then eluted with 3 
ml dichloromethane, 0.5 ml at a time using an automatic pipette. The eluent was 
collected in a screw-capped glass vial. A little pressure was applied on the top of 
the column using rubber teat to assist recovery of the eluting solvent. This was 
evaporated to dryness by placing the vial on a hot plate (60°C) under a stream of 
nitrogen gas, then the extract was redissolved in 1 0 0  ul of mobile phase, 
ultrasonicated for five minutes and 2 0  ul injected onto the HPLC system.
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3.7.2 - Non-Acid Drugs
3.7.2.1 - Benzodiazepine 'Temazepam"
Extraction Buffer Preparation
Disodium hydrogen phosphate dihydrate (Na2 HP0 4 - 2 H 2 O M.wt. 177.99) buffer 
was made up by dissolving 1.78 grams of Na 2 HP0 4  2 H 2 O in deionized water and 
made up to 1 litre, producing a buffer concentration of 0.01M with a pH of 7.4.
Standard Solution Preparation
Temazepam standard solution was made up in methanol by dissolving 1 mg of 
Temazepam in 100 ml methanol. The resulting concentration was 10 ug/ml. The 
internal standard Prazepam was prepared by dissolving 3 mg in 100 ml methanol 
to produce a Prazepam standard concentration of 30 ug/ml.
Extraction Procedure
1 ml of the phosphate buffer (0.01 M) and 0.1 ml of the internal standard prazepam 
(30 ug/ml) were added into a ground-glass stoppered test tube. 1 ml of sample
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(blood/aqueous solution/blank blood) were added into the tube. In the case of 
standard preparation 0.9 ml of blank blood or deionised water followed by 0.1 ml 
of standard Temazepam (10 ug/m l) were added then the above solutions were 
extracted with 5 ml dichloromethane in ground glass stoppered test tubes placed 
on a (rock and roll) machine for 20 minutes. The supernatant layer was removed 
by Pasteur pipette. The dichloromethane was filtered through phase separation 
paper into a clean screw-capped glass vial. The dichloromethane evaporated to 
dryness by placing the vial on a hot plate 60°C under nitrogen gas stream. The 
benzodiazepine was redissolved by adding 100 ul of HPLC mobile phase. 20 ul 
was injected onto the HPLC system.
3.7.2.2 Opiates 
Specimen Preparation 
Spiked Standard
In a 6  ml screw-capped vial 1 ml of sample (blood/aqueous solution/blank blood) 
was mixed with 0.1 ml of opiates internal standard (5 ug /m l L>3 -morphine, 2.5 
ug /m l D2 "buprenorphine), then the samples were buffered with 1 ml of 0.1M 
ammonia solution mixed and allowed to stand for 2  minutes before being applied 
to the Extrelut^ column.
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Extrelut Column Preparation
Extrelut^ (Merck) was placed in conical flask and washed with copious amounts of 
methanol/ethanol (1:1). The Extrelut was collected in filter paper and allowed to 
dry out completely. A plug of silanised glass wool was introduced into a plastic 
syringe of 10 ml capacity. This was filled with 2 gm of Extrelut^.
Conditioning of SCX Column
SCX columns of 1 ml capacity were positioned in a 10 column capacity Vac Elut^ 
system. Pressure was adjusted to 10-15 mm Hg. SCX column were conditioned by 
passing 2  x 1 ml methanol followed by 2  x 1 ml deinonized water and followed by 
2 x 1 ml ethylacetate/Isopropanol (9:1 v/v).
Extrelut-SCX Extraction of Opiates
The buffered specimens (blood spiked with morphine and buprenorphine) were 
applied to the Extrelut column and allowed to stand for 5-10 minutes. The 
columns were washed with 5 ml hexane. The Extrelut columns were then attached 
to the pre-conditioned SCX column via an adaptor. The SCX column was put on 
the Vac-Elut^ system. Morphine and buprenorphine were then eluted from the
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Extrelut column with 1 2  ml of ethylacetate/Isopropanol (9:1) V/V under vacuum 
of ~ 5 mm Elg. Discard the Extrelut column and wash the SCX column with 5 ml 
acetonitrile/methanol (1:1 v/v). Morphine/buprenorphine was eluted from SCX 
column with 3 x 1 ml of 10% ammonia in acetonitrile/methanol (1:1 v /v) into a 
screw-capped glass vial. The elute was evaporated to dryness on a hot plate 60°C 
under nitrogen gas stream then derivatized with 1 0 0  ul 
diethyltetramethyldisilazane (DETMDS). 1 ul was injected into the GC/MS system 
described in 3.5.2.2.
3.8 - APPLICATIONS
3.8.1 - Interfering Substances in Post-mortem Samples
As it is known that the putrefaction process begins in the cadaver immediately 
after death, post-mortem on the cadaver usually takes place within the first 24-48 
hours after death. Blood specimens are taken from different sites of several 
cadavers according to availability.
The specimens from the cadaver, in most cases, are delivered for toxicological 
analysis within a few hours of the post-mortem examination. A full toxicological 
investigation on the specimens usually takes three to four days from the time of 
receiving the specimens. No preservatives such as sodium fluoride are normally 
used in preserving the post-mortem specimens. Samples under toxicological 
investigation are usually kept at 5°C. When the investigation is complete the 
samples are stored at -20°C for six months for any further enquiry. The samples 
are then destroyed.
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Under the above procedure of handling and storing the post-mortem blood, some 
degree of putrefaction is expected to occur.
Eleven samples of post-mortem blood representing different storage periods have 
been analysed for the presence of the putrefactive amines. Two samples of blank 
blood which were left uncovered for two months were analysed for the presence of 
acid and non-acid interferences.
Analysis for Acid Interferences
Post-mortem blood samples were analysed for Indole by the method developed for 
Indole determination in post-mortem blood 3.4.1. Samples were extracted in 
duplicate as described in 3.6.1 on the same day. Deionised water was used as a 
blank and to prepared standard Indole solutions.
Analysis for Non-Acid Interferences
The same samples as above were analysed as described in 3.4.2 for the presence of 
2 -phenethylamine, tyramine and tryptamine by buffering 1 ml of blood with 2  mis 
of 5% w /v  NaHC 0 3 . Then 0.1 ml of the internal standard solution of 
dihydrocodeine (2 ug/ml) was added. The mixture was then poured into a 10 ml
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syringe filled with diatomaceous earth (Extrelut^ Merck). The three amines were 
eluted to a CBA-column, as described in 3 .6 .2 .
3.8.2 Analysis of Drug Positive Post-mortem Samples
Samples of post-mortem blood which had been shown to be positive for drugs 
were stored at 5°C and -20°C for different time periods. The samples were re­
analysed for the presence of putrefactive amines and the changes in drug 
concentrations.
3.8 .2.1 Acid Drugs 
Anticonvulsants
Post-mortem samples containing anti-convulsant drugs were analysed after 
different storage periods. The method of extraction was described in 3.7.1 and the 
HPLC system used for anti-convulsant drug analysis was described in 3.5.1.
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3.8.2.2 Non-acid Drugs 
Benzodiazepine
Post-mortem samples shown to be positive for Temazepam were re-analysed after 
different storage periods. The method of extraction and analysis used was as 
described earlier in 3.7.2.1 and 3.5.2.1 respectively.
Opiates
Five samples of the post-mortem blood were re-analysed after different storage 
periods. These samples had been analysed and found to be positive for morphine. 
A method of analysis used for opiate analysis was based on HPLC [211] described 
below.
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Extraction of Morphine from Post-mortem Blood 
Extrelut Column
The Extrelut was firstly washed with ethanol/methanol (1:1) and dried thoroughly 
in an oven at 100°C before use. 1.2g of Extrelut^ (Merck) was added to a 5 ml 
capacity syringe plugged with silanized glass wool as an outlet filter.
Preparation of Extraction Buffers
1M ammonia solution was titrated with 2M hydrochloric acid using a pH meter 
with glass electrode until pH 9 was obtained.
Preparation of Standard Solutions
A standard solution was prepared by dissolving 2 mg of morphine hydrochloride 
in 1 0 0  ml methanol to produce a standard concentration of 2 0  ug/ml.
1 mg. of nalorphine hydrochloride was dissolved in 1 0 0  ml of methanol to produce 
an internal standard of 1 0  ug /m l
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Sample Preparation for Extraction
One ml of post-mortem blood was mixed with 1 ml of buffer in a screw-capped 
vial and then 100 ul of internal standard (Nalorphine) was added followed by 100 
ul of deionised water to make the total volumes 2.2 ml. Standard morphine extract 
was prepared using 1 ml of blank blood, 1 ml buffer, 1 0 0  ul standard morphine and 
100 ul of internal standard (Nalorphine). The solution was mixed together in a 
screw-capped vial.
Blank samples were prepared by mixing 1 ml blank with 1 ml buffer, 100 ul 
internal standard (nalorphine) and 1 0 0  ul deionized water.
Extraction
The standard morphine, morphine samples and blank were transferred into a 
separate Extrelut^ columns and left for 5-10 minutes.
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Elution of Morphine
After 5 -1 0  minutes the Extrelut^ columns were washed with 5% v /v  solution of 
n-butanol in dichloromethane until 8  ml were eluted into 20 ml capacity tubes. The 
elution solutions were evaporated under nitrogen until there was sufficient 
solution (2 ml) to transfer into a small screw-capped vial (3 ml capacity). It was 
then evaporated to dryness.
Analysis of Opiates 
Mobile Phase
Potassium dihydrogen phosphate of 0.01 M was prepared by dissolving 1.3g of 
KH2 PO4  in one litre of deionised water. 400 ml of the buffer was mixed with 100 
ml acetonitrile, then degassed for five minutes, l . lg  of octane sulphonic acid 
sodium salt was added to the mixture as an ion pairing agent. The pH of the 
mixture was adjusted to pH3 by adding a few drops of orthophosphoric acid and 
then degassed.
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Equipment and Column
The HPLC system described in 3.4.1 was used to analyse morphine. The mobile 
phase used consisted of 0.01 M potassium dihydrogen phosphate/acetonitrile 
(400:100 v/v). The mobile phase preparation is described above. The column 
eluent was monitored at 2 1 0  nm.
3.9 - THE EFFECT OF INTERFERING SUBSTANCES ON DRUG ANALYSIS
The interferences from the four putrefactive amines on qualitative and quantitative 
determination of acidic drugs and benzodiazepines were investigated by analysing 
the four putrefactive amines through the HPLC systems usually used for acidic 
drugs and benzodiazepines analysis.
3.9.1 - Acid Drugs 
Anticonvulsant
The HPLC system used to analyse the acid drug studied in this thesis, 
phenobarbitone, carbamazepine and phenytoin were also being used to analyse 
other acid drugs like primidone, butobarbitone, amylobarbitone, methaqualone
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and quinal barbitone. Therefore, the possible interferences from the presence of 
the four putrefactive amines with this procedure was investigated.
Equipment and Column
The HPLC system consisted of a Pye Unicam pump (4015) double two-head piston 
used to deliver the mobile phase with flow rate of 1.5 m l/m in, incorporating a Pye 
4025 variable wavelength ultra-violet detector set at 210 nm to monitor the column 
eluent.
The column used was 25 cm x 4.6 mm internal diameter (I.D) and guard column 5 
cm x 4.6 mm (I.D) both pre-packed with Hypersil 5 um octadecylsilane C18 and 
fitted with a Rheodyne 7125 injection port with a 20 ul loop. The spectra were 
recorded on a BBC Goerz Metrawatt SE120 chart recorder operated at 1 cm/minute 
and lOmV full scale deflection.
Mobile Phase
The elution system was composed of 0.02M sodium acetate/acetonitrile/methanol 
(400:180:180 v/v). The pH of the mobile phase was adjusted with glacial acetic 
acid to 5.5.
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Preparation of Drugs Standard Solutions
A stock standard solution mixture of all acid drugs was prepared in methanol. The 
drugs are primidone, phenobarbitone, butobarbitone, butalbital "internal 
standard," phenytoin, carbamazepine, amylobarbitone, methaqualone and 
quinalbarbitone. Their concentrations were 12.42, 10.98, 1 0 .2 , 5.76, 11.63, 5.54, 
13.39, 11.68, 11.15 mg/100 ml respectively. 20 ul of this standard mixture was 
injected onto the acidic drugs HPLC system.
Preparation of Putrefactive Amines Standard Solution
A stock solution of each of the putrefactive amines in free base form were prepared 
by dissolving 5 mg of 2-phenethylamine, tyramine and tryptamine and Indole in 
100 ml deionised water individually to produce a standard concentration of 50 
ug/m l. 2 0  ul of each amine was injected onto the acid drug and benzodiazepine 
drug HPLC systems to determine their retention times.
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3.9.2 - Non-Acid Drugs 
Benzodiazepine
The method described in 3.7.2.1 is used routinely for the screening and quantitative 
analysis for Temazepam and other benzodiazepines such as Triazolam, 
chlorodiazepoxide, desmethyl diazepam and diazepam in blood samples.
Equipment Column and Mobile Phase
The HPLC system consists of Pye Unicam PU 4015 pump with two-head piston 
used to deliver the mobile phase incorporating with Pye Unicam PU 4025 variable 
wavelength ultra-violet detector set at 230 nm to monitor the column eluent. The 
column used was 25 cm x 4.6 mm (I.D.) and guard column 5 cm x 4.6 mm (I.D.) 
both pre-packed with Hypersil 5 um Octadecylsilane C18 and fitted with 
Rheodyne 7125 injection port with 20 ul loop. The elution system composed of 
0.01M N ^ H P O ^ m e th a n o l  30:70 v /v . The spectra were recorded on BBC Goerz 
Matrawatt SE120 chart recorder operated at 1 cm /m inute and 10 mV full scale 
deflection.
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Standard Solution Preparation
A stock standard benzodiazepines solution of 2 u g /m l for the six benzodiazepines, 
Triazolam, Temazepam, chlorodiazepoxide, desmethyl-diazepam, diazepam and 
prazepam (Internal Standard) were prepared in methanol. 2ul of this standard 
mixture was injected onto benzodiazepines HPLC system.
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CHAPTER FOUR
RESULTS AND DISCUSSION
4.1 SPIKED SAMPLES, STORAGE, EXTRACTION AND ANALYSIS 
PROTOCOL
Blood and aqueous solutions of the drugs under study were prepared at a toxic 
level since most of the forensic toxicological cases involve measuring the drugs in 
specimens following overdose. Therefore in an investigation of the stability of 
drugs of forensic interest in post-mortem blood, it is of paramount importance to 
the toxicologist interpreting results that the study should comply with actual 
casework.
The storage temperatures were chosen to reflect common laboratory practise. The 
5°C 'refrigeration' represents the first storage temperature for samples received 
from the mortuary until a full drug screening is completed, usually days. 
Sometimes, as a result of further enquiries, weeks pass between acquisition and 
drug quantitation. Then the samples were kept at -20°C prior to analysis. Usually 
they are destroyed after six months from receipt of sample. The 25°C represents 
the upper realistic temperature which the corpse may have been exposed to for a 
few days after death. Therefore, it is necessary to ensure that the drugs are 
sufficiently stable at different storage temperatures and time intervals. The blood 
and aqueous solutions of drugs were kept under the same storage conditions and 
then analysed at the designated time. This enabled a comparison to be made 
between the amount of chemical decomposition and the degree of putrefactive
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degradation for each drug. The concentrations of each drug in blood and aqueous 
solution was analysed at the designated time. Freshly prepared standard drug 
samples were used to calculate the concentration of the drug in the spiked samples. 
The results were compiled in a table. In calculating the recovered drug the initial 
quantitation (day zero) was assigned a value of 100%. Successive quantitations 
were made and the '% of original present’ was calculated. Figure 16 shows the 
protocol of storage, extraction and analysis of the specimens for both drug stability 
and the formation of putrefactive amines in blood. The decrease in drugs 
concentration with time was obtained from the linear regression curve constructed 
between concentrations (x) and the storage times (y). The linear regression was 
established for all drugs under study and at the three storage temperatures for 
blood and aqueous solution samples. The obtained decrease rates for acid drugs 
and non-acid drugs are presented in Tables 34 and 38.
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ACIDIC DRUGS
Blood and aqueous 
solution stored 2  weeks 4 6 8 13 26 39 52 65
for
5 25 - 2 0
Storage Temperature
oC
Storage Temperature
5 25 - 2 0
NON-ACIDIC DRUGS 
Figure 16. The spiked samples, storage, extraction and analysis protocol.
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4.1.1 - Temperature Monitoring of Spiked Samples
Samples of whole blood and water were spiked with anticonvulsant, 
benzodiazepine and opiate drugs and stored in a refrigerator (5°C), an incubator 
(25°C) and a deep freeze (-20°C). Storage temperatures were monitored regularly 
over 24 hours throughout the course of the experiment which started after two 
weeks from spiking date (day zero) and ended at twelve months in the case of non­
acid drugs and 15 months in the case of acid drug samples.
Results and Discussion
Figures (17, 18,19) demonstrate the fluctuation of the set storage temperatures 5°C, 
25°C, -20°C monitored over different time intervals (hours, days, months). The 
average of each storage temperature over the different time intervals and the 
variation in temperature are summarised in Table 3. It shows that there was a + 
2.6% variation at 5°C, a ± 0.9% variation at 25°C and a + 7.6% variation at -20°C 
over a 24 hour period. Over 7 days the fluctuation was ± 5.2% variation at 5°C, ± 
1% variation at 25°C and a ± 8 .1 % variation at -20°C. Over the 12 months there 
was a + 5.8% variation at 5°C, a + 1 .2 % variation at 25°C and a + 4.8% variation at - 
20°C. The measured temperatures are not significantly different from the set 
temperature at any given time throughout the course of the experiment.
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Figure 17. Fluctuation of storage temperature 5°C monitored over:
a) 24 hours: b) seven days: c) twelve months.
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Figure 18. Fluctuation of storage temperature 25°C monitored over:
a) 24 hours: b) seven days: c) twelve months.
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Figure 19. Fluctuation of storage temperature -20°C monitored over:
a) 24 hours: b) seven days: c) twelve months.
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TABLE 3.
The average measured temperature and the standard deviation of the three 
storage conditions monitored over different time intervals (24 hours, 7 days, 12 
months).
Monitoring
Intervals
Refrigerator 
Temperature 
set at 5°C
Incubator 
Temperature 
set at 25°C
Deep Freeze 
Temperature 
set at-20°C
24 hours 5.14 ±0.13 24.7 ±0.23 -19.8 ±1.52
7 days 5.16 ±0.27 24.9 ± 0.26 -19.0 ±1.54
1 2  months 4.95 ± 0.29 25.1 ±0.3 -20.0 ± 0.96
Conclusion
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The temperature fluctuation of the three storage conditions are shown to be 
minimal and not significant, and within the normal temperature fluctuation of 
refrigerators, incubators and freezers, with less than 5 % differences between set 
temperature and actual temperature of the three storage media.
4.2. - ANALYSIS OF INTERFERING SUBSTANCES
4.2.1 - Acid Interferences "Indole"
Indole was analysed on the HPLC system described in 3.4.1. fitted with 100 ul loop; 
the flow rate was 1.5 ml/min. The filter of the detector was set at 0.5 seconds and 
the column eluant was monitored at 273 nm.
Choice of Internal Standard
Six chemical compounds and drugs were tested for potential use as an Internal 
Standard for Indole analysis by HPLC. The structures of the compounds are 
shown in Figure 20. The similarity to that of Indole can be seen in some of the 
compounds. The others were selected because of their use with acidic drug 
analysis in the routine laboratory.
H
Indolin
CO-
c h 3o o
.N
5-ChloroIndole
Cl
CH
c h 2c o o h
Indomethacin
C H 2 : CH- C H 2
(c h 3)2c h . c h 2
N Q (
NH
O
Butalbital
c h 3c h 2 
c h 3. (c h 2)3 '
Butobarbitone
C H 3 . C H . COOH
Fenoprofen
Figure 20. Chemical structure of com pounds chosen as internal standard for 
Indole analysis.
Result and Discussion
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Indolin showed a very good response on the HPLC. The Indolin standard solution 
(concentration of 0.1 ug/m l) gave a peak height of 16 cm at range (AUFS) = 0.16 
compared to 6.9 cm for Indole (concentration of 5 ug/m l) when detected at 210 nm. 
Since Indole and Indolin co-eluted from the column, Indolin can not be used as an 
internal standard. Indomethacin eluted from the column at 20.3 minutes compared 
to 6.2 minutes for Indole at flow rate of 1.5 m l/m in. Indomethacin had a poor 
response, a broad peak and a long retention time. It would therefore be time- 
consuming to use Indomethacin as an internal standard for the Indole analysis.
Fenoprofen has a more reasonable retention time of 14 minutes (Indole has 6.2 
minutes) for the conditions used. It has, however, a poor response at the system 
working wavelength which would result in the use of a high concentration of 
Fenoprofen.
Barbiturates were tested as possible internal standards because they are known to 
separate extremely well using the system [158]. Butalbital and butobarbitone have 
sharp peaks with good retention times 3.8 and 4.2 respectively compared with 
Indole 6.2 minutes. Both were shown to have poor recovery with the method used 
for Indole extraction. 5-chloroIndole, an Indole derivative, was tested for its 
suitability as an internal standard for the Indole analysis. 5-chloroIndole would be 
expected to behave in the same manner as Indole on the HPLC and the extraction 
procedure. 5-chloroIndole was shown to have a symmetric peak shape with a 
retention time of 12.3 minutes compared to 6.2 for Indole. 5-chloroIndole also 
dem onstrated a good absorptivity within the working wavelength of the HPLC
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system. 5-chloroIndole was not mentioned as a putrefactive product in the 
literature, therefore it can be used as an internal standard.
The Maximum Absorptivity of Indole and 5-ChloroIndole (I.S)
The maximum absorptivity of Indole in the mobile phase was at 218 nm and 272 
nm, and for 5-chloroIndole was at 234 and 278 nm. The detector was set at 273 nm 
for Indole and 5-chloroIndole for analysis by HPLC. A very stable baseline was 
obtained at this wavelength and little interference was encountered from other co- 
extractable materials.
Linearity and Minimum Detectability of the HPLC
A series of standard Indole solutions was analysed by HPLC. The peak height to 
the Indole concentration response on the above system was linear over the 
concentration range 0.5 - 5 ug/m l. The regression equation (y = A + BX) and 
correlation coefficient (r) are as follows:
A
-0.14
B
2.37
r
0.998
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Where 'y' is the peak height and 'x' is the concentration of Indole. Table 4 shows 
the relation between Indole concentration and the peak height using HPLC system 
at AUFS = 0.02 and 0.08. The calibration curve produced between the peak height 
to concentration shown in Figure 21. A 50 ng/m l of Indole standard solution was 
found to be easily detected at range (AUFS) = 0.02 and filter set at - 0.5 secs. The 
response to background noise ratio was above five, Figure 22.
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TABLE 4.
Relation between Indole concentration and the peak 
height using HPLC system.
Indole Concentration 
ug/m l
Average Peak Height (cm) 
n = 2
0.5 2.4
1.0 7.0
2.0 10.6
3.0 15.7
4.0 19.4
5.0 24.0
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Figure 21. Indole m easurem ent by HPLC (linearity of response).
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Figure 22. Separation of Indole and 5-chloroIndole (I.S) by HPLC.
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Reproducibility of the HPLC
The reproducibility of the HPLC system for Indole analysis was shown to be 2.7% 
(n = 5) for the within-day variation, and in the range of 1.7% to 3.9% (n = 15) for the 
day-to-day variation at 0.02 absorbance unit full scale (AUFS).
Conclusion
The developed method for Indole analysis offered a very good sensitivity when the 
detector was set at 273 nm with a very stable baseline and little interference was 
encountered from other co-extractable material compared with the detection at 210 
nm. The reproducibility was excellent. From the materials tested, 5-chloroIndole 
was found to be suitable for use as an internal standard. The system also offered a 
reasonable analysis time of less than 15 minutes at a flow rate of 1.5 m l/m inute.
4.2.2 - Non-Acid Interferences
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Mobile Phase Development
In normal phase chromatography a non-aqueous mobile phase is usually used. 
Therefore, different organic solvent ratios have been investigated to obtain the best 
mobile phase to separate 2-phenethylamine, tyramine and tryptamine. The HPLC 
equipment used in developing the mobile phase was described earlier (3.4.2).
Result and Discussion
Table 5 shows the different ratios of organic solvents (v /v /v ) used to achieve 
separation of the three putrefactive amines. 2-phenethylamine and Tryptamine are 
soluble in ethanol while Tyramine is soluble 1 to 10 in boiling ethanol. The three 
compounds are primary amines. This group is responsible for the basic properties 
of these compounds. Separation achieved by 'adsorption' chromatography is 
usually based on the competition for sites on the active adsorbent surface of silica 
between the molecules of samples and the molecules of mobile phase 
"acetonitrile/methanol and the modifier ammonia." On this mobile phase 
ammonia and the (-NH2 ) group of the putrefactive amines are competing for the 
adsorptive sites of the column. Increasing the amount of ammonia leads to earlier 
elution of the putrefactive amines. If the affinity of the column packing for the 
sample molecules is greater than its affinity for the mobile phase, then the sample 
will be retained and the previously adsorbed solvent molecules displaced. 
Conversely, a stronger affinity for the mobile phase will lead to rapid elution of the 
sample. The chosen mobile phase gave an intermediate set of conditions with a
- 167 -
degree of retention rather than complete or zero retention of the putrefactive 
amines.
The initial solvent mixture chosen as mobile phase was acetonitrile/ methanol/ 
ammonia (60:40:0.3 v /v /v ). The obtained chromatogram is shown in Figure 23a. 
A poor separation of the three putrefactive amines was noted. By increasing the 
amount of acetonitrile and ammonia and decreasing the methanol content, a better 
separation was achieved. The shorter retention times could be explained by the 
increased amount of ammonia added, which reduced the availability of adsorptive 
sites for (-NH2 ) group of the putrefactive amines. This leads to faster elution of the 
three putrefactive amines Figure 23b. On the other hand, decreasing the amount of 
ammonia and acetonitrile gave a better separation of the three putrefactive amines 
Figure 23c but with poor baseline separation. Making a mobile phase with equal 
amounts of both acetonitrile and methanol gave a better separation betweeen 
Tyramine and Tryptamine at the base line but with a poor separation between 
Tyramine and 2-phenethylamine. There was no significant effect on the retention 
times of the three putrefactive amines when the amount of modifier (ammonia) 
was kept constant, Figure 23d.
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TABLE 5.
Different organic solvent ratios tested for putrefactive amines separation on a 
normal phase HPLC system.
Solvent Ratios 
(V/V/V)
Solvents
a 60: 40: 0.3 Acetonitrile /  Methanol /  Ammonia
b 70: 30: 0.4 Acetonitrile /  Methanol /  Ammonia
c 35: 65: 0.3 Acetonitrile/ Methanol /  Ammonia
d 50: 50: 0.3 Acetonitrile/ Methanol /  Ammonia
e 83: 22: 0.2 Acetonitrile /  Methanol /  Ammonia
f 82: 25: 0.3 Acetonitrile/M ethanol/Ammonia
g 82:10:15: 0.3 Acetonitrile /  Methanol /  Isopropanol /  Ammonia
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The best separation of the three putrefactive amines was observed with a mobile 
phase containing 80% acetonitrile and 20% methanol. An obvious effect of the 
modifier "ammonia" concentration on the retention times of the three putrefactive 
amines is shown in Figure 23e and 23f. As the amount of ammonia increases the 
retention time decreases.
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Figure 23. The effect of different ratios of acetonitrile/methanol/ammonia on 
the separation of the three putrefactive amines on a normal phase 
HPLC
1. 2-phenethylamine. 2. Tyramine.
3. Tryptamine.
- 171 -
i n l n
Time (minutes)
Figure 23 (Continued)
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Figure 23 (Continued)
Choice of Internal Standard
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Different compounds were tested for suitability of use as an internal standard for 
putrefactive amine analysis. All of them satisfy an important criteria in that they 
are not encountered as an interfering substance such as artefacts, naturally 
occurring substance or products of putrefaction. Their chemical structure is shown 
in Figure 24.
Result and Discussion
The behaviour of the tested internal standards on the normal phase HPLC system 
in mobile phase (f) are demonstrated in Table 6. It shows that most of the 
compounds are co-eluted with the first amine (2-phenethylamine) or eluted with 
solvent front. Only "Dihydrocodeine" appeared to be a candidate for use as an 
internal standard since it eluted from the HPLC system after the three putrefactive 
amines. It was, however, poorly separated from Tryptamine. Therefore different 
amounts of Isopropanol were added to the mobile phase (f) to improve the 
separation. The new mobile phase (g) resulted in a very good separation between 
Tryptamine and dihydrocodeine (I.S) and maintained a good separation between 
the other putrefactive amines, Figure 25, with an analysis time of less than five 
minutes.
The developed mobile phase (g) which consisted of acetonitrile /m ethanol/ 
isopropanol/ammonia (82:10:15:0.3 v /v /v /v )  was adopted for the analysis of the 
three putrefactive amines in putrefied blood.
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Figure 24. The chemical structure of compound tested for suitability of use as 
an internal standard in putrefactive amines analysis using normal 
phase HPLC system.
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TABLE 6.
The separation of chosen internal standards on the developed HPLC system for 
non-acid interfering substances analysis using mobile phase (f).
Compound
Elution order 
of chosen 
internal standard
5-chloroIndole
Failed to chromatogram
Amitriptyline
Eluted with 
2-phenethylamine
Phenylethylacetylurea Eluted with 
2-phenethylamine
Flupenthixol Eluted with 
Tyramine
Nalorphine Eluted with 
solvent front
Morphine Eluted with 
2-phenethylamine
Dihydrocodeine Eluted after 
Tryptamine with poor 
separation
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Figure 25,
1.
3.
Time (minutes)
Separation of the three putrefactive amines and the internal 
standard on normal-phase HPLC system.
2-phenethylamine. 2. Tyramine.
Tryptamine. 4. Dihydrocodeine.
Linearity of HPLC-Svstem
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The peak height of each putrefactive amine was plotted against its concentration 
over the concentration range 0.5 to 10 ug /m l for tyramine and tryptamine and 0.5 - 
16 u g /m l for 2-phenethylamine and were found to be linear, Figure 26. The 
regression equations (Y = A + BX). Where 'y' is the peak height, Y is the 
concentration of putrefactive amine and (r) the correlation coefficient for the three 
putrefactive amines. These are listed in Table 7 and the relation between the peak 
height of each putrefactive amine and concentration is shown in Table 8.
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TABLE 7.
The correlation coefficient (r), A and B values for the three putrefactive 
amines obtained from they regression equation (Y = B + BX).
A B r
2-phenethylamine -0.26 2.04 0.998
Tyramine 0.32 1.75 0.999
Tryptamine 0.24 1.70 0.999
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TABLE 8.
Relation between putrefactive amines concentration and peak height using 
normal phase HPLC system at range AUFS = 0.02 and 0.08.
Concentration ug/m l Average peak height (cm) 
n = 5
0.5 1.1
2 4.5
Phenethylamine 4 7.3
8 15.2
16 33
0.5 1
2 4
Tyramine 6 10.8
8 14.2
10 18
0.5 0.95
2 3.8
Tryptamine 4 7
6 10.6
8 13.8
10 17.2
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Minimum Detectability and Maximum Response
In the developed normal phase HPLC system with the mobile phase (g), a standard 
solution of 50 ng, 50 ng, 50 ng/m l for 2-phenethylamine, tyramine and tryptamine 
were found to be detected easily with signal to background noise above three at a 
range (AUFS) = 0.02, filter setting 2 sec. Figure 27. The standard solution of the 
three putrefactive amines in the mobile phase at a concentration of 20 ug /m l 
showed a maximum absorbance at 216 nm for 2-phenethylamine, 225 nm for 
tyramine and 226 nm for tryptamine. Tryptamine showed the best absorption over 
2-phenethylamine and tyramine, Figure 28.
Reproducibility of the HPLC-Svstem
The reproducibility of the developed HPLC system for the three putrefactive 
amines were tested over three days. A summary of the reproducibility for the 
three putrefactive amines shown in Table 9.
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Figure 27. Separation of the three putrefactive amines and dihydrocodeine 
(I.S) on normal phase HPLC at low concentrations. The HPLC condition: 
Range (AUFS) = 0.02 
Detection Wavelength = 210 nm 
Sample Volume = 100 ul 
Flow Rate = 1 ml/min 
Detector Filter = 2 sec.
Standard solution concentration - 50 ng/ml for each putrefactive amine. 
Internal standard concentration 100 ng/ml 
1. 2-phenethylamine 2. Tyramine
3. Tryptamine 4. Dihydrocodeine (I.S)
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Figure 28. The ultra-violet spectra of the three putrefactive amines in mobile 
phase (f).
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TABLE 9.
Reproducibility of normal phase HPLC system for the analysis of the 
three putrefactive amines.
Within Day Variation COV 
(Six Samples Analysed)
Day-to-day 
Variation COV 
Over three days 
(18 Samples Analysed)
2-phenethylamine 6.1% 3.3-7.01%
Tyramine 4.2% 2.9-5.1%
Tryptamine 4.9% 2.8 - 6.6%
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Conclusion
The developed method for 2-phenethylamine, Tyramine and Tryptamine offered a 
good senstitivity of 50 ng/m l for each amine. The reproducibility is good. The 
system also offered a short analysis time for the three putrefactive amines 
simultaneously with analysis time of less than five miutes at a flow rate of 1.0 
m l/m in.
4.3 DRUGS ANALYSIS
The sample of anticonvulsants, benzodiazepines and opiates spiked in whole blood 
and water and the blank blood which were stored at the three different 
temperatures (5, 25, -20°C) were analysed at the designated time according to 
protocol (4.1). Standard blood and aqueous solutions of each drug were prepared 
freshly for each analysis.
4.3.1 - Acid Drugs
4.3.1.1 - Anticonvulsants
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Whole blood and water spiked with the anticonvulsant drugs phenobarbitone, 
carbamazepine and phenytoin were analysed using the chromatographic system 
described (3.5.1) and extracted using the described method in 3.7.1.1.
Results and Discussion
The retention times of the three anticonvulsant drugs and their internal standard 
(Butalbital) are shown on Table 10. The day-to-day and within-day variation for 
the entire method of extraction and analysis of the anticonvulsant drugs by HPLC 
are shown in Table 11 and the chromatograms of phenobarbitone, carbamazepine, 
phenytoin and (I.S) butalbital analysed on this system is shown in Figures (29, 30, 
31).
- 1 8 8  -
TABLE 10.
Retention times of anti-convulsant drugs on acidic drug HPLC system.
Drug Retention Time
Phenobarbitone 6.2 mins
Carbamazepine 11 mins
Phenytoin 11.4 mins
Butalbital (6.5) 8.5 mins
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TABLE 11.
Variation of anti-convulsant drugs analysis within a day and from day-to-day.
Within the Day Variation Day-to-Day Variation
Drugs COV* in blood 
sample
COV* in aqueous 
solution
COV* in blood 
sample
COV*
solution
in aqueous
Phenobarbitone 4.7% n = 6 6.5% n = 5 8.5% n = 8 9.1% n = 8
Carbamazepine 8.2% n = 6 7.6% n = 6 9.5% n = 8 9.5% n = 8
Phenytoin 6.8% n = 6 8.1% n = 6 8.6% n = 8 9.3% n = 8
* C O V  = C o e ff ic ie n t  o f  varia tion  = (standard  d ev ia tio n /m ea n ) X 100
C o lu m n : H y p e r s il 5 u m  C18 = 25 cm  x 4.6 m m  I.D
M o b ile  p h a se : (0 .02M ) so d iu m  aceta te /a ce to n itr ile /m eth a n o l (400:180:180) p H  = 5.5
D e te c t io n  w a v e le n g th  210 n m
F lo w  R ate: 1.5 m l/m in u te
D ru g s  co n cen tra tio n  10 u g /m l p h en o b a rb ito n e
3 u g /m l ca rb a m a zep in e , 10 u g /m l p h e n y to in  and  10 u g /m l b u ta lb ita l (6.5)
- 190 -
I.S.
Phenobarbitone
Time (minutes)
Figure 29. The chromatogram of phenobarbitone and butalbital (I.S) on acid
drugs HPLC system.
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Carbamazepine
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Figure 30. The chromatogram of Carbamazepine and butalbital (I.S) on acid
drugs HPLC system.
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Figure 31. The chromatogram of Phenytoin and butalbital (I.S) on acid drugs
HPLC system.
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4.3.2 Non-Acid Drugs
4.3.2 . 1  - Benzodiazepine
Temazepam separation was achieved using the described HPLC system, 3 .5 .2 . 1  
and extracted using the described method in 3.7.2.1.. Fresh standards and blanks 
were used for each analysis.
Result and Discussion
The retention time of Temazepam and the internal standard prazepam were 5.4 
and 11.0 minutes respectively, Figure 32. The method of benzodiazepine analysis 
showed coefficients of variation of 4.1% and 4.8% for the within a day and day-to- 
day variations for temazepam in blood samples respectively, while the coefficients 
of variation for aqueous solutions were 5.2% and 5.4% repsectively.
4.3.2 . 2  Opiates
Gas chromatography-mass spectrometry was used to analyse morphine and 
buprenorphine as described, 3 .5 .2 .2 , and extracted using the method described in 
3.7.2.2. The derivatization reagent used was 40% DETMDS -(diethyltetramethyl- 
disilazane) in acetonitrile/toluene (7:3 v/v).
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Prazepam
Temazepam
Time (minutes)
Figure 32. The chromatogram of Temazepam and Prazepam (I.S) on 
benzodiazepine HPLC system.
Results and Discussion
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The derivatized morphine and buprenorphine molecular ions (MI) were recorded 
using selective ion recording (SIR) on the VG model 70-2505 mass spectrometer. 
The instrument was tuned on mass 454.9728 of perfluorokerosene (PFK) to a 
resolution of 1 0 0 0 .
The derivatized morphine has the molecular ion (m /z  457) as the most abundant 
ion on the mass spectrum. Derivatized buprenorphine has the most abundant ion 
at mass (464) formed by the loss of a neutral group (methanol) and the tertiary 
butyl group (57 a.m.v) from the molecular ion (m /z  553). The electron impact 
mass spectra of morphine and buprenorphine as EDMS derivatives are shown in 
Figure 33. The retention time of the morphine molecular ion (m /z  457) was 10:43 
minutes and 10:42 for the internal standard D3 ~morphine molecular ion (m /z  460). 
Buprenorphine molecular ion (m /z  464) had a retention time of 18:47 minutes and 
18:46 for the internal standard D2 -buprenorphine molecular ion m /z  (466). Figure 
34 shows the chromatogram of morphine and buprenorphine. The day-to-day 
variation for morphine analysis were 4% and 5% for blood and aqueous solution 
respectively at 500 ng/m l, and at the same time, buprenorphine showed 6 .2 % and 
5 .8 % for blood and aqueous solution respectively at a buprenorphine concentration 
of 250 ng/m l.
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Figure 33. The electron impact spectra of (a) BIS-EDMS-Morphine and (b) 
EDMS-Buprenorphine.
I
n
t
e
n
s
i
t
y
 
I
n
t
e
n
s
i
t
y
- 197 -
100,
9 - 4 0  1 0 : 0 8  1 0 : 0 8  1 8 : 4 0  1 1 : 0 0  1 1 : 0 0  1 1 4 0  10 08
1 8 0 .
1 0 8 0  10 0 8  1 8 4 0
100.
I B 4 8
100.
Figure 34. SIR trace of morphine (a) and the internal standard D3- morphine 
(b), Buprenorphine (c) and the internal standard D2-Buprenorphine 
(d) as EDMS derivatives obtained by electron impact, their SIR 
masses.
a. 457.2469 
c. 464.260
b. 460.2657 
d. 466.2747
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Conclusion
The chosen methods for anticonvulsant, benzodiazepine and opiate analysis 
demonstrate a good reproducibility with a reasonable analysis time. The methods 
have been in use for a few years. The possible interference from putrefactive 
amines with drugs analysis using these methods will be investigated.
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4.4 EXTRACTION OF INTERFERING SUBSTANCES
4.4.1 - Acid Interferences 
Protein Precipitation Methods
Removal of protein by precipitation is an effective method of sample preparation. 
The main reason for removing proteins is that they can precipitate when in contact 
with the mobile phase and thereby block tubing, cause increases in back pressure 
or deterioration of HPLC column performance. The advantages of this technique 
are the speed at which the sample can be prepared and its simplicity. Different 
protein precipitation reagents have been tested for their suitability in sample 
preparation for solid phase extraction of Indole .
Result and Discussion
- 2 0 0  -
Methanol and Isopropanol are organic solvents that are miscible with water. They 
precipitate proteins by lowering their solubility. The recoveries of Indole from 
spiked whole blood using methanol as the protein precipitation reagent showed 
recoveries of about 80% in the supernatant using small volumes of blood and 
methanol in the ratio of 1:3 v /v . Using isopropyl alcohol as the protein 
precipitation reagent recoveries of about 90% were obtained using a 
sample/isopropanol ratio of 1:3. Zinc sulphate is also known to precipitate 
proteins in whole blood sample preparations. It acts by forming insoluble salts 
with the proteins. Zinc sulphate is mixed with methanol in the ratio of 7:3 v /v  and 
two volumes of this are mixed with one volume of whole blood. After the sample 
was vortexed and centrifuged, the supernatant gave a recovery of Indole, of about 
35%. Using two volumes of perchloric acid (0.4M) with one volume of whole 
blood spiked with Indole gives the poorest recoveries (<5%). Also, a very poor 
recovery was obtained when using the sulphosalicylic acid (10%) method. These 
acids precipitate proteins by forming insoluble salts. The low recoveries of Indole 
could be due to instability in the acidic environment or the formation of an 
insoluble salt. In the preliminary test using methanol and isopropanol in ratio of 
5:1 v /v  a recovery of 95 + 4.5% was obtained.
-  2 0 1  -
Recovery of Indole with Methanol/Isopropanol
The recoveries of Indole and 5-chloroIndole (I.S) from blood using 
m ethanol/isopropanol as the protein precipitation reagent are shown in Table 12. 
The recoveries over the concentration range of 0.25, 1, 5 ug /m l Indole in whole 
blood was excellent for both Indole and 5-chloroIndole (I.S) with very good 
reproducibility.
Conclusion
A high recovery of Indole from spiked whole blood was obtained when using 
methanol and isopropanol in the ratio of 5:1 v /v  as protein precipitation reagent. 
Poor recoveries (5 - 35%) were obtained when using one of acid protein 
precipitation reagents. Therefore methanol/Isopropanol protein precipitation was 
adopted in this study as the sample preparation for solid phase extraction of 
Indole.
- 2 0 2  -
TABLE 12.
The average recoveries of Indole and 5-chloroIndole (I.S) from blood treated 
w ith m ethanol/Isopropanol to precipitate the protein.
Indole and
5-chloroIndole
Concentrations
5-chloroIndole 
% Recoveries
Indole 
% Recoveries of
Samples
0.25 ug /m l 93 ±3.5% 97 ±2.5% n = 5
1 u g /m l 94 ±4.7% 108 ±4.1% n = 5
5 u g /m l 112 ±4.8% 111 ±3.3% n = 5
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Solid Phase Extraction of Indole
The supernatant of whole blood spiked with Indole when treated with 
methanol/Isopropanol is not applicable for direct analysis on the HPLC system 
since the supernatant still contains other endogenous compounds and the sample 
volume is large. Therefore futher steps have to be considered to concentrate the 
sample and gave a cleaner extract. Solid phase extraction satisfies these criteria.
Bond Elute Certify
The Bond Elute Certify column was conditioned with 2 x 2 ml 0.1 M phosphate 
buffer KH2 PO4  (pH 6 ). The manufacturer, Analytichem International, claims that 
this column is capable of extracting acidic, basic and neutral components from 
biological specimens. Therefore this column was tested for its suitability in 
extracting Indole from blood as described in 3.6.1.
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Result and Discussion
Table 13 shows the percentage losses of Indole when extracted through the Certify 
Column.
Bond Elute Certify exhibited a very poor extraction recovery for Indole since 58% 
of Indole was found in the column effluent when the samples was draw n through 
the column (unretained). 2 0 % losses were observed during the rinsing step with 
80:20 v /v  of 0.1M phosphate buffer/m ethanol. Washing the column with hexane 
also caused a decrease in the Indole recovery. 18% of the Indole was washed from 
the column with the hexane. The total losses of Indole using the Bond Elut Certify 
column was about 96%. This makes the Certify column unsuitable for Indole 
extraction but would offer a clean extract in the case of drug extraction from 
putrefied specimens.
Non-Polar Sorbent C18
C18-column is known as a non-polar sorbent. Compounds with non-polar 
functional groups (e.g. alkyl chains, aromatic rings) can be extracted from polar 
solutions (water, buffer). The isolate should be neutral for the best non-polar 
retention.
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Buffering System
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The 6  ml capacity C18-column was activated by passing through 2 x 3 ml methanol 
followed by 2 x 3 ml deionized water and 2 x 3 ml phosphate buffer 0.05/0.5M 
disodium hydrogen phosphate (pH 9.0). 1 ml of Indole standard (5ug/m l in
methanol) mixed with 2  ml of buffer were poured into the column which was then 
washed with 3 ml deionized water and was dried by leaving the vacuum on for 
five minutes. Then Indole was eluted from the column by 2 x 0.5 ml methanol and 
analysed by HPLC.
Result and Discussion
No data is available on the pka value of Indole but Indole is known as a tertiary 
amine and it has been successfully extracted from blood by organic solvent at high 
pH value with excellent efficiency [28]. Therefore, buffering the Indole samples 
with phosphate buffer with high pH value will enhance the non-polar properties of 
Indole and a non-polar interaction will be expected to occur between the non-polar 
carbon-hydrogen bond of the Cl 8 -column and the carbon-hydrogen bond and 
benzene ring of the Indole molecule. Indole was eluted by 2 x 0.5 ml methanol. 
The Indole recoveries are shown in Table 14. Un-extracted standard Indole of 5 
ug /m l was used to calculate the recovery. When the Indole standard was 
prepared in methanol and mixed with the 0.5M N a 2 HP0 4  it caused crystallization 
of Na2 HP0 4  in the column reservoir and blocked the column filter. This could be 
explained as methanol added to phosphate solution. It changes the polarity of the 
solution. Methanol is less polar than water, as a result methanol will reduce the
- 207 -
TABLE 14.
Recoveries of Indole using different ionic strength buffering systems.
Buffer
used
Sample
Concentration
Average 
Measured 
Concentration 
after Extraction
Average 
% Recovery
Number 
of Samples
0.5M Na2 HP04 5 ug /m l 4.7 ug/m l 96% ± 2.4 5
0.05M Na2 HP04 5 ug /m l 4.92 ug/m l 99% ±3.3 5
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solubility of Na2 HP04  and causes the precipitation of Na2 HP04. The 0.05M 
Na2 HP04  exhibited the same problem with less effect on passing the mixture 
through the column at high pressure. Therefore another buffer was chosen to 
overcome the precipitation problem. Sodium acetate at 0.1M was found to be a 
good buffering system which gave high recoveries.
Recoveries of Indole on C18 Bond Elut with Sodium Acetate Buffering
The disodium hydrogen phosphate buffer was replaced by low ionic strength 0.1M 
sodium acetate and the pH of the buffer adjusted to 12 by adding a few drops of 
0.1 M sodium hydroxide. Following the extraction procedure described earlier, 
Indole and internal standard were eluted with 2 x 0.5 ml methanol, and the eluant 
was analysed by HPLC. The efficiency of the extraction produced using sodium 
acetate to buffer the Indole sample was investigated.
Result and Discussion
The recoveries of Indole and 5 -chloroIndole (I.S) at low and high concentrations 
are shown in Table 15. Un-extracted Indole and 5-chloroIndole was prepared at
0.5, 5 ug /m l to calculate the recoveries. Cl 8 -column conditioned with sodium 
acetate buffer showed good recoveries when standard Indole mixed with sodium 
acetate buffer in a ratio of 1:2 was passed through Cl 8 -column, Indole was eluted
- 209 -
from the column using methanol (2 x 0.5 ml). The recoveries of Indole was above 
93% from both high and low Indole concentrations. The internal standard (5- 
chlorolndole) showed recoveries of 90 ± 5.9% at 0.5 ug /m l (n = 10) and 84 + 6.5% 
at 5 ug /m l (n = 10).
-  2 1 0  -
TABLE 15.
Recoveries of Indole and 5-ChloroIndole (I.S) on C18-column using 0.1M 
sodium acetate buffer.
Concentration
ug/m l
Average 
% Recovery
Number of 
Samples
Indole 5 98 + 3.7% n = 1 0
0.5 93 ±5.7% n = 1 0
5-ChloroIndole 5 84 + 6.5% n = 1 0
0.5 90 ±5.9% n = 1 0
- 2 1 1  -
Day-to-day Recoveries of Indole on Bond Elut C18
The total number of samples used to estimate the day-to-day variation of the 
extraction procedure of Indole was 52 samples. Table 16 shows the average 
recoveries, coefficient of variation and number of samples used each time. 
Excellent recoveries were obtained for Indole samples at low and high Indole 
concentrations. The recovery was calculated by comparing the peak height of 
unextracted standard Indole with extracted samples.
-  2 1 2  -
TABLE 16.
Reproducibility of C18-column for Indole over three days at concentration of 0.5 
and 5 ug/ml.
Days
Average 
% Recoveries
Indole
Concentration
ug/m l
Coefficient
variation
Number
of
Samples
Extracted
First 98.4% 5 3.7% 1 0
92.6% 0.5 3.7% 1 0
Second 96% 5 8.7% 6
99.1% 0.5 2 .6 % 6
Third 93.0% 5 5.1% 1 0
91% 0.5 7.2% 1 0
Re-using Bond Elut Columns
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Cl 8 -Bond Elut^ columns have been tested for their ability to be re-used for Indole 
extraction (up to ten times). Different lot numbers of C18-column from the same 
supplier have been used in this investigation in duplicates. Their suitability for re­
use was found to vary between 7 and 10 times. The columns were washed and 
conditioned before re-used with three bed volumes of methanol followed by three 
bed volumes of deionised water. The recoveries of Indole when the Cl 8 -column 
was used up to ten times was always very good and in the range of 93-98%. The 
recoveries did not decline, gradually but showed a very sharp drop to less than 5 % 
in some columns after about 7 times. The reproducibility between the different 
column lot numbers was excellent with less than 5% variation, Table 17. The 0 8 -  
column was re-used only four times in this work as a safety measure.
Indole Extraction Calibration Curve
Samples of spiked blood with Indole and 5-chloroIndole (I.S) were treated with 
methanol/isopropanol (5:1 v /v) to precipitate the proteins. The supernatant was 
mixed with two volumes of 0.1 M sodium acetate and extracted through a 0 8 -  
column as described earlier. The relation between Indole concentration and 
average peak height ratio (std./I.S) of samples analysed by HPLC are shown in 
Table 18.
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TABLE 17.
The recovery of Indole extracted through C18-column of different lot 
numbers and the reproducibility of each column when used up to 7 - 10 
times.
Column Lot Number Recoveries Number of samples 
Extracted through 
The Column
A 98.4 ±3.7 n = 7
B 97.3 ± 2.9 n = 7
C 93.5 ±4.5 n = 1 0
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TABLE 18.
Relation between Indole concentration and average peak height 
ratio (Std./I.S) of samples extracted through C18-coluinn and 
analysed by HPLC.
Indole Concentration 
ug /m l
Average Peak Height 
Ratio 
n = 6
0 . 1 0.045
0.25 0.095
0.5 0 . 2 1
2.5 1.07
5 1.9
Extraction Procedure
-  2 2 1  -
1. Sample, standard and blank mixed with 0.1 ml 5-chloroIndole (50 ug/m l) in 
6  ml capacity screw-capped vials.
2. 2 ml of m ethanol/Isopropanol (5:1 v /v ) added to the above vials. Vortex 
the mixture for one minute and then centrifuge on an angle-head centrifuge 
for three minutes.
3. Transfer the supernatant (2.5 ml) to a clean vial and mix with 5 ml 0.1 M 
sodium acetate buffer.
4. The C18 column of 3 ml capacity was positioned in 10 ml column capacity
Vac Elut^ system and conditioned by 2 x 3 ml methanol followed by 2  x 3 
ml deionised water. The above mixture was transferred into a 10 ml syringe 
fitted above the conditioned column via adaptor.
5. The vacuum was applied and the sample was drawn slowly through the
column.
6 . Dry the column under full vacuum for two minutes.
7. Wash the column with \1%  methanol /w ater.
8 . Elute the Indole with 2 x 0.5 ml methanol into 3 ml capacity screw-capped 
vial. 500 ul injected into the developed HPLC system as described in 4.2.1.
-  2 2 2  -
Indole Losses with Storage
Indole standard solution of 0.6 ug/m l was stored at room temperature and 
analysed after five days. It showed losses of above 80%. This could be due to 
adsorption of Indole into the wall of the glass container.
Conclusion
The method developed for extracting the acid interference Indole from putrefied 
whole blood had a good recovery of above 91% using methanol/isopropanol as 
protein precipitation reagent and solid-phase extraction (C18-columns) with 
sodium acetate as the buffering agent pH = 12. Washing the C18-column with 12% 
m ethanol/w ater gave a cleaner extract without reducing the recovery. Extracted 
Indole should be analysed within the same day it is extracted and a freshly 
prepared Indole standard is desirable since there are significant losses on storage.
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4.4.2 Acid Interferences in Blood Samples Spiked With Drugs
Indole formation in blood spiked with the anticonvulsant drugs has been 
monitored from the day of spiking up to 52 and 65 weeks for non-acid and acid 
drugs respectively using the HPLC system described in 3.4.1. The HPLC system 
was fitted with a 500 ul loop and the column effluent monitored at 273 nm. Indole 
was extracted from whole blood spiked with the drugs under study using the 
developed method described in 4.4.1. Spiked blood samples stored at the three 
different conditions and time intervals were analysed at preset times as described 
in the analysis protocol, 4.1.
Result and Discussion
Figures 37, 38 and 39 show the concentrations of Indole in whole blood spiked with 
anticonvulsant drugs, benzodiazepines and opiates respectively when stored at 5, 
25, and -20°C for different time intervals. The figures show low Indole 
concentrations <50 ng /m l regardless of the storage temperature. This value 
represents the detection limit of Indole analysis methods. A higher concentration 
of Indole was noticed in 2 2  - 25% of samples only at the end of the experiment and 
usually in the samples stored at 5, 25°C.
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F ieu re 37 Indole concentration in blood samples spiked with anti-
8  convulsant drugs stored at: a) 5°c; b) 25°c; c) -20°c
over different time periods.
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Figure 38. Indole concentration in blood samples spiked with Temazepam
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Conclusion
Indole formation in whole blood samples spiked with anticonvulsant 
benzodiazepine and opiates was monitored. A considerable delay in Indole 
formation was noticed in all samples up to twenty-six weeks regardless of the 
storage temperature. Production of Indole was reduced by storing blood samples 
at -20°C.
4.4.3 Non-acid Interferences
Protein Precipitation/Diatomaceous Earths (ExtrelutR)
Two measures have been considered for sample preparation in the extraction of the 
three putrefactive amines through solid phase sorbent. Firstly using different 
protein precipitation reagents and secondly using diatomaceous earth (ExtrelutR).
-  228 -
Result and D iscussion
Applying post-mortem blood to Bond Elut columns causes complete blockage of 
the column filter. Therefore different measures were considered to make the post­
mortem blood usable with solid phase extraction. These were protein precipitation 
and diatomaceous earth extraction. Table 19 shows the recoveries of the three 
putrefactive amines with different protein precipitation reagent. In the case of 
whole blood spiked with 2 -phenethylamine, the methanol protein precipitation 
failed to give a good recovery since 30 - 40% of the spiked putrefactive amine was 
lost Another known protein precipitation reagent, zinc sulphate, was tested on 
sheep serum  spiked with 2-phenethylamine. It gave poor recoveries of (<10%) 
Acetonitrile/Isopropanol (5:1 v /v ) recoveries (50%) of putrefactive amines from 
whole blood.
The diatomaceous earth ExtrelutR, is an alternative measure for whole blood 
sample preparation for solid phase extraction. Samples of 1 ml whole blood spiked 
with the three putrefactive amines in different concentrations were buffered with 2  
ml 0.5M N a2 HP 0 4  with a pH value of 9.0 and mixed well in a screw-capped vial 
then poured into 10 ml capacity syringes containing around 1.5 gm of 
diatomaceous earth. The column preparation methods were described earlier, 
[3.6.2]. The mechanism of extracting the three putrefactive amines by ExtrelutR 
involves adsorption of aqueous phase into diatomaceous earth, a porous material 
of which acts as a support for the aqueous phase. This provides a large surface 
area for partition into the elution solvent which flows through the immobilized 
specimen under gravity eluting the putrefactive amines. Tyramine has a pka 
values of 9.5 for the phenol and 10.8 for the amine group. The other two 
putrefactive amines have no pka values available in the literature, but these
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compounds are known to exhibit basic characteristics due to the presence of amine 
group and are successfully extracted from blood at high pH [28].
A standard of the three putrefactive amines in blood buffered with 2 ml 0.5M 
Na2 HP0 4  were successfully eluted from Extrelut column with 
diethylether/Isopropanol (7:3 v /v ) and collected in 10 ml capacity tubes to a total 
volume of 8  ml. The pH of the collected eluent was 8.5. The other buffering 
system was 5% w /v  NaHCC^ (pH 8.0) spiked blood samples extracted and eluted 
from the column as above. The pH of the collected eluent was 7.5. The recoveries 
of the three putrefactive amines for the two buffering systems was measured by 
injecting 100 ul of the eluant in the HPLC system. The un-extracted standard was 
injected into the HPLC to calculate the recoveries. Table 20 shows the recoveries of 
the three putrefactive amines for each buffering system.
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TABLE 20.
The absolute recoveries for the three putrefactive amines from Extrelut using 
different buffering systems.
Putrefactive
Amine
Average Recovery Using 
0.5M Na2HP04  
n = o
Average Recovery using 
5% w /v  NaHCOo 
n = 5
2 -phenethylamine 8 6  ±6.5% 95 ± 8.4%
Tyramine 72 ± 6.5% 81 ±6.4%
Tryptamine 83 ± 5% 98 ±4.3%
- 232 -
Conclusion
The recoveries using Extrelut for extracting the three putrefactive amines is good 
compared with their recoveries when using protein precipitation reagent for 
samples preparation. At the same time, the Extrelut^ eluent contains other 
endogenous compounds co-eluted with three putrefactive amines, and a large 
sample volume. Further purification and concentration steps are necessary to 
produce a small sample volume and a cleaner extract suitable for HPLC analysis.
Solid Phase Extraction
Different types of solid phase sorbent have been tested for their suitability to clean 
up the extracts from the ExtrelutR column prior to analysis.
Non-Polar-Sorbent C18
Three ml capacity C18-column was conditioned with 2 x 3 ml methanol to activate 
the column by opening up the hydrocarbon chain and as a result increasing the 
surface area available for interaction. Washing the column with methanol removes 
residue from the packing material that might interfere with the analysis. The 
column was washed with 2 x 3 ml deionized water to remove the excess methanol.
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1 ml of standard 2 -phenethylamine at a concentration of 1 0  ug /m l were prepared 
in methanol and deionised water and mixed with 2  ml sodium acetate buffer 
(pH12). These were poured into the column reservoir and the samples drawn 
slowly through the column by vacuum. The column was then washed with 1 ml 
deionized water. Elution of 2-phenethylamine was achieved by adding 2 x 0.5 ml. 
of methanol or a solvent mixture acetonitrile/m ethanol/am m onia (82:25:0.3 
v /v /v ) . 20 ul of the recovered 2-phenethylamine was injected to the HPLC system 
described in 3.4.2.
Result and Discussion
Table 21 shows the recoveries of standard 2-phenethylamine prepared in methanol 
and in deionized water. 2 -phenethylamine was eluted from the column using 
different elution solvents.
2-phenethylamine samples prepared in water and extracted through C18-colum 
showed a very good recovery due to the presence of 2 -phenethylamine in a high 
polar environment. The recoveries obtained for 2-phenethylamine were above 90% 
when eluted with methanol and a solvent mixture of acetonitrile/m ethanol/ 
ammonia (82:25:0.3 v /v /v )  respectively. On the other hand, samples of 2- 
phenethylamine prepared in methanol extracted and eluted as above showed a 
lower recovery of about 50% due to the presence of methanol which had enough 
non-polar character to disrupt the non-polar interaction between the 2 - 
phenethylamine and the Cl 8 -column non-polar chain. Buffering the 2- 
phenethylamine samples at high pH value will increase the non-polar properties
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TABLE 21.
Recoveries of 2-phenethylamine prepared in different solvents and eluted from 
C18-column using different elution solutions.
Standard 
2 -phenethylamine 
Prepared in
Average Absolute 
Recovery of 
2 -phenethylamine 
Eluted with Methanol
Average Absolute 
Recovery of 
2 -phenethylamine when 
Eluted with 
Acetonitrile /  MeoH /  Ammonia 
(82:25:0.03 v /v /v )
Methanol 60 + 7% n = 4 52 ± 7% n = 4
Deionized Water 99 + 5% n = 6 93 ±9% n = 6
- 235 -
of 2 -phenethylamine by suppressing the ionization of the amine group and as a 
result increase the lipophilicity of 2 -phenethylamine and enhance the non-polar 
interaction with the non-polar side chain of C18-column.
Conclusion
Using the Cl 8 -column for extraction is limited since whole blood can not be 
applied directly to solid phase sorbent and non-polar sorbent C18 can not extract 
compounds present in organic solvents with a good recovery as noted in the case 
of 2 -phenethylamine in methanol.
Bond Elut Certify Column
The recoveries of the three putrefactive amines using this relatively newly 
marketed Bond Elut Certify column was investigated by extracting a standard 
mixture of 2 -phenethylamine, Tyramine, Tryptamine in a concentration of 10 
ug /m l through the Certify column as described in 3.6.2.
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Result and Discussion
The eluted amines were analysed by the HPLC system described in 3.4.2. Table 22 
shows the recoveries of 2-phenethylamine, Tyramine and Tryptamine using the 
Certify column. The table shows a poor recovery of the three putrefactive amines 
when extracted through the Certify column.
Therefore, the Certify column can not be used as an extracting column for 
putrefactive amines. On the other hand this column would be a good extraction 
column for putrefied urine and blood since around 75-95% of the putrefactive 
amines would not be retained on the column and lost during the extraction 
procedure. Therefore a clean extract would be expected when this column was 
used for basic drug extraction from putrefied biological specimens.
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Cationic Exchange Sorbent
- 238 -
In cationic exchange extraction the interaction occurs between an isolate molecule 
carrying a positive charge like "ionised amine" and the sorbent negative charge 
(sulfonic acid or carboxylic acid). Ion exchange sorbent in general is capable of 
extracting ionized molecules from a non-polar matrix. A Cationic exchange 
column was investigated for its suitability in retaining the three putrefactive 
amines.
SCX Sorbent
Benzene sulfonic acid (SCX) is known as a strong cation exchanger with very low 
pka, SCX exhibited ionic interaction, non-polar and ionic secondary interactions 
due to unbonded silanols on the silica substrates. A standard solution mixture of 
the three putrefactive amines, 2-phenethylamine, Tyramine and Tryptamine in a 
concentration of 1 , 1 , 0 . 5  ug /m l respectively, were prepared in the elution solvent 
of ExtrelutR to explore the possibility of a specific retention of the three 
putrefactive amines eluted from ExtrelutR with diethylether/isopropanol (7:3 
v/v). One ml of the standard mixture was drawn through a preconditioned SCX- 
column as described in 3.6.2. The column effluent was collected and analysed by 
HPLC. The percent losses are shown in Table 23.
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TABLE 23.
The losses of the three putrefactive amines during the extraction through SCX.
Putrefactive
Amine
Standard Mixture 
Concentration
Measured 
Concentration 
in the Column 
Effluent
%
Losses
2 -phenethylamine 1  ug /m l 0 . 1 2  ug /m l 1 2 %
Tyramine 1  ug /m l 0.16 ug /m l 16%
Tryptamine 0.5 ug/m l 0.08 ug /m l 8 %
Elution of the Sample
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Different elution solutions were used to disrupt the interaction between the 
sorbent and the putrefactive amines. Elution solvents with a pH of two units 
above the pka of the isolate are usually recommended to disrupt the cationic 
interaction and a non-polar solvent to disrupt the non-polar interaction. The first 
elution solvent tested was composed of 15% ammonia in diethylether/isopropanol 
(7:3 v /v ) and the other was 20% ammonia in methanol; their pH values were 11.0 
and 12.0 respectively. The recoveries of the three putrefactive amines from SCX- 
column using the three elution solutions are shown in Table 24. The first two 
elution solutions failed to give recoveries of more than 1 2 % for the three 
putrefactive amines. Eluting the three putrefactive amines from SCX column by 
using a solvent with a low pH value of 2 was tried. Recoveries of less than 23% 
were obtained for the three putrefactive amines which means that the three 
putrefactive amines were strongly retained on the SCX-column. Therefore, using 
SCX-column for putrefactive amine extraction is of little value due to the strong 
interaction between the functional groups of the sorbent and putrefactive amines.
CBA-Column
Carboxylic acid (CBA) columns (weak cation exchangers) were tested as an 
alternative of SCX for retaining the three putrefactive amines from the elution 
solvent of Extrelut. Standard solution mixture of 2-phenethylamine, Tyramine 
and Tryptamine in a concentration of 1, 1, 0.5 ug /m l and 10, 10, 5 ug/m l 
respectively were prepared in diethylether (DEE)/isopropanol (IPA) (7:3 v/v). 1 
ml of the standard mixture was passed through the precondition CBA-column.
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Result and Discussion
Table 25 shows the recoveries of the three putrefactive amines extracted through 
CBA-column. The interaction between the carboxylic group of the CBA sorbent 
and the amine group of the putrefactive amines was easily disrupted using acidic 
methanol pH2 which was two units below the pka of CBA sorbent of 4.8. 2 x 0.5 
ml acidic methanol successfully eluted the three amines. The recoveries were 
found to be excellent and above 95% for low and high concentrations of the three 
putrefactive amines.
It was noticed that direct injection of acidic methanol (CBA- column elution 
solvent) into the HPLC causes a temporary back pressure on the system and 
resulted in irreproducible retention time of the three putrefactive amines. This 
could be due to the presence of SO4  ions on the CBA-eluent. This problem has 
been solved by passing the acid methanol through the NT^-column. This is 
discussed later.
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TABLE 25.
Percentage recoveries of the three putrefactive amines from CBA-Column.
Putrefactive Amine Average 
% Recovery
Concentration
2 -phenethylamine 97 + 6.1%
98 ± 5.97o n = 6
1 u g /m l 
1 0  ug /m l
Tyramine 1 1 2  + 6 .8 % 
95 ±6.0% n = 6
1 u g /m l 
1 0  ug /m l
Tryptamine 103 + 7.4% 
97 ±5.9% n = 6
0.5 ug /m l 
5 ug /m l
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Re-using CBA-Columns
The possibility of using the CBA-column several times has been investigated. Six 
samples of standard 2-phenethylamine, Tyramine and Tryptamine in a 
concentration of 1 ug /m l were extracted through each CBA-column. Also a 
different lot number of CBA-column from the same manufacturer was used to 
investigate the reproducibility of different CBA-column batches. Unextracted 
standard solution ( 1  ug/m l) of the three putrefactive amines was prepared in acid 
methanol and analysed by HPLC to calculate the recoveries.
Result and Discussion
The recoveries of the three putrefactive amines were calculated by comparing the 
peak height of extracted to unextracted amines. Table 26 summarizes the 
recoveries and reproducibility of CBA of different lot numbers supplied by the 
same manufacturer. The recoveries after six extractions on different lot number 
CBA-colum was within the range of 96-105% and the variation between the three 
different lot number CBA-column was less than 8 %.
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TABLE 26.
The recoveries of the three putrefactive amines on CBA-column of different lot 
numbers and the reproducibility of the CBA-column when each column was 
used up to six times.
Lot
No
2 -phenethylamine 
Recovery ± COV
Tyramine
Recovery
±COV
Tryptamine
Recovery
±COV
Number 
of Samples 
extracted 
through 
each column
A 105 ± 6 % 104 ± 6 .8 % 103 ±7.9% 6
B 100 + 6.7% 98 ± 7.2% 96 ± 6 .6 % 6
C 103 + 6.5% 101+7.4% 99 ±8.0% 6
Anion Exchange Column
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Amino propyl is known to have polar and anion exchange as a prim ary interaction 
and non-polar, cation exchange as a secondary interaction. Amino propyl N H 2  
column was tested as a purification step of the CBA extract. Six samples of the 
three putrefactive amines mixture in a concentration of 1 , 1 , 0 . 5  u g /m l of 2 - 
phenethylamine, Tyramine and Tryptamine respectively, were prepared in acid 
methanol.
Result and Discussion
The recoveries of the three putrefactive amines prepared in acidic methanol and
passed through NT^-column were excellent. These are shown in Table 27. This
could be explained due to presence of the three putrefactive amines in organic
solvent (methanol) which disrupts the polar and non-polar interaction between the
sorbent and the amine. At pH2 the sorbent would not exhibit any cationic
interaction but it will exhibit its primary interaction (anionic). In this environment
— +
anionic interaction between the SO4  ions and (NH 3 ) of the sorbent is expected to 
occur resulting in a very low SO4  ion in the column effluent. When the N H 2- 
column effluent was injected into the normal-phase HPLC system no back pressure 
was noticed due to the absence of SO4  ions in the effluent.
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TABLE 27.
The percentage recoveries ’'unretained" when the three putrefactive amines 
passed through NH2 column.
Putrefactive Amine Average Recoveries + COV
2 -phenethylamine 98 ±3.5% n = 6
Tyramine 102 ±4% n = 6
Tryptamine 96 ± 6 % n = 6
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Recoveries from Combined Extrelut-CBA-NH 2
The preliminary investigation of the extraction of the three putrefactive amines 
from whole blood using diatomaceous earth column and CBA-column 
individually showed good recoveries. Different standard concentrations (0.1, 1, 5, 
10 ug /m l) of 2-phenethylamine, Tyramine and Tryptamine (six samples at each 
concentration in blood) were extracted using Extrelut-CBA-NH2  to investigate the 
efficiency of the combined Extrut-CBA-NH2  for extracting the three putrefactive 
amines, then the eluted amines were analysed using the described HPLC system, 
3.4.2.
Result and Discussion
Table 28 shows good recoveries of the three putrefactive amines from spiked blood 
with the highest recoveries for 2 -phenethylamine and the lowest recoveries for 
Tyramine over the concentration range of 0.1 -10 ug/m l.
Calibration Curve
The relation between putrefactive amines concentrations and peak height ratio 
(std./I.S) is shown in Table 29. A series of standard putrefactive amines mixture
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TABLE 28.
The recoveries of the three putrefactive amines from spiked blood extracted 
through the combines Extrelut-CBA-NH? over the concentrations range of 0.1 - 
10 ug/ml.
Putrefactive Amine Average recoveries 
n = 6
2 -phenethylamine 94 + 7.1% at 0.1 ug /m l 
93 + 4.5% at 1 ug /m l
95 + 8.4% at 5 ug /m l 
8 6  + 7.0% at 10 ug /m l
Tyramine 71 + 10% at 0.1 ug /m l 
74 + 8 % at 1 ug /m l 
81 + 6.4% at 5 ug /m l 
72+ 6.5% at 10 ug /m l
Tryptamine 94 + 8 % at 0.1 ug /m l 
81 +5.4% at 1 ug /m l 
89 + 8 % at 5 ug /m l 
83 + 6.7% at 10 ug /m l
- 250 -
TABLE 29.
Relation between the three putrefactive amine concentrations and the peak 
height ratio (std./I.S) for samples extracted through Extrelut-CBA-column and 
analysed by normal phase HPLC system.
Concentration ug /m l Peak height ratio
0 . 1 0.042
1 0.38
2 -phenethylamine 5 1 . 8
1 0 3.9
0 . 1 0.051
Tyramine 1 0.43
5 2 . 8
1 0 5.0
0 . 1 0.048
Tryptamine 1 0.57
5 2.3
1 0 4.7
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were extracted through the combined Extrelut-CBA-NIH^-column. A standard 
calibration curve constructed between the peak height ratio (std./I.S) and the 
concentrations of each putrefactive amine a linear relations were obtained, Figure 
40. The regression equation Y = A + BX. Where 'y' is the peak height ratio 'x' is the 
concentration of each putrefactive amine in ug/m l.
Table 30 shows the correlation coefficient (r) the slope (B) and the constant (A) for 
each amine.
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Figure 40. Standard calibration curves of the three putrefactive amines.
The concentration of each amine is plotted against peak 
height ratio: a) 2-phenethylamine. b) Tyramine. c) 
Tryptamine.
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TABLE 30.
The Linear Regression of the Three Putrefactive Amines extracted through 
combined Extelut-CBA and analysed by normal-phase HPLC.
A B r
2 -phenethylamine 0.04 0.44 0.998
Tyramine 0.07 0.78 0.999
Tryptamine 0 . 1 1 1.25 0.998
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Experimental Details
The Resulting M ethod for Extraction of the Three Putrefactive Amines.
The search to develope a method for the simultaneous extraction of the three 
putrefactive amines from blood resulted in the following extraction procedure.
A. Standard Preparation
To 0.9 ml of blank blood, 0.1 ml of the standard mixture of three putrefactive 
amines ( 2 0  u g /m l in water) were added and mixed well in a 6  ml capacity screw- 
capped vial.
13. Sample and Blank Preparation
1 ml of blood sample and blank blood were transferred to 6  ml capacity screw- 
capped vial.
Extraction Procedure
1. 2  ml of 5% w /v  NaHC 0 3  and 0.1 ml of dihydrocodeine I.S (20 ug /m l) were 
added to the prepared standard, sample and blank, then mixed well.
2. Transfer the mixture on to the Extrelut-Column and allow to stand for 10
minutes.
3. Elute the three amines with 12 ml diethylether/Isopropanol (7:3 v /v ) into a
pre-conditioned C13A-Column.
4. Discard Extrelut Column and elute the three putrefactive amines from CBA- 
Column with 2  x 0 . 5  ml acidic methanol (25 ul 1 0 % H 2 SO4  in 5 ml methanol) into
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NH 2 -column and collect the Nh^-column effluent and analyse using the 
developed HPLC system as described in 4.2.2.
Conclusion
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A m ethod for non-add putrefactive amines extraction from putrefied whole blood 
has been developed based on Extrelut and solid phase sorbent as an alternative 
measure of liquid-liquid extraction. The combined Extrelut and carboxylic acid 
(CBA) sorbent has excellent efficiency for simultaneous extraction of the three 
putrefactive amines. The CBA-eluent should be passed through the NT^-column 
to retain the SO4  ions to overcome the back pressure on the normal phase HPLC. 
The CBA-column showed excellent recoveries and reproducibility even when they 
were used several times and came from different batches.
4.4.4 Non-Acid Interferences in Blood Samples Spiked w ith Drugs
Samples of whole blood spiked with anticonvulsants, benzodiazepine and opiates 
were analysed for the presence of the three putrefactive amines being stored at 
three different storage conditions and different periods of time according to the 
analysis protocol described in 4.1.
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Result and Dicussion
A duplicate analysis had been conducted representing the standard, blank and 
blood samples extracted as described in 4.4.3. The samples were analysed using 
the developed HPLC system described in 4.2.2. The system was fitted with 100 ul 
loop at a range (AUFS) = 0.02, Filter = 2 sec.
Blood samples spiked with drugs under study showed low concentrations <50 
n g /m l of the three putrefactive amines regardless of the storage temperatures and 
the period of time. Sealing the vials containing the blood samples and using 
sterilised blood from blood transfusion could minimise the possibility of bacterial 
contamination
Conclusion
Low concentrations of the three putrefactive amines were found in all blood 
samples spiked with drugs regardless of the storage temperature. Therefore, no 
interferences are expected from the three putrefactive amines on the stability of 
drugs in whole samples.
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4.5 DRUGS EXTRACTION
Samples of whole blood and water spiked with drugs were extracted and analysed 
at the designated times. In each analysis a standard and blank were prepared to 
calculate the concentration of drugs under study. Data of each analysis were 
accumulated and tabulated at the end of the experiment. The standard for 
significant breakdown of drug to have occurred was a level measured which had 
decreased by greater than + 3 SD for the analytical technique from the day zero 
concentration.
Blood and aqueous drug solutions were stored for the same period and 
temperature to investigate the stability of the drug in putrefying blood, the 
influence of putrefactive products on the analysis and the effect of storage 
temperature. For comparative purposes, fresh spiked samples were prepared on 
the day of analysis. Additonally, they were used to determine the within-day and 
day-to-day coefficient variation of the technique for the whole expected period.
Drugs Stability
There is a large number of possible reactions leading to drug degradation and most 
of those that do occur are classed as either hydrolysis or oxidation. In hydrolytic 
reactions temperature, pH and the presence of water are the major factors that 
influence drug decomposition, while oxidation reactions are strongly influenced by 
environmental factors such as light and metal ions. One major problem of
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oxidation reactions is that some reactants such as oxygen need not be present in 
more than trace quantities to produce a significant stability problem, [2 2 2 ].
4.5.1 - A dd  Drugs
4.5.1.1 Anticonvulsants
Phenobarbitone, carbamazepine and phenytoin are examples of anticonvulsant 
drugs whose stability in blood at different storage temperatures were investigated.
Phenobarbitone Stability
Samples of blood and water spiked with phenobarbitone were prepared to give a 
concentration of 1 0  u g /m l then stored for analysis according to the protocol 
described in [4.1]. The samples were extracted using the described method, 3.7.1.1 
and analysed by the HPLC system described in 3.5.1.
Result and Discussion
The phenobarbitone concentrations following storage for the designated times and 
temperatures are presented in Table 31. The results for blood and water have been 
plotted in Figures 41 and 42. The per cent standard deviations for the entire
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method for phenobarbitone analysis were 8.5% and 9.1% for blood and aqueous 
solution respectively.
Figures 41 and 42 display the decline in phenobarbitone concentration in blood 
and aqueous solution stored at the three different temperatures, 5, 25, -20°C. 
Blood phenobarbitone samples analysed at twenty-six weeks (six months) showed 
no significant decrease in concentration with average recoveries of 79 + 3.9% 
regardless of the storage temperature. The first significant decrease in blood 
phenobarbitone concentration was observed after one year of storage with 
recoveries ranging from 56 - 6 6 %. At the end of the experiment (15 months) the 
average recovery for phenobarbitone was 46 + 7.5% regardless of the storage 
temperature. The values for the rate of decrease of phenobarbitone concentration 
(Table 34) shows no significant difference in degradation rates at the three storage 
temperatures. An average loss rate of 102 (+ 9%) ng /m l/w eek  was observed in the 
samples, (Table 34). On the other hand, the aqueous solutions of phenobarbitone 
stored for the same period of time showed a significant decrease in phenobarbitone 
levels. Samples stored at 5 and 25°C had recoveries ranging from 57 - 79%, and at 
the end of the experiment the recovery of phenobarbitone ranged from 18 - 41%.
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TABLE 31.
The concentration of phenobarbitone (ug/ml) in blood and aqueous solution 
stored at 5, 25, -20°C from day zero up to 65 weeks.
Storage Concentration 
when stored at 
5°C
Concentration 
when stored at 
25°C
Time when stored 
at 
-20°C
Weeks Blood Aqueous Blood Aqueous Blood Aqueouse
Solution Solution Solution
0 11.31 10.71 11.31 10.71 11.31 10.71
2 12.5 6.9 1 1 . 2 7.3
4 10.7 9.0 1 0 . 1 9.0
6 12.5 10.7 13.1 1 1 . 0
8 11.4 9.2 13.0 8.07
13 8 . 6 10.4 9.13 7.2 12.3 8.16
26 9.3 7.4 8 . 6 7.77 8.87 8.51
52 7.5 5.28 6.5 4.38 6.3 6.04
65 5.58 4.39 4.8 1.89 5.29 4.25
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Figure 41. Changes in phenobarbitone concentration with time in blood
samples stored at 5,25, -20°C from day zero to 65 weeks.
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Figure 42. Changes in phenobarbitone concentration with time in aqueous
solution stored at 5,25, -20°C from day zero to 65 weeks.
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From the above finding, phenobarbitone in blood showed a better stability 
compared with aqueous solutions stored at the same temperature for the same 
period of time. This could be explained by the hydrolysis of barbiturates in 
aqueous solutions. The hydrolysis mechanism of phenobarbitone in water [216, 
217] has been shown to depend on whether the phenobarbitone was in ionized or 
unionized forms. Generally unionized barbiturates were hydrolysed at the 1,2 
position Figure 45 while ionized barbiturates were hydrolysed at the 1,6 position 
Figure 46. The relatively better stability of phenobarbitone in blood was probably 
due to the reduced formation of the putrefactive amines in the blood and therefore 
the pH value for the blood would remain throughout the experiment were slightly 
acidic or neutral which favoured chemical stability of phenobarbitone since 
phenobarbitone hydrolysis is a base-catalyzed hydrolysis, [216].
Conclusions
Phenobarbitone in blood was shown to be more stable compared with 
phenobarbitone in aqueous solution when stored at the same temperature and 
time. The recovered phenobarbitone from blood samples at the end of the 
experiment were higher than those recovered from the aqueous solutions 
regardless of the storage temperature. Phenobarbitone in blood kept at the three 
storage temperatures for up to six months showed recoveries of 79 ± 3.9% 
regardless of the storage temperature, and even after 15 months of storage 
phenobarbitone was detected easily.
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Figure 43. D egradation m echanism of unionised phenobarbitone in aqueous 
solution.
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Figure 44. Degradation mechanism of ionised phenobarbitone in aqueous 
solution.
Carbamazepine Stability
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Samples of blood and water spiked with carbamazepine were prepared in a 
concentration of 3 ug /m l and then stored for analysis according to the protocol 
described in 4.1. The samples were extracted using the described method (3.7.1.1) 
and analysed by the HPLC system described in 3.5.1.1.
Result and Discussion
Carbamazepine concentrations measured in blood and aqueous solutions at the 
three different storage temperatures and time periods are listed in Table 32. The 
per cent standard deviation for the entire method of extraction and analysis for 
both blood and aqueous solutions was found to be 9.5% for for carbamazepine.
The measured concentrations of carbamazepine in blood and aqueous solutions 
stored at the three storage temperatures is shown in Figures 45 and 46. The 
figures show a consistent decline in blood carbamazepine levels stored at 5, 25 and 
-20°C from day zero to the end of the experiment (sixty-five weeks). A significant 
decrease in the blood carbamazepine concentration was found in samples stored at 
25°C only six weeks after of storage. Only 69% of the drug was recovered. After 
six months of storage, the recoveries at the three storage temperatures ranged from 
60 - 84% and at the end of the experiment (15 months). The recovered
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TABLE 32.
The concentration of carbamazepine (ug/ml) in blood and aqueous solution 
stored at 5, 25, -20°C from day zero up to 65 weeks.
Storage
Time
Concentration 
when stored at 
5°C
Concentration 
when stored at 
25°C
Concentration 
when stored at 
-20°C
Weeks Blood Aaueous
Solution
Blood Aaueous
Solution
Blood Aaueous
Solution
0 2.61 2 . 6 8 2.61 2 . 6 8 2.61 2 . 6 8
2 3.34 3.13 3.11 3.0
4 2.44 3.14 2.18 3.11
6 2.26 3.44 1 . 8 3.12
8 2.54 2.92 2 . 2 3.04
13 2 . 2 2.83 1 . 8 2.95 2.76 3.28
26 2 . 2 1 2.9 2 . 0 2 . 8 1.58 2.26
52 1.5 2 . 0 1.42 2.05 1.18 1.98
65 1.06 1.03 0.77 1.07 0.84 1.09
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Figure 45. Changes in carbamazepine concentration with time in blood stored
at 5,25, -20°C from day zero to 65 weeks.
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Figure 46. Changes in carbamazepine concentration with time in aqueous
solution stored at 5,25, -20° from day zero to 65 weeks.
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The recovered carbamazepine from blood samples was only 31% (±5.7%).
Blood carbamazepine samples showed no significant difference in their 
degradation rates when stored at 5, 25, -20°C. The average loss was 27 (± 9.4%) 
n g /m l/w eek , (Table 34). Temperature, therefore, has no effect on the stability of 
carbamazepine in blood. In contrast, no significant decrease in carbamazepine 
levels in aqueous solutions was noticed when stored at the three storage 
temperatures up to six months. Recoveries measured ranged from 84 - 108%. At 
the end of the experiment (15 months) a significant decrease was observed in the 
aqueous solution of carbamazepine. An average recovery of 40 ± 2.8% for the three 
storage tem peratures was obtained. For the aqueous solutions of carbamazepine 
no significant difference in the degradation rates regardless of the storage 
temperature was observed. An average loss of 27 (± 4%) n g /m l/w eek , (Table 34) 
was measured.
The above findings show that the loss of carbamazepine was similar regardless of 
the storage temeprature or the storage media. A reasonable am ount of 
carmabazepine would be recovered even after 15 months of storage.
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Conclusion
Carbamazepine was found to be reasonably stable in blood and aqueous solution 
up to six months regardless of the storage temperature, with recoveries ranging 
from 60 - 84% and 84 -108% for blood and aqueous solutions respectively. After 15 
months of storage at any temperature, a considerable amount of carbamazepine 
could be expected to be detected in blood samples from post-mortem cases 
involving a toxic dose of carbamazepine.
Phenvtoin Stability
Samples of blood and water spiked with phenytoin were prepared to give a 
concentration of 1 0  ug /m l then stored for analysis according to the protocol 
described in 4.1. Samples were extracted using the described method, 3.7.1.1 and 
analysed by HPLC system as described in 3.5.1.1.
- 273 -
Result and Discussion
The levels of phenytoin measured in the spiked blood and aqueous solutions and 
stored at the three storage temperatures and analysed at the designated time are 
listed in Table 33. The per cent standard deviation of the phenytoin analysis was 
8 .6 % and 9.3% for blood and aqueous solution respectively.
The measured drug levels have been plotted in figures 47 and 48 A significant 
fluctuation in phenytoin concentration in aqueous solution (Figure 50) was noticed. 
The same observation was reported [218, 219 and 220]. Phenytoin sodium, on 
exposure to air, absorbs carbon dioxide with the liberation of practically insoluble 
phenytoin [80].
Figure 47 shows less variation in blood phenytoin concentration compared to the 
aqueous solutions over the same period of time. Blood phenytoin samples showed 
a slower decline in the drug concentration over the period of twenty-six to fifty- 
two weeks of storage than the aqueous solutions for the same period. In blood the 
phenytoin showed no significant decrease in concentration with storage time or 
temperature over six months. An average recovery of 93 ± 5.4% was obtained. 
Over the next six month interval the recovery fell to 74 + 10% (i.e. after one year of 
storage) At the end of the experiment the average recovery dropped to 36 ± 5%.
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TABLE 33
The concentration of phenytoin (ug/ml) in blood and aqueous solution stored at 
5, 25, -20°C from day zero up to 65 weeks.
Storage
Time
Concentration 
when stored at 
5°C
Concentration 
when stored at 
25°C
Concentration 
when stored at 
-20°C
Weeks Blood Aaueous
Solution
Blood Aaueous
Solution
Blood Aaueous
Solution
0 10.73 10.3 10.73 10.3 10.73 10.3
2 13.8 8 . 1 1 11.5 9.46
4 1 0 . 0 11.9 9.55 11.4
6 12.9 1 1 . 6 1 0 . 8 1 1 . 2
8 10.4 8.97 1 1 . 2 7.69
13 9.7 11.3 8.7 13.0 12.4 15.5
26 1 0 . 0 11.5 9.45 10.45 10.54 9.69
52 8.9 8.06 7.69 7.76 7.36 7.58
65 4.01 4.13 3.65 4.64 3.94 4.26
Co
nc
en
tr
at
io
n 
ug
/m
l
- 275 -
18.0
storage temperature
5’C 25’C -20’C
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Phenytoin in Blood
Storage time(weeks)
Figure 47. Changes in phenytoin concentration with time in blood stored at 5,
25, -20°C from day zero to 65 weeks.
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Figure 48. Changes in phenytoin concentration with time in aqueous solution
stored at 5, 25, -20°C from day zero to 65 weeks.
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A significantly high phenytoin concentration was m easured in the aqueous 
solution samples stored at -20°C for three months. The sample was re-analysed 
several times and confirmed the high recovery. Further storage up to six months 
and one year at the three storage temperatures, resulted in average recoveries of 
102 + 8 .6 % and 76 + 3% for the samples analysed after six months and one year 
respectively. At the end of the experiment the average recovered phenytoin was 40 
+ 6 % regardless of the storage temperature.
Conclusion
Phenytoin was found to be relatively more stable of the anticonvulsant drugs 
studied in this work. Blood and aqueous solutions at the three storage 
temperatures showed average recoveries of 93 + 5.4% and 102 + 8 .6 % respectively 
after twenty-six weeks of storage. After fifty-two weeks (one year) of storage 74 ± 
1 0 % and 76 ± 3 % of phenytoin were recovered regardless of the storage 
tem perature in the blood and aqueous samples.
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TABLE 34.
The decrease rate in acid drugs concentration in blood and aqueous solution 
samples stored at 5,25 and -20°C, from day zero up to 65 weeks.
Decrease Rate in Acid Drugs concentration 
ng /m l/w eek  when stored from day zero up 
to 65 weeks at:
Drugs 5°C 25°C -20°C
Phenobarbitone in blood 91 107 107
Phenobarbitone in aqueous 
solution 83 109 8 8
Carbamazepine in blood 27 24 29
Carbamazepine in aqueous 
solution 28 26 26
Phenytoin in blood 96 93 1 1 2
Phenytoin in aqueous 
solution 76 76 1 2 1 *
*High decrease rate in the phenytoin aqueous solution is due to the high 
phenytoin concentration in samples stored at -20°C and analysed after three 
months.
4.5.2 - Non-acid Drugs
4.5.2.1 Benzodiazepines
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Temazepam is a 1,4 benzodiazepine. It is subject to abuse by ingestion and 
injection. Its stability in post-mortem blood has not been reported.
Temazepam Stability
The stability of temazepam during the putrefaction process in blood was 
investigated. Samples of blood and water spiked with temazepam to a 
concentration of 1  ug /m l were prepared and then stored and analysed according 
to the protocol described in 4.1
Samples of blood and water spiked with temazepam were extracted as described in
3.7.2.1 and analysed by HPLC system as described in 3.5.2.
Result and Discussion
The levels of temazepam measured in the blood and water samples stored at the 
three storage temperatures and analysed at the designated time are presented in 
Table 35. The results for blood and water have been plotted in Figures 49 and 50.
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The percent standard deviation for the entire temazepam analysis was found to be 
4.8% for blood temazepam and 5.4% for aqueous solution temazepam. The 
standard for significant breakdown of temazepam to have occurred was a level 
measured which had decreased by greater than (+) 3 S.D from the day zero 
concentration.
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TABLE 35.
The concentration of Temazepam (ug/ml) in blood and aqueous solution stored 
at 5, 25, -20°C from day zero up to 52 weeks.
Storage
Time
Concentration 
when stored at 
5°C
Concentration 
when stored at 
25°C
Concentration 
when stored at 
-20°C
Weeks Blood Aaueous
Solution
Blood Aaueous
Solution
Blood Aaueous
Solution
0 0.84 0.8 0.84 0.8 0.84 0.8
2 0.88 0.79 0.9 0.87
4 0.9 0.86 0.88 0.85
6 0.77 0.84 0.84 0.83
8 0.71 0.83 0.81 0.85
13 0.68 0.82 0.7 0.86 0.85 0.81
26 0.67 0.7 0.67 0.69 0.81 0.71
39 0.53 0.5 0.5 0.49 0.72 0.54
52 0.42 0.35 0.41 0.4 0.71 0.48
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Figures 49 and 50 show the decline in temazepam concentration with time in blood 
and aqueous solution samples when stored at 5, 25, -20°C. Samples of blood 
temazepam stored at 5 and 25°C showed the first significant decrease in 
concentration after three months of storage and also showed the same rate of 
decline in their concentration with time, (Table 38). After six months of storage at 5, 
25°C the average recovery of temazepam was 80%, while samples stored at -20°C 
showed no significant decrease in concentration with a recovery of 95%. This 
corresponded to a low decrease rate of 3 ng /m l/w eek , compared with the rate of 
8.9 (+ 9.5%) n g /m l/w eek  for the samples stored at 5 and 25°C (Table 38). At the 
end of the experiment (one year) the amount of temazepam recovered from blood 
ranged from 48 - 84% regardless of the storage temperature. The temazepam 
stored in aqueous solution followed the same slow rate of decline in concentration 
with an average recovery of 88 ± 1.4% after six months. After one year of storage, 
the average recovery dropped to 41 + 16%. The significant variation in the 
recoveries is due to the significant effect of temperature on the decrease rate which 
had an average of 8.4 (+ 15%) n g /m l/w eek  (Table 38). Samples of temazepam in 
blood and aqueous solution stored at -20°C were more stable. A low decrease rate 
compared to those stored at 5 and 25°C, (Table 38) was measured. This 
demonstrates the effect of temperature on temazepam stability.
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Figure 49. Changes in temazepam concentration with time in blood stored at
25°C from day zero to 52 weeks.
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Figure 50. Changes in temazepam concentration with time in aqueous
solution stored at 5,25, -20°C from day zero to 52 weeks.
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Temazepam (3-hydroxydiazepam) is one of the 1,4-benzodiazepine substitutes. It 
is a known metabolic product of diazepam. 1,4-benzodiazepine's substitutes are 
known to undergo hydrolysis in aqueous solution Figure 51 with the 
benzophenone as the major decomposition product [221,222].
Conclusion
Although temperature has a marked effect on temazepam stability, after one year 
of storage the drug is still easily detected in blood regardless of the storage 
temperature, since samples stored at -20°C show the best recoveries and low 
decrease rate when compared with those stored at 5, 25°C regardless of the storage 
time.
Temazepam in water was shown to be stable for up to twenty-six weeks of storage 
regardless of the storage temperature with a recovery of 88%.
4.5.2.2 - Opiates
Morphine and buprenorphine are the chosen opiates in this study. Their stability 
when stored at the three different temperatures and time intervals were 
investigated.
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Figure 51. Degradation mechanism of 1,4 benzodiazepine in aqueous 
solution.
M orphine Stability
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Samples of blood and water spiked with morphine were prepared in a 
concentration of 500 ng /m l and then stored and analysed according to the protocol 
described in [4.1]. For comparative purposes aqueous solutions of morphine were 
similarly prepared and studied. The samples were extracted as described in 3.7.22  
and analysed by GC-MS using the described method in 3.5.2.2.
Result and Discussion
The morphine concentrations measured following storage for the designated times 
and at the set temperatures are presented in Table 36. The percentage standard 
deviations for the entire method for morphine analysis were + 4% and + 5% for 
blood and aqueous solution respectively.
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TABLE 36.
The concentration of morphine (ng/ml) in blood and aqueous solution stored at 
5, 25, -20°C from day zero up to 52 weeks.
Storage Concentration 
when stored at 5°C
Concentration 
stored at 25°C
Concentration when 
when stored at 
-20°C
Weeks Blood Aaueous
Solution
Blood Aaueous
Solution
Blood Aaueous
Solution
0 519 498 519 498 519 498
2 514 493 538 472
4 525 512 532 411
6 485 490 499 204
8 456 487 498 230
13 432 491 484 10 501 489
26 426 305 452 10 460 526
39 431 298 425 10 451 496
52 426 194 396 10 435 468
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Figure 52. Changes in morphine concentration with time in blood stored at 5,
25, -20°C from day zero to 52 weeks.
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Figure 53. Changes in morphine concentration with time in aqueous solution
stored at 5,25, -20°C from day zero to 52 weeks.
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The standard for significant breakdown of morphine to have occurred was a level 
measured which had decreased by greater than (+/-) 3.SD from day zero 
concentration.
A comparison between the measured blood and aqueous solution concentration 
stored at the three storage temperatures (5, 25, -20°C) are displayed in Figures 52 
and 53. The first significant decrease in blood morphine concentrations was found 
after 13 weeks of storage at 5°C with a recovery of 83%. Figure 54 shows, 
however, that morphine in blood is relatively stable regardless of the storage 
temperature up to one year with recoveries of above 80 + 4.8% measured. 
Morphine solutions are relatively stable at low pH values. It is known that post­
mortem blood pH is slightly acidic which offers a good medium for morphine 
stability and as the pH goes up due to the formation of putrefactive amines, the 
rate of morphine degradation will increase. In this study, the formation of the 
putrefactive amines in the blood morphine samples were measured regularly at 
each designated time according to the drugs and putrefactive amine analysis 
protocol [4.1]. The amount of the four putrefactive amines present in morphine 
samples were shown to be minimal and around the detection limit of the 
developed methods. Only Indole showed a high concentration after 39 and 52 
weeks of storage as discussed earlier (4.4.2.3). As a result, there were no increases 
in the pH of the blood because of the very limited formation of the putrefactive 
amines. The rate of morphine loss in blood was low (1.6 - 2.6 ng /m l/w eek) Table 
38. In contrast, morphine stored in aqueous solution showed the effect of 
temperature on its stability with time. At a temperature of -20°C morphine was 
shown to be very stable regardless of the storage time with a recovery of 99 ± 4.8% 
in all samples stored at -20°C. As the temperature goes up the morphine stability 
in aqueous solution is affected dramatically. At 5°C a steady decline of morphine 
concentration in water with time was observed.
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The lowest recovery of 39% was reached after one year of storage. Morphine 
stored at a higher temperature 25°C showed a sharp decline in morphine 
concentration to reach a recovery of 2% after thirteen weeks. The rate of morphine 
loss in aqueous solution was varied (0.4 - 40 ng/m l/w eek), Table 38. The 
instability of morphine at high temperatures has also been reported where 
morphine was estimated to have a half-life of 24 days at 25°C and pH 6.0 [222].
Oxidation is the most important reaction contributing to the degradation of 
aqueous morphine solution. The phenolic moiety of morphine is known to be 
responsible for its instability in aqueous solution [222]. This group readily 
undergoes oxidation producing the major products pseudomorphine and 
morphine-N-oxide Figure 54. Morphine derivatives not possessing the free 
phenolic group as in the case of codeine and acetyl morphine, do not undergo this 
type of reaction [223]. As the temperature goes up the rate of degradation also 
increases. The decrease rate in morphine concentration shown in Table 38 
indicated that morphine in aqueous solution has a higher rate compared with those 
of morphine in blood, and it also shows that the highest decrease rate was in 
morphine samples stored at a higher temperature, regardless of the storage media. 
Another factor affecting the stability of morphine solutions was the quality of the 
glass. Non-silanised glass allows the release of caustic materials increasing the pH 
and thus the rate of degradation. In this experiment, all the glass containers were 
silanised with dichlorosaline before use to minimise the effect of this phenomena.
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Figure 54. Degradation mechanism of morphine in aqueous solution.
Conclusion
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Morphine in blood is shown to be reasonably stable regardless of the storage time 
and temperature with an expected recovery of 86 ± 4% and 80 ± 4.8% after six 
months and one year of storage respectively. Storage temperature showed a 
greater effect on morphine stability on aqueous solution samples. The recovery of 
morphine in aqueous solution varied with the storage time and temperature and 
ranged from 2-94%.
Buprenorphine Stability
Samples of blood and water spiked with Buprenorphine were prepared in a 
concentration of 250 ng /m l then stored and analysed according to the analysis 
protocol described, 4.1. The samples were extracted as described in 3.7.2.2 and 
analysed by GC-MS using the method described in 3.5.2.2.
Result and Discussion
Buprenorphine concentrations in blood and aqueous solution samples kept at the 
three storage temperatures for different periods of time were summarised in Table
37. The per cent standard deviation for buprenorphine analysis were 6.2% and 
5.8% for blood and aqueous solution respectively.
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The standard for significant breakdown of buprenorphine to have occurred was a 
level measured which had decreased by greater than +3. S.D from day zero 
concentration.
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TABLE 37.
The concentration of buprenorphine (ng/ml) in blood and aqueous solution 
samples stored at 5,25, -20°C from day zero up to 52 weeks.
Storage
Time
Concentration 
when stored at 
5°C
Concentration 
when stored at 
25°C
Concentration 
when stored at 
-20°C
Weeks Blood Aaueous
Solution
Blood Aqueous
Solution
Blood Aqueous
Solution
0 270 249 270 249 270 249
2 284 252 280 232
4 265 261 257 220
6 270 260 262 206
8 281 235 268 142
13 281 240 253 159 286 251
26 257 120 207 150 271 261
39 239 132 192 148 247 255
52 221 108 185 145 268 247
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A comparison between the recoveries of blood and aqueous buprenorphine kept at 
the three storage temperatures 5, 25 and -20°C from day zero to one year, is shown 
in Figures 55 and 56. A significant decrease in blood burprenorphine 
concentration was found only after six months of storage at 25°C. At the end of 
the experiment (one year) a reasonable amount of buprenorphine was recovered at 
the three storage temperatures and it was found to be in the range of 68 - 99%. 
Buprenorphine was expected to follow morphine degradation mechanism to some 
extent due to similarities in their structure. Buprenorphine and morphine have 
one phenolic moieties, which is known to be responsible for its instability. The 
decrease rates of buprenorphine in blood and aqueous solution samples are shown 
in Table 38.
The first significant decrease in buprenorphine concentration in aqueous solution 
was noticed only after eight weeks of storage at 25°C. On the other hand, samples 
stored at 5°C showed the first significant changes in buprenorphine concentration 
after six months, while samples stored at -20°C showed no significant changes in 
buprenorphine. At the end of the experiment, the buprenorphine recovery was in 
the range of 43 - 99%.
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Figure 55. Changes in buprenorphine concentration with time in blood stored
at 5,25, -20°C from day zero to 52 weeks.
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Figure 56. Changes in buprenorphine concentration with time in aqueous
solution stored at 5,25, -20°C from day zero to 52 weeks.
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Conclusion
Storage tem peratures have an effect on buprenorphine stability regardless of the 
storage time and the media as the tem perature increased less buprenorphine 
recovered and the effect of media became im portant on the drug stability. 
Buprenorphine in aqueous solution was found to be less stable compared with 
those of blood for the same storage time and temperature.
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TABLE 38.
The decrease rate in non-acid drugs concentration in blood and aqueous solution 
samples stored at 5,25 and -20°C, from day zero up to 52 weeks.
Decrease Rate in Drugs concentration 
n g /m l/w eek  when stored from day zero up 
to 52 weeks at:
Drugs 5°C 25°C -20°C
Temazepam in blood 8.3 9.5 3.0
Temazepam in aqueous 
solution 9.2 9.2 7.0
M orphine in blood 1.8 2.6 1.6
M orphine in aqueous 
solution 6.2 40* 0.41
Buprenorphine in blood 1.0 1.9 0.33
Buprenorphine in 
aqueous solution 3.3 1.6 0
*The high decrease rate is due to disappearance of morphine in aqueous 
solution only after three months of storage at 25°C.
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4.6 APPLICATIONS
4.6.1 - Interfering Substances in Post-mortem Samples
Eleven samples of post-mortem blood and two blank blood samples were analysed 
for the presence of acid and non-acid interfering substances according to the 
developed extraction and analysis m ethods described earlier in this thesis.
Result and D iscussion
A sum m ary of information related to the post-mortem samples analysed for the 
presence of Indole, 2-phenethylamine, Tyramine and Tryptamine, are show n in 
Table 39. The table shows the time of death, the date of receiving the samples for 
drugs screening and the time elapsed before the samples were analysed for the 
presence of putrefactive amines.
The concentration of four putrefactive amines in putrefied blank blood and the 
post-mortem blood samples was measured. Figure 57 shows that a high 
concentration of acid and non-acid interfering substances were observed in the 
putrefied blank blood samples stored at room tem perature in open containers for 
two months. The two blank blood samples show different concentrations of 
interfering substance even when both were stored under the same conditions. 
These blank blood samples were from difference sources.
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The formation of the four putrefactive amines in post-mortem cases stored for 
different time intervals between eight weeks to thirty-seven weeks was monitored. 
The post-mortem cases under investigation were usually stored at 5°C for a few 
days until a full toxicological investigation was completed then stored at -20°C. 
Table 39 shows the time elapsed before analysing the samples for the presence of 
Indole, 2-phenethylamine, Tyramine and Tryptamine.
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The results given in Figure 58 show a different concentration of the four 
putrefactive amines. This appears to be independent of the storage time. The 
figures also show that storing the samples at -20°C did not prevent the formation 
of the four putrefactive amines but reduced the rate of formation.
No significant correlation could be found between the production of the four 
putrefactive amines so it is probable that independent mechanisms of production 
exist. The study shows that the blank blood samples stored at room tem perature in 
open containers for nine weeks resulted in a high concentration of the four 
putrefactive amines compared to post-mortem blood stored in closed containers at 
5 and -20°C. The concentration of putrefactive amines in open containers were 10 - 
27 times higher than those of post-mortem cases stored at 5 and -20°C in a closed 
container for different periods of time. The high concentration of the four 
putrefactive amines in blood samples stored in open containers could be due to 
samples being exposed to all types of bacteria which are known to be responsible 
for the progress of the putrefactive process.
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Figure 57. The concentration of the four putrefactive amines in blank blood 
samples stored at room temperature in open container for two months.
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Figure 58. The concentration of the four putrefactive amines in post-mortem 
blood samples.
1. Indole.
3. Tyramine.
2. 2-phenethylamine.
4. Tryptamine.
Lo
g 
Co
nc
en
tra
tio
n 
(u
g/
m
l) 
Lo
g 
Co
nc
en
tra
tio
n 
(u
g/
m
l) 
Lo
g 
Co
nc
en
tra
tio
n 
(u
g/
m
l)
- 308 -
Case4
0.1 ii|illillllilii||lllllliliilimimilllllili isiiiiiii
o
Time elapsed before analysis(31 Weeks)
Case5
m a u n
0.01
Time elapsed before analysis(29 Weeks)
Case6
inuiniiiiiiiiii
Time elapsed before analysis(9 Weeks)
Figure .58 (continued) The concentration of the four putrefactive amines in
post-mortem blood samples.
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Figure 58 (continued) The concentration of the four putrefactive amines in
post-mortem blood samples.
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Figure 58 (continued) The concentration of the four putrefactive amines in
post-mortem blood samples.
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Conclusion
The investigation showed no relation between the production of different 
putrefactive amines and storage time in post-mortem samples stored in closed 
containers. On the other hand blank blood samples stored in open containers at 
room tem perature showed higher concentrations of putrefactive amines compared 
to those of post-mortem samples stored at -20°C for longer periods of time. This 
could be explained by the samples being exposed to different types of bacteria 
which appeared to be the main factor in promoting putrefaction. The speed of 
putrefactive decomposition was considerably reduced in post-mortem samples 
stored at -20°C in a closed container.
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4.6.2 - Analysis of Drug Positive Post-mortem Samples
Table 40 gives a summ ary of information on eleven post-mortem samples which 
were found to be positive for the drugs under investigation. The concentration of 
drugs in post-mortem samples was predicted using the decrease rates of acid and 
non-acid drugs concentration with time at a given storage tem perature, Tables 34,
38. The predicted drug concentration after being stored for 'W' weeks at a given 
storage tem eprature calculated as follows:
P = D x W Equation 17
W hen P is the predicted drug concentration, W is the storage time 'weeks' and D is 
the adjusted decrease rate (ng /m l/w eek) for a given drug at a given tem perature. 
D can be obtained from the following equation:
D = *gX ~  Equation 18
W here R is the decrease rate (ng /m l/w eek) in spiked blood drug at a given 
tem perature Tabes 34, 38, while C is the measured concentration of the drug in the 
post-mortem sample at the day of receiving the sample and S the concentration of 
the drug spiked blood at day zero which was obtained from Tables 31, 32, 33 in 
case of acid drugs and from Tables 35, 36, 37 in the case of non-acid drugs. The 
above two equations were used to calculate the predicted concentration in the 
eleven post-mortem samples, as a trial to examine the usefulness of the decrease 
rates obtained in this study.
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4.6.2.1 - Acid D rugs 
A nticonvulsants
Four samples of post-m ortem  blood were found to be positive for phenobarbitone, 
carbam azepine and phenytoin. The samples were usually kept at 5°C until the full 
d rug screening test was finished then the sample were stored at -20°C for a few 
m onths before being re-analysed for the concentration of drugs to investigate the 
stability of anticonvulsant drugs in post-m ortem  blood. The anticonvulsant drugs 
were extracted using the m ethod described in 3.7.1.1 and were analysed by the 
HPLC system  described in 3.5.1.1.
R esults and D iscussion
Table 41 shows the concentration of phenobarbitone, carbam azepine and 
phenytoin at the time of receiving the sam ples from the m ortuary and the
- 315 -
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concentration of the drugs after being left for a few days at 5°C then stored at - 
20°C for several weeks before being analysed again for the concentration of each 
drug.
Phenobarbitone sam ple (Case 1), Table 41, shows agreem ent betw een the 
concentration of phenobarbitone analysed after 27 weeks and the predicted 
concentration using the decrease rate in phenobarbitone concentration in blood 
sam ples stored at -20°C, Table 34. W ith phenytoin and carbam azepine (Case 1, 5, 
9,11) there was agreem ent between the predicted concentration using the decrease 
rate in carbam azepine and phenytoin concentration with time in blood sam ples 
stored at -20°C, Table 34, and the authentic concentration after storage only in 50% 
of the samples, Table 41.
4.6.2.2 Non-Acid D rugs 
B enzodiazepine
Post-m ortem  blood samples found to be positive for tem azepam  were stored at - 
20°C for several weeks before being re-analysed for tem azepam  concentration. 
The storage time varied in the range of tw o weeks to twenty-six weeks. Post­
m ortem  blood was extracted for the presence of benzodiazepine using the m ethod 
described in 3.7.1.1 and was analysed by the HPLC system  described in 3.5.2.I.
- 317 -
Results and D iscussion
Table 42 shows the concentration of tem azepam  after being stored for different 
storage periods.
The cause of death in all of the cases was drug overdose. The drugs involved were 
benzodiazepine and flupenthixol in Case 2, benzodiazepine, chlormethiazole and 
alcohol in Case 4, opiates and benzodiazepine in Case 8. In Case 10, the cause of 
death was acute left ventricular failure with positive screening tests for 
benzodiazepine, prothiaden and alcohol.
In Table 42, Cases 4 and 10 show a significant difference in tem azepam  
concentration between the predicted concentration using the decrease rate in blood 
temazepam concentration with time when stored at -20°C at 5°C while no 
significant difference within the m ethod percent standard deviation was noticed 
between the predicted concentration and the m easured concentration in Cases 2 
and 8, Table 42.
The predicted concentration was calculated by multiplying the adjusted 'decrease 
rate' (D) in blood temazepam concentration stored at 5, 25 and -20°C by the 
num ber of weeks the sample 'case' were stored, equation 17. The decrease rate in 
the study based on initial temazepam concentration of 0.84 u g /m l on day zero 
which is different from the initial concentration of authentic post-mortem cases, the 
adjusted decrease rate was calculated using equation 18. Therefore, each case has 
its adjusted decrease rate which was used to calculate the predicted tem azepam  
concentration of each case.
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In Case 10 a high temazepam concentration was noticed when samples were stored 
at 5°C for two weeks. This could be explained as a result of tem azepam  being 
released from temazepam bound to protein.
Opiates
Four post-mortem cases were found to be positive for morphine. The samples 
were usually kept at 5°C until the full drug screen test was finished. The samples 
were then stored at -20°C for a few weeks before being re-analysed for m orphine 
concentration. Post-mortem blood was extracted and was analysed for the 
presence of m orphine using the m ethod described in 3.8.2.2.
Result and D iscussion
Table 43 shows no significant difference w ithin the m ethod per cent standard 
deviation between the concentration of morphine in samples analysed after 18 and 
13 weeks. Cases 6, 8 and the predicted concentration, while in Cases 3 and 7 the 
m orphine concentrations after 26 and 27 weeks of storage was found to be about 
50% lower than the predicted concentration using the decrease rate.
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Conclusion
Using the decrease rate in drug concentration to predict the authentic 
concentration of drug after being stored for a certain period of time at any of the 
three storage tem peratures (5, 25, -20°C) showed limited usefulness (50% 
agreement between the predicted and the authentic drug concentration). 
Increasing the num ber of post-mortem samples tested by this m ethod could give 
more information on the agreement between the predicted concentration and the 
authentic concentration.
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4.7 - THE EFFECT OF INTERFERING SUBSTANCES ON DRUG ANALYSIS
4.7.1 - Acid D rugs
A nticonvulsants
A standard  solution of acid drugs containing the nine drugs were extracted as 
described in 3.7.1.1 20 ul was injected to the HPLC system which was usually used 
to analyse these drugs (described earlier 3.9.1). The four putrefactive am ines were 
spiked in blank blood to give a concentration of 10 u g /m l and extracted using 
acidic drugs m ethod, then analysed on the same HPLC system  to establish their 
retention times.
R esults and D iscussion
Com paring the retention times of acidic drugs, Table 44, w ith the retention times of 
the four putrefactive amines, Table 45 show ed a possibility of interferences from 
Indole w ith the qualitative and quantitative analysis of carbam azepine and 
am ylobarbitone, since the difference in retention time betw een Indole and 
am ylobarbitone is only 0.1 minutes while carbam azepine and Indole have the sam e 
retention times of 11.0 minutes. Ten u g /m l. of Indole could give a false positive of 
21.12 u g /m l carbam azepine and 64.45 u g /m l am ylobarbitone. The presence of 
Indole in putrefied blood analysed by HPLC for carbam azepine and 
am ylobarbitone could give false positives or a four-fold increase of the authentic
- 323 -
TABLE 44.
The retention times of the eight acidic drugs and Internal Standard Butalbital on 
acid drugs HPLC.
Drug Retention Times 
Minutes
Concentration
u g /m l
*Peak H eight 
Ratio
Primidone 4.27 12.42 1.97
Phenobarbitone 6.17 10.98 1.4
Butobarbitone 7.82 10.20 0.76
Butalbital
(I.S)
8.29 5.76 -
Phenytoin 10.21 11.63 0.98
Carbamazepine 11.0 5.54 0.96
Amylobarbitone 11.1 13.39 0.76
Methaqualone 13.86 11.68 0.28
Quinalbarbitone 14.54 11.15 0.87
* Peak height ratio = drug peak height/butalbital (I.S) peak height
- 324 -
concentration of each drug. Therefore in the case of putrefaction post-m ortem  
sam ples show n to be positive for carbam azepine or am ylobarbitone by HPLC 
system  another m ethod such as GC or G C /M S should be used to confirm the 
HPLC results.
4.7.2 - Non-Acid D rugs
The possibility of interference between benzodiazepine and the four putrefactive 
amines has been investigated. The other group of non-acid drugs, 'opiates' is 
om itted because the m ethod used to analyse the opiates in the study was G C /M S 
which provides unquivocal identification of m orphine and buprenorphine w ith 
selective ion recording.
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The standard benzodiazepines solution was injected into the HPLC system 
described in 3.9.2 at a flow rate of 1.5 m l/m in .
Result and D iscussion
The retention times of the five benzodiazepines and the internal standard  are 
shown in Table 46. A separate analysis of each of the four putrefactive amines on 
the benzodiazepine HPLC system was conducted. The retention times of the four 
putrefactive amines are shown in Table 47.
Com paring the retention times of the five benzodiazepines and the four 
putrefactive amines, Tables 46 and 47, show that two of the four putrefactive 
amines eluted before the first benzodiazepine 'triazolam' while 2-phenethylamine 
did not elute from the column. Tryptamine has a retention time close to 
chlordiazepoxide but the possibility of a false positive chlordiazepoxide due to the 
presence of tryptam ine is very slim, since chlordiazepoxide shows a good sharp 
peak with peak width of 0.2 cm while tryptam ine shows a broad peak w ith peak 
w idth of 3.0 cm.
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TABLE 46.
The Retention Times of Five Benzodiazepines and Internal Standard Prazepam 
on benzodiazepines HPLC System.
Benzodiazepines Retention Times 
Minutes
Concentration
ug/m l
Peak Height 
cm
at AUFS = 0.16
Triazolam 5.9 2 7.6
Temazepam 7.1 2 7.0
Chlordiazepoxide 7.6 2 1.0
Desmethyldiazepam 8.3 2 9.3
Diazepam 9.2 2 8.1
Prazepam  (I.S.) 15.7 2 4.2
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Indole would be considered as a major interfering putrefactive amine with 
carbamazepine and amylobarbitone determ ination by HPLC. The possibility of 
interferences between benzodiazepines and the four putrefactive amines were 
found to be minimal.
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CONCLUSIONS
a) Drugs Stability
The study was prim arily concerned with the stability of drugs in putrefied 
biological material and was conducted for periods of time under three storage 
conditions. In this work the stability of some commonly encountered 
anticonvulsant, benzodiazepine and opiate drugs spiked in blood, was 
investigated for over one year of storage at three different tem peratures (5,25 and - 
20°C). Phenytoin was found to be very stable over a period of six m onths with 
above 90% recovered regardless of the storage tem perature. Phenobarbitone and 
carbamazepine show ed a steady but slow decline in their concentration with time 
up to six months, when at least above 70% of the drugs were recovered.
The non-acid drugs, temazepam, morphine and buprenorphine were also found to 
be very stable under the storage conditions studied, with a very slow steady 
decline in their concentration with time up  to six months. At least 85% of the 
drugs were recovered regardless of the storage tem peratures. The storage 
tem peratures showed an obvious effect on drugs stability in aqueous solution. The 
study showed that at therapeutic and toxic concentrations of the studied drugs, a 
reasonable am ount of the drugs were still detectable after one year of storage 
regardless of the temperature. This finding provides im portant inform ation for 
forensic toxicologist to assist with the interpretation of results even in one year-old 
samples.
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b) Putrefactive Amines Formation
It was found that the formation of putrefactive amines was dramatically retarded 
in blood spiked with the drugs under study when stored at 5, 25 and -20°C in 
sealed vials. Post-mortem blood samples showed that a reasonable am ount of the 
four putrefactive amines were found. Storing the post-mortem blood at -20°C did 
retard the rate of formation of the putrefactive amines but no significant correlation 
could be found between the production of the four putrefactive amines with the 
storage time in the eleven post-mortem samples. On the other hand, the formation 
of the four putrefactive amines in blood samples stored at room tem perature in 
open containers even for a short period of time showed 1 0 - 2 7  times higher 
concentration of the four putrefactive amines. This is probably due to the blood 
samples stored in open containers being exposed to different types of airbone 
bacteria which appeared to be the m ain factor in prom oting putrefaction.
c) Methods of Analysis and Extraction of Acid and Non-Acid Substances
Acid interfering substance "Indole" is normally determ ined by m easuring the 
ultraviolet absorbence of Indole in acidic or basic aqueous solution which contains 
other endogenous compounds. A m ethod to analyse Indole by reversed-phase 
HPLC which separated Indole and the internal standard (5-chloroIndole) in less 
than 15 minutes was developed. The system was sufficiently sensitive for the 
determ ination of Indole in putrefied blood samples.
In the literature, no methods have been reported for the sim ultaneous analysis of 2- 
phenethylam ine, Tyramine and Tryptamine using normal phase HPLC. M ethods 
using reversed-phase separation with gradient elution or ion pairing agents have
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been described. The analysis times, however, are unacceptably long (>15 minutes 
to separate the three putrefactive amines. In this study a m ethod was developed to 
analyse the three putrefactive amines simultaneously using normal-phase HPLC. 
The separation was achieved in less than five minutes with sufficient sensitivity to 
determine the presence of the three putrefactive amines in putrefied blood 
samples.
Indole was usually extracted from blood using liquid-liquid extraction which is a 
tedious and time-consuming method. The extraction of Indole from putrefied 
blood was explored using m ethanol/isopropanol for protein precipitation and 
bonded sorbents. It show ed that Indole could be efficiently extracted using non­
polar sorbents. On the other hand, extracting the non-acid interfering substance 
from putrefied blood was usually achieved by liquid-liquid extraction. In the 
literature, there is some data regarding extraction of putrefactive amines from 
serum  and urine using solid-phase sorbent. These methods have their limitations 
since post-mortem blood can not be applied directly on to solid-phase sorbent and 
the methods are not capable of extracting the three putrefactive amines 
simultaneously. Extracting the three putrefactive amines from putrefied blood was 
explored using Extrelut^ (diatomaceous earth) and different solid-phase sorbents. 
Ion-exchange sorbents showed the best efficiency to extract the three putrefactive 
amines. The ion exchange sorbent was shown to be suitable to extract prim ary 
amines from biological samples. The possibility of re-using the solid-phase 
sorbents was investigated and showed good efficiencies when used up to seven 
times in the case of non-polar sorbents for Indole extraction and up to six times in 
the case of ion-exchange sorbents for 2-phenethylamine, Tyramine and Tryptamine 
extraction.
d) A pplications
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The decrease rate in drug concentrations with time and storage tem perature was 
tested in a trial to make a correlation between the authentic drug concentration and 
the predicted concentration using the decrease rates obtained in this study. This 
was found to be of limited usefulness (50% agreement between the authentic 
concentration and the predicted concentration).
The possible interferences from acid and non-acid interfering substance with 
extraction and analysis of acidic drugs and benzodiazepines by HPLC system 
showed Indole to be the m ost im portant interfering substance in carbamazepine 
and amylobarbitone analysis by HPLC system. Therefore, another m ethod should 
be considered for qualitative and quantitative determ ination of the two drugs.
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PUBLICATION
STABILITY OF SOME DRUGS OF FORENSIC INTEREST IN WHOLE BLOOD 
STORED AT DIFFERENT CONDITIONS
K. H adidi and J.S. Oliver
D epartm ent of Forensic Medicine and Science, University of Glasgow, Scotland, 
U.K.
ABSTRACT
Whole blood spiked with phenobarbitone, carbamazepine and phenytoin was 
stored in sealed vials for different time intervals and at different tem peratures 
prior to analysis. Phenytoin was found to be very stable over a period of six 
months. Also, phenobarbitone and carbamazepine were found to be reasonably 
stable since recoveries of more than 76% and 70% respectively were obtained for 
each drug after six months. At the end of fifteen m onths storage, however, for all 
of the drugs, less than 50% of the parent drugs were recovered. D rug losses 
appeared to be relatively independant of both media and tem perature of storage.
INTRODUCTION
There is a shortage of data regarding the stability of drugs of forensic interest in 
hum an postm ortem  blood, especialy when the postm ortem  tissue sample has been 
subject to a variable degree of putrefaction or,in some cases, acquisition by the 
laboratory to perform a full drug screen is after a few months of storage due to a
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requirem ent for new evidence. Therefore it is necessary to establish whether these 
drugs are stable over a period of time under different storage conditions. 
Attempts to study this problem date back to 1942 and from that time until the early 
seventies m ost of the work suffers from lack of sensitivity and specificity (2,3,4). 
The stability of some drugs in hum an liver macerates spiked with drugs over 
different periods of time have been studied (1,9). The results show a large 
coefficient of variation within the homogenate(liver macerates) due to a variable 
distribution within the tissue. Intratissue differences in drug distribution are 
known for certain chemicals.
Studies in the early 1970s on the stability of some barbiturate drugs in blood from 
dogs(3) and humans(4,5) have been reported. The techniques used, however, still 
lacked sensitivity and specificity. They used ultraviolet detection to m easure the 
barbiturates in the basic extract following a poor recovery liquid-liquid extraction 
procedure. Other findings at about the same time gave contradictory information 
on the stability of plasm a and serum  phenytoin and phenobarbitone stored at 4°C 
for eight, twelve and twenty six weeks prior to analysis(10,11,12).
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EXPERIMENTAL
Chemicals: Phenobarbitone was obtained from B.D.H., Poole, U.K., Carbamazepine 
from Geigy Pharmaceuticals, Macclesfield, U.K., Phenytoin from Parke Davis and 
Company, Hounslow, London, U.K. and butalbital (internal standard) from 
Sandoz, Basel, Switzerland.
HPLC grade methanol and acetonitrile and Analar grade sodium  acetate and 
disodium  hydrogen phosphate were supplied by B.D.H., Poole, U.K.
The blood used in this study was part packs supplied by the Scottish Blood 
Transfusion Service, Carluke, Strathclyde, Scotland.
Apparatus: The HPLC system used was isocratic based on a Pye Unicam PU 4015 
pum p and PU 4025 ultraviolet detector. The extracts were introduced using a 
Rheodyne 7125 valve with a 20ul sampleloop. The column (25cm * 4.6mm i.d.) 
and guard column (5cm * 4.6mm i.d.) stainless steel were packed w ith C18- 
Hypersil ODS, 5um  particle size, supplied by Jones Chrom atography. The 
chromatograms were recorded on a strip chart recorder set at 10 mV full scale 
deflection with 1.0 cm chart speed
The separation and detection of each drug was achieved using the HPLC system 
with a mobile phase consisting of 0.02M sodium  acetate/m ethanol/acetonitrile in 
a ratio of 400:180:180 v /v /v  respectively, the pH  of mobile phase was adjusted to 
5.5 with glacial acetic acid. The flow rate used was 1.5 ml per minute. The 
detector was set to monitor 210 nm.
- 353 -
PROCEDURE
The blood used was screened for the presence of the drugs under study before use. 
A methanolic standard of each drug was evaporated to dryness at 60C under a 
nitrogen stream and the residue was reconstituted with a known am ount of blood 
to produce a level above the therapeutic range of each drug in the sample. 
Duplicate portions of each spiked blood sample for each period of time under 
study were transferred to a clean vial, sealed, and stored under one of three 
different tem peratures (5, 25, -20°C). Duplicate control solutions of each drug at 
the same concentration as the blood samples, were made in water at pH7.4 with 
these control aqueous solutions were stored with the blood under the same storage 
conditions.
On the day of analysis duplicate specimens of fresh spiked blood and control 
aqueous standards were prepared and analysed with the stored specimen. They 
were extracted using a previously reported m ethod (6) to m easure the 
concentration of the drugs under investigation
Extraction procedure
Into a 5ml vial add the following;
1 0.4ml of specimen (spiked b lood/control aqueous solution).
2 0.4ml of 0.5M disodium  hydrogen phosphate buffer (pH 9.2).
3 0.1ml butalbital "internal standard."
4 Mix thoroughly using whirly mix (30 sec).
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5. Transfer 0.65ml of the mixture to the extre-lut column (a pasteur pipette 
filled with diatomaceous earth granules washed with dichloromethane and 
dried off before use).
6 Allow to stand for 15 minutes.
7 Elute the drug with 3ml dichloromethane into a clean vial.
8 Evaporate to dryness at 60C under a nitrogen stream.
9 Reconstitute the residue with 200ul of mobile phase.
10 Analyse 20 u\ aliquots by HPLC.
RESULTS AND DISCUSSION
Our standard for significant breakdown of drug to have occurred was a level 
m easured which had decreased by greater than three standard deviations of 
variation for the method (Table 1). The stability of phenobarbitone in putrefied 
blood samples stored at three different conditions (5, 25, -20°C) for different 
periods of time can be seen in figure(l).
5°C is the tem perature most frequently used for short term storage of biological 
specimens, while -20°C is mostly used for their long term storage.
After eight weeks of storage, blood phenobarbitone levels at 5°C were shown to be 
stable with no changes in their concentration outw ith (+/-) 3 S.D for the method. 
The concentration of phenobarbitone aparently increased up to 15% from the initial 
concentration when stored at 25°C for the same period of time.
Using this (+/-) 3 S.D param eter as an indicator of decomposition of the drug, 
blood containing phenobarbitone started to display losses after thirteen weeks of 
storage at 5°C (24%). Samples stored at 25°C exhibited losses of 19% while 
samples stored at -20°C exhibited no losses over the same time period. Between 
13 and 26 weeks no significant changes were observed.
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A slow and steady decline in phenobarbitone concentration were observed for all 
samples stored at the three different storage conditions for 52 weeks and reached 
losses up to 34% for samples stored at 5°C, 43% losses at 25°C and 42% for 
samples stored at -20°C.
After 65 weeks (15 MONTHS) of storage the concentration of phenobarbitone 
dropped to the half of it's initial concentration in all samples (losses of 51% at 5°C, 
58% at 25°C and 53% for samples stored at -20°C). The average loss in 
phenobarbitone concentration was 54% when stored at any of the three conditions 
for 65 weeks.
Figure 2 shows that the blood carbamazepine levels declines at different rates 
when stored at three different conditions. After 13 weeks blood carbamazepine 
samples stored at 5°C showed no changes in their concentration outw ith (+/-) 3 
S.D for the method. 33% losses were found for storage at 25°C for the same period 
of time, with no changes in concentration for samples stored at -20°C. Losses in 
carbamazepine concentration of 41% were measured in samples stored at - 
20°C after 26 weeks For samples stored at 5°C over the period of 13 to 26 weeks 
the changes in carbamazepine concentration is still within (-/+) 3 S.D of the 
m ethod variation, samples at 25°C almost m aintain the same percentage losses 
after 26 weeks (6 MONTHS).
At the three different storage conditions carbamazepine show ed an average losses 
49% after 52 weeks ( ONE YEAR) and the average losses of carbamazepine reach 
up to 69% after 65 weeks (FIFTEEN MONTHS). Losses of carbamazepine in blood 
showed a steady decline over the period 26-65 weeks.
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TABLE 1
The standard deviation for the entire extraction and 
analysis of anticonvulsant drugs.
Drug Standard Deviation 
n = 8
Phenobarbitone in blood + 8.5%
Phenobarbitone in water ±9.1%
Carbamazepine in blood + 9.5%
Carbamazepine in water ±9.5%
Phenytoin in blood + 8.6%
Phenytoin in water ±9.3%
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Phenytoin concentrations in blood samples stored at 5°C showed losses of less 
than 10% from the initial concentration after 26 weeks compared with 12% losses 
for samples stored at 25°C for the same period of time. At -20°C phenytoin 
showed no significant changes in concentration from the initial value. A very 
slow decline in phenytoin concentration was observed in samples stored at 5°C to 
reach 17% losses at 52 weeks, Figure 3.
At 25°C and-20°C phenytoin showed losses in concentration of up to 28% and 31% 
respectively from the initial concentration after 26 weeks. For the three storage 
conditions (5,25,-20°C), after 65 weeks (15 MONTHS), phenytoin had an average 
loss of 64%.
The decline in phenobarbitone aqueous solution stored at (5, 25, -20°C)for up to 65 
weeks can seen in figure 4. It shows a linear decrease in concentration w ith time 
regardless the storage tem perature and reaches a maximum loss in phenobarbitone 
concentration of up to 67% compared with the 54% average losses for 
phenobarbitone in blood samples for the same period of time. As the differences 
between blood and water losses are small and water occurs in both samples a 
hydrolysis of phenobarbitone in blood and water samples could explain the losses 
in phenobarbitone concentration with time. The mechanism of phenobarbitone 
degradation in aqueous solution has been studied (7,8) and it has been proposed 
that the degradation mechanism depends on whether the barbiturate 
(phenobarbitone) were in ionised or unionised forms. Unionised barbiturates were 
hydrolysed at the 1,2-position while ionised barbiturates were hydrolysed at 1,6- 
position. Different breakdown products could be formed.
Carbamazepine stored in aqueous solution under the three different conditions, 
see figure 5, showed a slow deterioration in carbamazepine to reach a m aximum 
average loss of 24% compared with carbamazepine in blood which reached an 
average loss of up to 49% after 52(weeks). Carbamazepine therefore shows greater 
stability in aqueous solution than in blood. A factor of greater effect in blood than
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in water is the presence of microorganisms which could exert a great effect on the 
deterioration of carbamazepine in blood with time. The decline in phenytoin 
concentration in aqueous solution stored at 5, 25, -20°C for up to 65 weeks can be 
seen in figure 6 to show m inimum average losses of up to 24% and 58% after being 
stroed for 52 and 65 weeks respectively.
Conclusions
Under the storage conditions studied, phenytoin was found to be very stable over 
a period of six months. Phenobarbitone and carbamazepine showed a steady slow 
decline in their concentration with time. Up to 6 months, at least 70% of the drugs 
were still recoverable. All three drugs could still be detected after 15 months 
irrespective of the storage condition dem onstrating that an analysis could still 
provide useful information. The interpretation of the result would have to take 
into account both the storage conditions and the storage times. No interference 
with the analytical technique was experienced from the products of putrefaction.
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Figure 1. Changes in phenobarbitone concentration with time in blood
stored at 5,25, -20°C from day zero to 65 weeks.
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Figure 2. Changes in carbamazepine concentration with time in blood stored
at 5,25, -20°C from day zero to 65 weeks.
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Figure 3. Changes in phenytoin concentration with time in blood stored at 5,
25, -20°C from day zero to 65 weeks.
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Figure 4. Changes in phenobarbitone concentration with time in aqueous
solution stored at 5,25, -20°C from day zero to 65 weeks.
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Figure 5. Changes in carbamazepine concentration with time in aqueous
solution stored at 5,25, -20°C from day zero to 65 weeks.
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Figure 6. Changes in phenytoin concentration with time in aqueous solution
stored at 5,25, -20°C from day zero to 65 weeks.
